Investigating the biomarker potential of exosomes in preeclampsia. by Pillay, Preenan.
 
 
 
 
Investigating the Biomarker Potential of 
Exosomes in Preeclampsia 
 
 
 
 
Preenan Pillay 
 
 
 
 
Submitted in fulfilment of the requirements for the degree of 
Doctor of Philosophy in Medical Science 
 
Department of Physiology, College of Health Sciences, University of KwaZulu-Natal, Durban 
South Africa. 
 
2019 
 
Preface 
 
The experimental work described in this thesis was conducted at the University of KwaZulu Natal 
(Durban, South Africa), University of Witwatersrand (Johannesburg, South Africa) and in conjunction 
with the University of Oxford (London, United Kingdom) from March 2017 to July 2019, under the 
supervision of Professor Irene Mackraj. 
 
This work has not been submitted in any form for any degree to any tertiary institution, where use has 
been made of the work of others, it is duly acknowledged in the text. 
 
 
        21/06/2019 
         P. Pillay              Date 
 
 
As the candidate’s supervisor, I agree to the submission of this thesis. 
 
 
___________________                           21/06/2019              
Professor I Mackraj                 Date 
 
 
 
 
 
 
 
Asoka ENGLISH LANGUAGE EDITING 
14 Boundary Rd., Escombe, 4093 
 
Cell no.: 0836507817 
 
 
 
 
 
 
DECLARATION 
 
This is to certify that the FOLLOWING THESIS has been English 
Language Edited 
 
Investigating the Biomarker Potential of Exosomes in Preeclampsia 
 
Candidate:  Pillay P 
 
DISCLAIMER 
Whilst the English language editor has used electronic track changes to facilitate corrections and has 
inserted comments and queries in a right-hand column, the responsibility for effecting changes in 
the final, submitted document, remains the responsibility of the client. 
 
Director: Prof. Dennis Schauffer, M.A.(Leeds), PhD, KwaZulu (Natal), TEFL(London), TITC Business English, Emeritus 
Professor UKZN. Univ. Cambridge Accreditation: IGCSE Drama. Hon. Research Fellow, DUT.  Durban University of 
Technology. 
 
i 
 
Declaration 
I Preenan Pillay declare that: 
 
(i) The research reported in this thesis, except where otherwise indicated, is my original 
work. 
(ii) This thesis has not been submitted for any degree or examination at any other university. 
(iii) This thesis does not contain other persons’ data, pictures, graphs or other information 
unless specifically acknowledged as being sourced from other persons. 
(iv) That my contribution to the project was as follows:  
 
Identification of research topics, experimental design, execution, data analysis and 
interpretation, manuscript & thesis write-up.  
 
(v) That the contributions of others to the project were as follows:  
 
Professor Irene Mackraj (supervisor) has reviewed the entire project and the write-up of the 
manuscript and thesis.  This project was funded by the NRF (Grant no.: 91544). 
 
Professor Jack Moodley and Dr Manu Vatish has reviewed the clinical design of the project 
and manuscripts. 
 
Professor Raquel Duarte (University of Witwatersrand) assisted with the experimentation and 
the review of Chapter 3.  
 
 
        21/06/2019 
         P. Pillay              Date 
 
 
 
ii 
 
Publications and Presentations  
 
Peer-reviewed Publications contributing to this thesis  
 
Preenan Pillay, Kogie Moodley, Jagidesa Moodley, Irene Mackraj. Placental-Derived 
Exosomes: Potential Biomarkers of Preeclampsia, International Journal of Nanomedicine. 
2017:12. Pages 8009-8023. (Chapter Two of this thesis) 
 
Preenan Pillay, Manu Vatish, Raquel Duarte, Jack Moodley, Irene Mackraj. Exosomal 
microRNA profiling in early and late onset pre-eclamptic pregnant women reflects 
pathophysiology. Accepted: International Journal of Nanomedicine. (Chapter Three of this 
thesis) 
 
Peer-reviewed Publications not part of the thesis but contributed to the prior knowledge 
 
Preenan Pillay, Niren Maharaj, Jagidesa Moodley, Irene Mackraj. Placental exosomes and pre-
eclampsia: Maternal circulating levels in normal pregnancies and, early and late onset pre-
eclamptic pregnancies. Placenta. 2016: 45, Pages 18-25. (Appendix 7.4 – not part of this 
thesis but was a significant study which lead to the subsequent studies presented in this 
thesis)  
 
Sonal Verma, Preenan Pillay, T Naicker, Jagidesa Moodley, Irene Mackraj. Placental Hypoxia 
Inducible factor −1α & CHOP Immuno-histochemical expression Relative to Maternal 
Circulatory Syncytiotrophoblast Micro-vesicles in Preeclamptic and Normotensive 
Pregnancies, European Journal of Obstetrics and Gynecology, 2017:220, Pages 18-24. 
(Appendix 7.5 – Not part of the thesis but the significant findings contribute to the prior 
knowledge)  
 
Nomfundo Mchunu, Preenan Pillay, Jagidesa Moodley, Irene Mackraj. Circulatory Levels of 
Tumor Necrosis Factor-α, Interleukin-6 and Syncytiotrophoblast Microvesicles in the First 
Trimester of Pregnancy. Clinical and Experimental Obstetrics and Gynecology. 2018: 45(4), 
Pages 575-581. (Appendix 7.6- Not part of the thesis but the significant findings contribute 
to the prior knowledge) 
 
 
Presentations 
P Pillay & I Mackraj. Placental-derived exosomes: Future biomarkers of preeclampsia. Journal 
of Nanomedicine and Nanotechnology. 2017. 8:6, page 40.  
 
Kaminee Maduray, Preenan Pillay, Jagidesa Moodley, Irene Mackraj. Immunological effects 
of plasma-derived exosomes on BeWo cells under in vitro hypoxic conditions. Placenta 2018 
Apr;64 Suppl 1: S2-S3.  
 
W Phoswa, P Pillay, I Mackraj, K Moodley & K Madurary.  Effect of titanium dioxide 
nanoparticle aggregation on myoblast cytotoxicity and nitric oxide synthesis.  Journal of 
Nanomedicine and Nanotechnology. 2017. 8:6, page 41.  
 
 
iii 
 
Statement 
 
The following publications have been included as chapters in this thesis: 
 
Chapter Two: Placental-Derived Exosomes: Potential Biomarkers of Preeclampsia. 
(Published: International Journal of Nanomedicine. 2017:12. Pages 8009-8023). 
 
Chapter Three: Exosomal microRNA profiling in early and late onset pre-eclamptic pregnant 
women reflects pathophysiology. (Accepted: International Journal of Nanomedicine) 
 
Chapter Four: Exosomal Th1/Th2 Cytokines in Preeclampsia and HIV-positive Preeclamptic 
Women on Highly Active Anti-Retroviral Therapy (Under Review: Cytokine – CYTO-19-358) 
 
The PhD candidate performed experimental work described in this thesis, where others have 
made contributions it is duly acknowledged in the text.  The candidate drafted this publication 
in full and it has been reviewed by co-authors. 
 
 
        21/06/2019 
         P. Pillay              Date 
 
 
___________________                    21/06/2019     
Professor I Mackraj            Date 
 
 
 
 
iv 
 
Acknowledgements 
 
Professor Irene Mackraj and Professor J. Moodley for their guidance and support throughout 
the project. 
 
Dr Kogi Moodley for the review of the manuscripts, thesis, and help and guidance throughout 
the project. 
 
Dr Manu Vatish from the University of Oxford for his support and guidance in ensuring that 
the clinical aspects of the project were addressed. 
 
Dr Raquel Duarte for providing me with laboratory space and experimental help with the 
Nanostring instrumentation. 
 
Dr Karminee Maduray ensuring that sample collection was completed on time. 
 
Miss Zinhle Mkhize for the collection of blood samples. 
 
Dr Mogie Singh for access to her facility and the use of the NanoSight500 for Nanoparticle 
tracking analysis.   
 
Professor Thirumala Govender for access to her facility and the use of the ultracentrifuge. 
 
Mr Subashen Naidu from the UKZN Electron Microscopy unit for assistance with the 
transmission and scanning electron microscopy. 
 
Miss Prathna Dudhraj for ensuring that the research and registration process was as efficient 
as possible.  
 
The National Research Foundation for funding the project, financial support and access to 
specialised facilities/equipment.  We would not have achieved these outcomes without this. 
 
 
 
 
 
 
 
 
 
1 
 
Table of Contents 
Declaration…………………………………………………………………………………..…….....…i 
Publications and Presentations……………………………………………………………..………...ii 
Statement…………………………………………………………………………………….………..iii 
Acknowledgements…………………………………………………………………………………...iv 
Table of Contents…………………………………………………………………………………........1 
List of Tables…………………………………………………………………………………………...3 
List of Figures……………………………………………………………………………………….....4 
Abstract (Engish).……………………………………………………………………………………...5 
Abstract (isiZulu)……………………………………………………………………………………...6 
1. Chapter One: Introduction and Literature Review……………………………….………..…......7 
1.1 Preeclampsia: A Hypertensive Disorder of Pregnancy………………………….…….….……...8 
1.2 Etiopathogenesis of Preeclampsia…………………………………………………………..….....9 
1.2.1 Unifying Theory……………………………………………………………..…..…..…...9 
1.2.2 Angiogenic factors associated with the pathophysiology of preeclampsia …….…......…12 
1.2.2.1 Soluble fms-like kinase-1, Placental Growth Factor & Vascular  
Endothelial Growth Factor (VEGF)…………..…………………………………….. 12 
1.2.2.2 Soluble Endoglin………….…………………………………….….………...13 
1.2.3 Cytokines in Preeclampsia………………………………………………………………13 
1.2.4 MicroRNAs in the pathophysiology of Preeclampsia………………………..…....…….14 
1.2.5 Extracellular vesicles in the pathophysiology of Preeclampsia………………...….…….16 
1.3 Exosome Morphology and Biogenesis………………………………………………..…...……..17 
1.3.1 Morphology…………………………………………………………………..….……...17 
1.3.2 Biogenesis of Exosomes………………………………………………..….…….……...18 
1.4 Exosomes in normal and preeclamptic pregnancies……………………………..………..……20 
1.4.1 Exosomes in Pregnancy………………………………………………………...……20 
1.4.2 Exosomes in Preeclampsia………………………………………………..…….……20 
1.5 Association of Highly Active Antiretroviral Therapy and Preeclampsia……………...............21 
1.6  Purpose of the study…………………………………………………………………………..….22 
2. Chapter Two: Manuscript One………………………………………..…………...………….….25 
2.1 Placental-Derived Exosomes: Potential Biomarkers of Preeclampsia (Published:     
       International Journal of Nanomedicine. 2017:12. Pages 8009-802) 
3. Chapter Three: Manuscript Two………………………………………………...…………….…26 
3.1 Exosomal microRNA profiling in early and late onset pre-eclamptic pregnant women  
      reflects pathophysiology. (Accepted: International Journal of Nanomedicine. 2019) 
 
2 
 
 
4. Chapter Four: Manuscript Three………………………………………………………………...27 
4.1 Exosomal Th1/Th2 Cytokines in Preeclampsia and Human Immunodeficiency Virus (HIV)-positive 
Preeclamptic Women on Highly Active Anti-Retroviral Therapy 
5. Chapter 5: Synthesis……...……………………………………………………..…………………28 
5.1 Synthesis………...……………………………………………………………….…………..……28 
5.2 Conclusion……………………………………………………………………….…......…………31 
5.3 Recommendations………………………………………………………………………..………32 
6. References…………………………………………………………………………….……………33 
7. Appendices…………………………………………………………………………………………38 
7.1 Human Ethics Approval………………………………………………………………….............38 
7.2 Hospital Approval…………………………………………………………………....…………..39 
7.3 South African Department of Health Approval……………………………….………………..40 
7.4 Placental exosomes and pre-eclampsia: Maternal circulating levels in normal   
      pregnancies and, early and late onset pre-eclamptic pregnancies.  
      (Published: Placenta. 2016: 45, Pages 18-25)………………….………………...……..41 
 
7.5 Placental Hypoxia Inducible factor −1α & CHOP Immuno-histochemical expression  
      Relative to Maternal Circulatory Syncytiotrophoblast Micro-vesicles in  
      Preeclamptic and Normotensive Pregnancies. (Published: European Journal of  
      Obstetrics and Gynecology, 2017:220, Pages 18-24)…………………………...……...42 
 
7.6 Circulatory Levels of Tumor Necrosis Factor-α, Interleukin-6 and  
       Syncytiotrophoblast Microvesicles in the First Trimester of Pregnancy.  
       (Published: Clinical and Experimental Obstetrics and Gynecology. 2018: 45(4),     
        Pages 575-581)………….………………………………………………………………43 
 
 
 
 
 
 
 
 
 
 
 
3 
 
List of Tables 
 
Table 1. Placenta-associated microRNAs involved in preeclampsia ……….……..14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
List of Figures 
 
Figure 1.  Current Understanding of the Etiopathogenesis of Preeclampsia….……..…..10 
Figure 2. Abnormal Placentation and Preeclampsia……………………………..……...11 
Figure 3.  The Th1/Th2 cytokine-mediated maternal immune balance in normal  
Pregnancy and in Preeclampsia……………………………………………….14   
 
Figure 4.  Subtypes of Syncytiotrophoblast Microvesicles…………………….……….17 
Figure 5.  Exosome Morphology……………………………………………..………...18  
Figure 6.  Intracellular mechanisms involved in exosome biogenesis…….…….………19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
Abstract (English) 
 
Preeclampsia is a hypertensive disorder of pregnancy and one of the leading causes of maternal 
and perinatal morbidity, affecting up to 7 -10% of pregnancies globally which results in 50 000-
76 000 maternal deaths per  year worldwide.  Preeclampsia remains an enigmatic phenomenon 
due to its unknown etiology.  This is attributed to its multifactorial nature, which complicates 
clinical diagnosis and management, hence the need for a definitive biomarker.  Several 
candidate biomarkers of preeclampsia have been identified but none have the potential to 
diagnose preeclampsia in early pregnancy.  Exosomes have recently emerged as promising 
biomarkers of the disease and the present study, therefore, focuses on determining the context 
of the use of exosomes as biomarkers of preeclampsia. In our approach, we developed a 
theoretical framework for the evaluation of exosomes as potential biomarkers of preeclampsia 
in terms of the specified criteria defined by the Food & Drug Administration (US) (FDA) 
Biomarker Workgroup.  This subsequently led to the evaluation of the context of use of 
exosomes as biomarkers of preeclampsia by determining the role of exosomal microRNA in 
the pathophysiology of preeclampsia using direct digital detection, computational algorithms 
and biological databases. We identified distinct exosomal miRNAs signatures involved in the 
aberrant pathophysiology of preeclampsia which serve as promising biomarkers.  Furthermore, 
in terms of the FDA criteria, it is important to incorporate the intent-to-diagnose preeclampsia 
in combination with comorbidities associated with the increased susceptibility/risk of 
preeclampsia. It is clinically evident that HIV-positive pregnant women on (Highly Active 
Antiretroviral Therapy) HAART are at a greater risk of developing preeclampsia due to an 
unknown immune-related pathology caused by HAART.  We, therefore, determined the 
potential diagnostic application of exosomal cytokines in preeclamptic and HIV-positive 
preeclamptic women on HAART.  In doing so we have identified altered exosomal cytokine 
levels in both preeclampsia and HIV-positive pregnant women, which suggests an aberrant 
mechanism of exosomal cytokine encapsulation, which modulates immune responses in both 
disease states.  Importantly, we show that exosomal Tumor necrosis factor alpha (TNF-α) may 
have clinical validity in diagnosing preeclampsia and preeclampsia in HIV-infected pregnant 
women.   
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Abstract (isiZulu) 
 
I-preeclampsia iyinkinga ephezulu yokukhulelwa kanye neyodwa yezimbangela ezibangela 
ukugula komama nokubeletha, okuphazamisa ama-7 -10% wezokukhulelwa emhlabeni wonke 
okuholela ekufeni kwabantu abangu-50 000-76 000 emhlabeni wonke. I-preeclampsia iyisici 
esiyinkimbinkimbi ngenxa ye-etiology engaziwayo. Lokhu kubangelwa uhlobo 
olunezinhlobonhlobo zezinto ezihlukahlukene, okubandakanya ukuxilongwa nokuphathwa 
kwemitholampilo, ngakho-ke isidingo se-biomarker ecacile. Kunezimboni eziningana ze-
preeclampsia ezikhethwe yi-candidate kodwa azikho ongakwazi ukuhlolisisa i-preeclampsia 
ekukhulelwe kokuqala. Ama-Exosome asanda kuvela njengezicikumezi ezithembisayo zesifo 
futhi isifundo samanje, sigxile ekunqumeni umongo wokusetshenziswa kwama-exosomes 
njengama-biomarkers we-preeclampsia. Endleleni yethu, sathuthukisa uhlaka lwezinhlelo 
zokuhlola ama-exosomes njengama-biomarkers angaba yi-preeclampsia ngokwemigomo 
ebekiwe echazwe yi-Food & Drug Administration (US) (FDA) Biomarker Workgroup. Lokhu 
kwaholela ekuhlolweni kokusetshenziswa kwama-exosomes njengama-biomarkers of 
preeclampsia ngokunquma indima ye-exosomal microRNA ekuziphatheni kwe-preeclampsia 
esebenzisa ngokuqondile ukutholakala kwedatha, ukuhlelwa kwezinto zokusebenzisa izibalo 
kanye nolwazi lwezinto eziphilayo. Sithole amasignesha ama-miRNA ahlukile asebenzayo ku-
perosis of preeclampsia esebenza njengama-biomarkers athembisayo. Ngaphezu kwalokho, 
ngokwemigomo ye-FDA kubalulekile ukufaka i-preeclampsia ye-inten-to-diagnostic 
ngokubambisana nama-comorbidities ehambisana nokwehluleka / ukulimala kwe-
preeclampsia. Kuyabonakala emitholampilo ukuthi abesifazane abane-HIV abakhulelwe (i-
Highly Active Antiretroviral Therapy) i-HAART ingengozini enkulu yokuthuthukisa i-
preeclampsia ngenxa yokugula okungaziwa komzimba okubangelwa i-HAART. Ngakho-ke, 
sinquma ukuthi kungenzeka yini ukuhlolwa kwesifo se-cytokines exosomal ku-preeclamptic 
nakwabesifazane abane-HIV ngaphambili kwe-HAART. Ngokwenza kanjalo sesiye sabona 
amazinga e-cytokine ashintshiwe eguquguqukayo kokubili preeclampsia nabesifazane 
abakhulelwe abane-HIV, okusikisela indlela engavamile yokukhipha i-exosomal cytokine 
encapsulation, eyenza ukuthi izimpendulo zamasosha omzimba zisetshenziswe. Okubaluleke 
kakhulu, sibonisa ukuthi i-tumor necrosis factor alpha (TNF-α) ingaba nokusebenza 
komtholampilo ekuhloleni i-preeclampsia kanye ne-preeclampsia kwabesifazane abakhulelwe 
abane-HIV.  
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1. Chapter One: Introduction and Literature Review 
 
Preeclampsia (PE), a pregnancy-specific systemic inflammatory syndrome which affects 7-
10% of pregnant women globally, is commonly characterised by new-onset hypertension and 
proteinuria after 20 weeks of gestation [1, 2]. Reports indicate that the incidence of pre-
eclampsia, perinatal death and preterm delivery in women is higher in South Africa in 
comparison to other low- and middle-income countries, despite access to tertiary care [3].  
Preeclampsia remains one of the leading causes of maternal and foetal morbidity and mortality 
due to its unknown etiopathophysiology [4] and to its lack of biomarkers for early detection.  
Although the exact etiology of PE is unknown, the pathophysiology [4, 5], is believed to 
originate in the placenta, due to improper and shallow trophoblast invasion in early pregnancy 
[1, 6] leading to the maternal clinical symptoms observed. 
 
Reports indicate that the cause of placental maladaptation is due to several factors [7], however, 
the specific and collective role of these factors in the etiology and pathogenesis of PE remains 
elusive, which makes it difficult to ascribe biomarker status for early detection of preeclampsia. 
This further complicates the clinical management and contributes to maternal and foetal 
morbidity and mortality. Placental ‘particles’ viz. syncytiotrophoblast microvesicles (STBMS) 
have been reported to be the central link between the placental maladaptation and the systemic 
manifestation of PE. However, more recently exosomes, a sub-constituent of STBMS, have 
been identified as a possible factor involved in the etiology and pathogenesis of PE [8, 9]. 
Exosomes contain cellular derived ‘molecular cargo’, including membrane-bound proteins, 
cytosolic RNA and lipids, which are reported to be involved in transferring specific biological 
codes in mediating physiological as well as disease processes [10]. 
 
In a preliminary study, undertaken in 2016, we identified increased exosomes in PE [11]. It is 
these characteristics and findings, which make exosomes promising biomarkers of PE; 
however, there is still limited evidence supporting their role in the pathogenesis of PE.  This, 
therefore, necessitates research into unravelling the nature and characteristics of exosomes in 
the pathogenesis of preeclampsia, based on an internationally regulated framework to facilitate 
their clinical application as biomarkers. 
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1.1 Preeclampsia: A Hypertensive Disorder of Pregnancy  
 
Hypertensive disorders of pregnancy (HDP) account for approximately 10% of pregnancy-
related complications and are a major cause of maternal/perinatal morbidity and mortality [12].  
Hypertensive disorders in pregnancy can be classified into four groups: (1) Preeclampsia and 
eclampsia (2) Chronic hypertension (of any cause) (3) Chronic hypertension with 
superimposed preeclampsia and (4) Gestational hypertension. Preeclampsia (PE),  the 
predominant HDP, is associated with a greater risk of foetal and maternal morbidity [13].  
Preeclampsia is defined as new onset hypertension with proteinuria [13, 14] and in the absence 
of proteinuria, it can be identified as hypertension in conjunction with thrombocytopenia, 
impaired liver function, new onset renal insufficiency, pulmonary oedema, or new onset 
cerebral or visual disturbances [12]. 
 
Preeclampsia can be sub-categorised into early- and late-onset [14-17], due to the differences 
in the timing and severity of the clinical manifestation [16].  Early-onset pre-eclampsia (EOPE) 
is defined by new onset hypertension at < 33 weeks plus 6 days of gestation and, late-onset 
pre-eclampsia (LOPE) defined by new onset hypertension > 34 weeks of gestation [15-17]. 
Although the clinical features of EOPE and LOPE overlap, they are associated with different 
maternal and foetal outcomes. 
 
Early-onset PE occurs in approximately 5-20% of PE cases and is closely associated with the 
placental maladaptation due to the restriction of blood flow as a result of inadequate trophoblast 
invasion and transformation of spiral arteries [15, 17].  This results in poor foetal development 
thereby causing the more severe clinical outcomes associated with EOPE. In contrast, LOPE 
occurs in 8-75% of PE [18] cases and is associated with normal placental volume and weight 
of newborns [19].  In addition, LOPE is associated with more favourable maternal and neonatal 
outcomes and the possibility of pregnancy prolongation.  One of the major differences between 
the PE subtypes is that EOPE is usually complicated by intrauterine growth restriction (IUGR), 
which may be a consequence of the severe placental maladaptation associated with EOPE [24] 
in comparison to LOPE. Additionally, there are distinct differences in placental pathological 
features between the PE subtypes [20]. Early onset PE is more closely associated with 
uteroplacental lesions and placental malperfusion in comparison to LOPE [21] due to the 
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uteroplacental spiral artery maladaptation in early pregnancy, resulting in oxidative stress and 
infarction which damages placental tissue [22].  Since EOPE and LOPE both result from 
malperfusion, with different causes, it is critical that the subtypes are studied as separate entities 
due to the differences in their etiopathophysioloy. 
 
While the pathogenesis of PE and its subtypes are partially understood, the etiology of 
preeclampsia remains unclear.  The difficulties in unravelling this disorder are attributed to the 
multiple maternal and foetal factors which contribute to the placental maladaptation [4, 5].  
Extensive research has focused on various biological factors involved in the preeclampsia 
disease pathway including identification of maternal and foetal factors, which may serve as 
potential biomarkers of preeclampsia.  Identification of key biological factors in preeclampsia 
would enable definitive clinical diagnosis/prognosis in early pregnancy and serve as a useful 
screening tool. This could lead to the development of strategies that would enable early 
therapeutic intervention in this disorder. 
 
1.2 Etiopathogenesis of Preeclampsia 
1.2.1 Unifying Theory 
Although there have been recent advances in understanding the etiopathogenesis of PE, the 
pathophysiology triggering the disease is not fully understood. Nevertheless, preeclampsia is 
believed to originate in the placenta due to abnormal placentation [11]. Based on current 
literature, the etiopathogenesis of PE can be segmented into two parts (i.e. pre-clinical and 
clinical phase) consisting of six stages (Fig. 1). The pre-clinical phase (Stages 1-3) occurs in 
the first half of pregnancy and is characterised by poor placentation whereas the clinical phase 
(Stages 4-6) occurs in the second half of pregnancy and is characterised by the hypoxic placenta 
which results in the clinical manifestations of PE. 
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Figure 1: Current Understanding of the Etiopathogenesis of Preeclampsia.  The figure 
represents the etiopathogenesis of PE as a disorder occurring in two phases with six stages 
which contribute to the disease progression.  This model is based on theoretical principles 
presented by (Redman, 2014: [23]). 
 
In the preclinical stage of PE, it is hypothesised that the maternal immune response to paternal 
antigens contributes to abnormal embryogenesis and implantation which subsequently leads to 
abnormal placentation caused by inappropriate extravillous trophoblast invasion (Fig 2). This 
ultimately leads to the clinical phase whereby the stressed placenta releases excessive or 
insufficient quantities of biological factors (i.e antiangiogenic protiens, signaling molecules 
and nucleic acids) which contribute to the maternal endothelial dysfunction, resulting in the 
clinical manifestation of PE [24].  On the contrary, in normal pregnancy, placentation results 
in structural alterations which are associated with physiological processes whereby the 
placental spiral arteries are modified to become low-resistance vessels, and thus they are less 
sensitive to vasoconstrictive substances [5]. This is a carefully controlled process, involving 
tightly regulated molecular mechanisms, thereby ensuring appropriate cytotrophoblast 
invasion which is a requirement for proper spiral artery remodelling during pregnancy (Fig 2). 
Pre-Clinical Phase (First Half of Gestation) 
Stage 1  
Conception challenges due to the lack of maternal 
tolerisation of paternal antigens. 
Stage 2  
Poor Embryo Development due to preimplantation 
challenges. 
Stage 3 
Defective placentation due to inappropriate cytotrophoblast 
invasion. 
Clinical Phase (Second Half of Gestation) 
Stage 4 
Excessive or deficient synthesis of placentally 
derived factors in the mother’s blood, secondary to 
placental damage, a precursor to the appearance of 
clinical symptoms. 
Stage 5 
Clinical Manifestation of Preeclampsia 
Stage 6 
Acute atherosis due to spiral artery lesions. 
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Figure 2: Abnormal Placentation and Preeclampsia.  (A) During normal placental 
development, the foetal cytotrophoblasts invade the maternal spiral arteries, converting them 
from high to low resistance vessels capable of providing adequate placental perfusion to sustain 
the growing foetus.  (B) In preeclampsia, cytotrophoblasts fail to invade the maternal spiral 
arteries.  Instead, invasion of the spiral arteries is shallow and they remain high resistance 
vessels (Powe et al., 2011:[25]). 
 
Although the cause of PE remains unknown, evidence supports the immunological origin of 
PE due to the inability of the mother to accommodate the genetic foreignness of her unborn 
child [26].  Reports suggest that the trophoblast signaling to decidual immune cells in PE is 
weak and fails to stimulate collaboration, which is essential for placentation [1]. The current 
theoretical understanding of this phenomenon suggests that it may be due to the unknown link 
between the primary placental causes and the secondary maternal systemic inflammatory 
response in the third trimester of pregnancy, which may be triggered by a single or a cohort of 
defined and undefined biological factors (i.e antiangiogenic protiens, signaling molecules and 
nucleic acids) [27-32]. 
 
Although the immunological basis for PE has been assessed in terms of the maternal response 
to pro- and anti-inflammatory cytokines [7, 9, 32], the role of dNK (decidual Natural Killer) 
A 
B 
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cells have recently emerged as central factors involved in the etiopathogenesis of PE.  The 
uterus contains immune cells consisting of approximately 70% of dNK cells, which have 
unique properties involved in regulating placental immunity and development during 
pregnancy [33, 34]. Previous studies have shown the beneficial function of dNK cells in the 
remodelling of placental vasculature and the recruitment of trophoblasts at the maternal-foetal 
interface in normal pregnancy [33, 35-37] which occurs through carefully regulated receptor 
interactions between dNK and trophoblast cells [34]. Therefore, defective communication 
between trophoblasts and dNK cells may provide insight into the etiopathogenesis of 
preeclampsia.  The exact mechanisms involved in this process remain unknown. 
 
1.2.2 Angiogenic factors associated with the pathophysiology of preeclampsia 
Angiogenic factors, antiangiogenic factors, and cytokines have been identified as modulators 
of PE pathogenesis and serve as potential biomarkers of the disease [4-10].  To date, combined 
biomarkers, Soluble Flt-1(sFlt) and Placental Growth Factor (PIGF) are of clinical significance 
in the diagnosis of overt preeclampsia in the late second trimester of pregnancy [8-11]. Even 
though these biomarkers may be effective, there is still a clinical need for the diagnosis of PE 
in early pregnancy. 
 
1.2.2.1 Soluble fms-like kinase-1, Placental Growth Factor & Vascular Endothelial 
Growth Factor 
The widespread endothelial cell dysfunction associated with preeclampsia occurs in response 
to ischemic or hypoxic conditions resulting in the release of circulating placental pro- and anti-
angiogenic factors which modulate the pathogenesis of PE [38]. Soluble fms-like kinase-1 
(sFlt-1) has emerged as one of the key anti-angiogenic proteins involved in the pathophysiology 
of PE by inhibiting the activity of pro-angiogenic vascular endothelial growth factor (VEGF) 
and Placental Growth Factor (PlGF) produced by invasive cytotrophoblasts [39]. 
 
PlGF has the ability to enhance the actions of VEGF by binding to the Flt-1 receptor, 
subsequently sequestering those binding sites and forcing VEGF to bind to Flt-1 instead [40], 
which is important for VEGF’s proliferative activity [41].  Therefore, the co-expression of 
VEGF or PlGF has the ability to modulate blood pressure [42].  Furthermore, since clinical 
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studies have shown that a decrease in circulating levels of PlGF correlated with the increased 
sFlt-1 and decreased VEGF, in PE women [43] these factors, therefore, have a key role to play 
in the pathophysiology of preeclampsia.  Moreover, since circulating levels of sFlt-1 and PlGF 
are dysregulated in PE women, the ratio between these factors has been shown to reflect the 
pathogenesis of PE [44]. Therefore, the sFlt-1/ PlGF ratio is a promising biomarker of PE but 
at very high cut-off values, which mostly has application in the late second trimester of 
pregnancy. 
 
1.2.2.2 Soluble Endoglin 
Soluble endoglin (sEng) is a glycosylated transmembrane protein, which acts as an auxiliary 
receptor of several members of the TGF-β superfamily of proteins [45].  Additionally, it has a 
role in regulating angiogenesis and has been shown to be highly expressed in endothelial and 
syncytiotrophoblast cells [46]. Notably soluble endoglin (sEng) is elevated in the sera of 
preeclamptic individuals, and correlates with disease severity and falls after delivery, 
supporting its role in the pathophysiology of PE.   The increased expression of soluble endoglin 
contributes to the pathophysiology of PE by inhibiting TGF-β1 binding, which results in the 
dysregulation of endothelial cell proliferation and tubule formation in PE [47]. 
 
Several in vivo studies have shown that sEng, led to a severe preeclamptic phenotype in mice 
due to the manifestation of foetal growth restriction, proteinuria and hypertension [25, 47, 48]. 
In addition, low platelet levels and elevated lactate dehydrogenase was observed,  both of 
which are hallmarks of the manifestation of haemolytic anaemia, elevated liver enzymes, low 
platelet count (HELLP) in severe preeclampsia [49].  These findings directly implicate sEng as 
a factor involved in the pathogenesis of PE. 
 
 
1.2.3 Cytokines in Preeclampsia 
Recent research has shown that cytokines are involved in several pregnancy-related events such 
as ovulation, implantation, placentation, and parturition, which are critical requirements for 
successful pregnancy [51].  Granulocyte-macrophage-colony-stimulating factor (GM-CSF), 
colony-stimulating factor-1 [53], IL-4 [54], IL-10 [55], IL-2, TNF-α and IFN-γ [56] are key 
cytokines involved in ensuring successful pregnancy, however, their dysregulation is 
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associated with the pathophysiology of PE [52].  Numerous studies have supported the role of 
cytokines in the pathogenesis of PE in early placentation and in the clinical manifestation of 
the disorder [50-52]. These studies have shown that increased levels of pro-inflammatory Th1 
cytokines (IL-2, TNF-α, and IFN-γ) induce several cell-mediated cytotoxic and inflammatory 
reactions in PE pathogenesis. In addition, Th2 anti-inflammatory cytokines (IL-4, IL-5 and IL-
10) are commonly decreased in PE which promotes the proinflammatory state [52].  Moreover, 
cytokine levels in maternal circulation remain controversial as the exact source and mechanism 
of release remains unknown. What is known however is that these cytokines are released in a 
controlled ratio which is shifted towards Th2-type immunity in normal pregnancy, whereas an 
intensified shift towards Th1 immunity is associated with PE (Fig 3) [59]. 
 
 
 
Figure 3. The Th1/Th2 cytokine-mediated maternal immune balance in normal 
pregnancy and Preeclampsia.  The proinflammatory Th1 immune response is responsible for 
extravillous trophoblast invasion, parturition, and host defence. The anti-inflammatory Th2 
reaction is crucial for tolerance to the foetus, decidualisation, and remodelling. Imbalance of 
immune response will lead to adverse pregnancy outcomes such as preeclampsia and 
miscarriage. Th1 indicates type 1 CD4+ helper T (Yeh et al., 2013: [59]). 
 
1.2.4 microRNAs in the pathophysiology of Preeclampsia 
Over recent years, miRNAs have emerged as central role players in the pathophysiology of 
preeclampsia since numerous studies have linked the aberrant expression of several miRNAs 
with PE and other pregnancy-related complications [60, 61]. MicroRNAs are small (~22–
25 nt), non-coding, single-stranded RNAs which preferentially regulate gene expression. They 
are regulatory molecules, which play an important role in the post-transcriptional regulation of 
gene expression by instigating translational inhibition or cleavage of mRNA that silences gene 
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expression [62]. MicroRNAs are involved in critical cellular processes such as cell 
differentiation and migration. Therefore, they contribute to the biological aspects of pregnancy 
and related complications such as PE by regulating key processes such as immune tolerance, 
inflammation, apoptosis and angiogenesis [63]. Recently a number of miRNA have been 
isolated from placental tissue (Table 1). These have been found to be linked to the 
pathophysiology of PE and pregnancy, however, the exact mechanism of miRNA cellular 
discharge and the manner in which they contribute to endothelial dysfunction and hypertension 
in pregnancy remains unknown. However, it is proposed in this study that the cytokines and 
miRNA involved in the pathogenesis of PE may be encapsulated in microvesicles which serve 
as a mechanism of delivery to distant or target cells. 
 
Table 1: Placenta-associated microRNAs involved in preeclampsia. 
Function miRNAs involved Known targets/pathways 
Angiogenesis miR-16, miR-29 Vascular endothelial growth factor 
(VEGF)-A 
  
miR-494 CDK6/CYCD1 
 
miR-17 miR-20a, miR-20b Ephrin B2, B4 
 
miR-125b-1-3p S1PR 
 
miR-155 CYR 6, VEGF-A 
 
miR-21 PTEN, positive regulator of VEGF-A 
and HIF-1α 
 
miR-210 EFNA3, HOXA9, HSD17 
      
   
Trophoblast proliferation miR-16, miR-29b Inhibits trophoblast proliferation 
    
miR-34a SERPINA3 
  
miR-210 KCMF-1 
  
miR-155 CYCD1 
  
miR-378a-5p, miR-376c, miR-
21 
Promotes trophoblast proliferation by 
nodal signaling pathway 
 
miR-17-92 cluster Differentiation of primary trophoblasts 
Bounds et al., (2017:[63]) 
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1.2.5 Extracellular vesicles in the pathophysiology of Preeclampsia 
 
Syncytiotrophoblast microvesicles (STBMs) are directly released from the placenta into 
maternal circulation and consist of a variety of microvesicles of different sizes and functional 
properties (Fig. 4) [64]. These include exosomes (30–100 nm), apoptotic bodies (1–5 µm) and 
syncytial nuclear aggregates (20–500 µm) which are released by syncytiotrophoblast cells of 
the placenta [7, 64].  Previous studies have identified STBMs as key factors involved in 
immune modulation, angiogenesis and endothelial dysfunction in pregnancy and PE [9, 65]. 
According to Redman & Sargent (2005), oxidative stress, as a result of abnormal placentation, 
induces the release of ‘placental debris’ which stimulates apoptosis and necrosis, resulting in 
an exaggerated maternal systemic inflammatory response (MSIR) [1, 9]. In addition, these 
authors claim that the normal process of regeneration of syncytiotrophoblast cells of the 
placenta is dependent on cellular apoptosis, which is modulated by placental microvesicles 
which activate the maternal endothelium [66]. 
 
Syncytiotrophoblast microvesicles have been reported to provoke a balanced MSIR in normal 
pregnancies, but, in PE, the increase in placental debris contributes to the pathogenesis by 
enhancing the MSIR [9, 32, 67]. Moreover, recent scientific evidence suggests that exosomes, 
a key constituent of STBM’s, may play a significant role in the etiology and pathogenesis of 
PE due to their role in feto-maternal immune tolerance and endothelial cell migration [68-70]. 
Scientific evidence to support this hypothesis is currently emerging [1].  Research within our 
group in collaboration with others is underway to validate STBMs and its constituent (i.e. 
exosomes) as an early biomarker of PE. 
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Figure 4: Subtypes of Syncytiotrophoblast Microvesicles. Exosomes (30–100nm) are 
produced from reverse budding of the endosome membrane, resulting in a multivesicular body, 
which fuses with the plasma membrane of the cell and releases exosomes by exocytosis. 
Microvesicles (100nm–1µm) are produced by direct budding of the plasma membrane in 
response to stimuli that trigger an increase in intracellular calcium levels. Apoptotic bodies (1–
5µm) are released from cells undergoing apoptosis, while syncytial nuclear aggregates (20–
500µm) are released from the syncytiotrophoblast on the placental surface. (Tannetta et al., 
2013:[7]). 
 
1.3 Exosome Morphology and Biogenesis 
1.3.1 Morphology 
Exosomes are a constituent of STBMs, which fall within the smaller size spectrum of about 20 
– 130nm [17-19].  These nanovesicles serve as vehicles for the transfer of ‘exosomal cargo’ 
which consist of nucleic acids, cytosolic and membrane-bound proteins, and lipids (Fig 5C).    
These vesicles function mainly by communicating with cells to re-programme their phenotype 
and regulate cell function [71, 72]. Exosomes have a defined morphology (Fig 5A and B) and 
are synthesised by several cell types such as hematopoietic cells, epithelial cells, neural cells, 
adipocytes, fibroblasts, stem cells, tumour cells, as well as the syncytial cells of the placenta 
[65]. These vesicles are found in biological fluids such as blood, urine, saliva, breast milk, 
mucus and cerebral spinal fluid [73]. The key physiological function of exosomal cargo is to 
stimulate cell-to-cell communication, and hence serve as mediators in biological processes 
[74]. Cellular communication is complex and is an essential requirement for normal cellular 
functioning. If the normal cellular function is disrupted it may result in pathological states such 
as cancer, autoimmunity and diabetes [75-77]. 
 
18 
 
 
pote 
 
 
 
 
 
 
 
 
 
Figure 5. Exosome Morphology. Morphological characterisation of exosomes isolated from 
maternal circulation by (A) Transmission Electron Microscopy (TEM) and (B) Scanning 
Electron Microscopy (SEM). Electron microscopy reveals the structure of exosome-like 
vesicles from the plasma of pregnant women. For TEM the purified exosomes were fixed, 
stained with 2% uranyl acetate and analysed using electron microscopy. SEM samples were 
dropped cast and air dried before analysis. Scale bar, 100 nm (original magnification X45 K).  
(C) Illustration of the types of molecular cargo associated with exosomes [78]. 
 
1.3.2 Biogenesis of Exosomes 
 
The exact cellular mechanisms involved in the biogenesis of exosomes is unknown. 
Nevertheless, it has been shown that the Endosomal Sorting Complex Required for Transport 
(ESCRT) machinery and associated proteins (MHC class II) are involved in protein sorting and 
the formation of the intraluminal vesicles (ILVs) destined to be secreted as exosomes [79]. The 
ESCRTs consist of twenty proteins that agglomerate into four soluble complexes (i.e. ESCRT 
0, I, II & III). These complexes have associated proteins such as VPS4 (Vacuolar protein 
sorting-associated protein 4), VTA1 (Vesicle tracking associated protein 1) and ALIX (ALG-
2-interacting protein X) [80, 81]. 
 
Figure 6 illustrates the pathway of exosome biogenesis. Endosomal sorting complex required 
for the transport-0 complex is involved in endocytosis and the recruitment of ubiquitinated 
proteins on the cell surface [82]. Endosomal sorting complex required for transport I & II, work 
A C 
B 
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in homeostasis in late endosomal formation by co-ordinating membrane budding & scission 
and ESCRT III is responsible for the fusion of MVB’s with the cell wall to release exosomes 
via exocytosis [83]. Exosomes usually contain a variety of molecules that are native to the 
originating cell and are enriched with endosome-associated protein markers such as RAB 
proteins (Ras-related proteins), ALIX, TSG101 (Tumor susceptibility gene 101) and endocytic 
proteins which provide definitive information about their origin [73]. Further understanding of 
the molecular mechanisms of exosome biogenesis will lead to resolving the complexities of 
many diseases such as PE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Intracellular mechanisms involved in exosome biogenesis. Schematic 
representation of the origin and release of exosomes by eukaryotic cells. Exosomes are 
formed as intraluminal vesicles (ILVs) by budding into early endosomes and MVBs. Several 
molecules are involved in the biogenesis of ILVs, such as the ESCRT machinery, lipids (such 
as ceramide) and the tetraspanins. It is still unknown whether these mechanisms act 
simultaneously on the same MVB or on different MVBs. The fate of MVBs can be either fusion 
with lysosomes or fusion with the plasma membrane, which allows the release of their content 
to the extracellular milieu. Several RAB proteins (RAB11, RAB27 and RAB35) have been 
shown to be involved in the transport of MVBs to the plasma membrane and in exosome 
secretion (Alenquer & Amorim, 2014: [84]). 
 
 
 
 
 
 
Endoplasmic 
Reticulum   
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1.4 Exosomes in normal and preeclamptic pregnancies 
1.4.1 Exosomes in Pregnancy 
 
Pregnancy has often been described as an immunological challenge to the maternal immune 
system, as it entails a foeto-maternal co-existence which has been described as a ‘paradox of 
nature’ [70]. Whilst, there is no single unifying theory for maternal tolerance to the foetus, this 
adaptation requires a balance of maternal and foetal factors, essential for successful pregnancy 
[85].  Factors such as cytokines, angiogenic proteins and STBM’s, have been shown to have a 
role in the foeto-maternal immune balance as well as the maintenance of placental vasculature 
[25, 85, 86]. 
 
More recently, exosomes have emerged as key biological factors in pregnancy, as they are 
involved in intracellular signalling which may be responsible for maternal immune adaptation 
[87]. In normal pregnancies, it has been reported that placental-derived exosomes with no 
associated pathologies are biologically active molecules with a regulatory role in endothelial 
cell migration [88, 89]. Additionally, placental-derived exosomes in maternal circulation are 
known to increase with gestational age and has been shown to be directly correlated with 
endothelial cell migration in the first trimester. However, in the second and third trimester of 
pregnancy, the lower ratio of placental-derived exosomes to total exosomes in maternal 
circulation results in the inhibition of endothelial cell migration [88, 89]. 
 
1.4.2 Exosomes in Preeclampsia 
 
Under pathological conditions, the dysregulation of the biogenesis of exosomes results in target 
cell dysfunction, which directly influences cellular activities such as angiogenesis, translational 
activity, proliferation, metabolism and apoptosis [90]. Since exosomes are central factors 
involved in cellular signalling in normal pregnancies, it is possible that their dysregulation is 
involved in the etiopathology of preeclampsia. Importantly, exosomes released from the 
hypoxic placenta could increase circulating levels of exosomes in maternal plasma. Placental- 
or maternal-derived exosomes in maternal circulation could result in endothelial dysfunction, 
resulting in the clinical manifestations of preeclampsia. The identification of new proteins and 
biomolecules in placental-derived exosomes are of considerable interest for early diagnostic, 
drug delivery and therapeutic applications. 
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It is known that preeclampsia is a disorder that originates in the placenta, as a result of poor 
placentation due to inadequate trophoblast invasion, with the exact cause of this maladaptation 
being unknown [24].  Exosomes could be involved in this maladaptation, due to their role in 
cell signalling. Therefore, determining its role in preeclampsia could provide valuable insight 
into its pathogenesis and serve as an early definitive biomarker. Importantly, the exosomes 
released from the hypoxic placenta could increase the levels of circulating exosomes in 
maternal plasma. These circulating exosomes could affect the endothelial cells and therefore 
result in the manifestation of the clinical symptoms of the disease. 
 
In our preliminary experiments, we have identified a dysregulation in the relative concentration 
of placental-derived exosomes in early and late onset preeclampsia [11]. Our data indicate that; 
(i) the concentration of total exosomes are significantly increased in early and LOPE (p<0.05)  
(ii) The concentration of Placental Alkaline Phosphatase (PLAP+) exosomes significantly 
increases in early onset pre-eclampsia (p<0.05) but decreases in LOPE (p<0.05)  (iii) The ratio 
of PLAP+ exosomes to the total number of exosomes significantly decreases in EOPE (p<0.01) 
and LOPE (p<0.05) (iv) A positive correlation between the CD63+ and PLAP+ exosomes was 
obtained in normotensive pregnancies (r = 0.60, p<0.05) and EOPE (r = 0.51, p<0.05) with the 
inverse in LOPE (r = -0.62, p<0.001).  These findings obtained may relate to the dissimilarities 
in the etiology of the two subtypes, suggesting that placental-derived exosomes could play a 
pathological role in PE.  Our findings, therefore, form the rationale for the determination of the 
role of placental-derived exosomes in PE and suggests that exosomes may be a useful 
tool/biomarker for the prognosis/diagnosis of PE. 
 
1.5 Association of Highly Active Antiretroviral Therapy and Preeclampsia 
It is well known that untreated pregnant women with HIV have a decreased risk of developing 
PE due to the maternal immune compromised state which facilitates foeto-maternal immune 
tolerance [48]. However, several studies have implicated Highly Active Anti-Retroviral 
Therapy (HAART) with the pathophysiology of PE in HIV-positive pregnant women [48-50] 
since 10.2% of these women develop preeclampsia [48]. The increased risk seems to be as a 
result of the maternal immune reconstitution induced by HAART whereby the maternal 
immune reconstitution (restoration of CD4+ T cells) may contribute to an inflammatory state 
which dysregulates the foeto-maternal immune tolerance and subsequently leads to PE [48]. 
Even though the immunological events leading to these alterations remain unclear, it is 
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evidently associated with the abnormal activation of the immune system, which plays a pivotal 
role in the etiology and pathogenesis of preeclampsia. 
 
Immune-related studies in PE and HIV-positive PE pregnant women on HAART have 
suggested that the changes in cytokine levels may occur due to the alteration in the Th1/Th2 
dichotomy (Fig. 6), which subsequently contributes to PE [49]. This may provide novel 
perspectives in determining the pathological mechanisms in PE and identifying definitive 
biomarkers of PE in HIV-positive pregnant women on HAART since clinically, antiretroviral 
therapy could overlap and complicate diagnosis and management in these patients.  We 
therefore, incorporated the isolation and characterisation of exosomes in PE, and PE with 
HIV/HAART into this study, as we will be able to gain insight into the possible role of 
exosomal cytokines in immune function. To the best of our knowledge, this has not been 
previously investigated. Therefore the observations made from this study will contribute to 
understanding the possible associations between Highly Active Antiretroviral Therapy and PE. 
 
1.6 Purpose of the study 
 
Current medical biotechnological applications have revolutionised the way we perceive, 
diagnose and treat diseases leading to innovative medical breakthroughs. Exosome diagnostics, 
an emerging medical biotechnological approach, provides a powerful platform to identify 
promising biomarkers and therapeutic agents for diseases,  due to their specific molecular 
content/cargo (i.e. lipids, proteins, nucleic acids), which carry precise biological codes relating 
to their cellular origin, capable of changing the functioning of target cells in normal and 
pathological states. 
 
In recent years, studies conducted have identified exosomes and their cargo in normal 
pregnancies, however, there has been no conclusive and robust studies pertaining to specific 
exosomal molecular cargo in preeclampsia per se, and their role in the etiopathogenesis.  This 
is a critical requirement for evaluating the validity of exosomes as biomarkers, for 
preeclampsia, as defined by the FDA Biomarker Workgroup [91, 92]. Therefore, our 
preliminary studies have focused on the assessment of exosomes as potential biomarkers of 
preeclampsia. The presented studies contribute to the foundational framework in support of the 
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clinical application of exosomes as biomarkers of preeclampsia, with a focus on its context of 
use.  The preliminary scientific evidence in support of this was categorised into three studies 
as follows: 
 
i) AIM 1: To determine the theoretical framework for the evaluation of exosomes 
as biomarkers of preeclampsia (Chapter two). 
 
Objectives 
 To evaluate the current state of biomarkers of preeclampsia and unmet medical 
needs, which the proposed biomarker must address; and 
 
 To evaluate the application of exosomes in diagnosing preeclampsia in terms of 
the FDA biomarker criterion and unmet medical needs. 
 
 
ii) AIM 2: To determine the context of use of exosomes with respect to the specific 
role of exosomal miRNA in the pathophysiology of preeclampsia (Chapter 3): 
 
Objectives 
 To isolate and characterise exosomal microRNA objectively in maternal 
circulation using rapid and reliable technology in support of its application in 
the clinical setting. 
 
 To validate results statistically using analytical systems (nSolver -R based 
platform) which support the validity of the diagnosis. 
 
 To use Computational Merging and Meta-analytical Pathway Analysis (Diana 
miRPATH) to determine the role of exosomal miRNA in the pathophysiology 
of preeclampsia. 
 
 To identify significant exosomal miRNA signatures as candidate biomarkers of 
preeclampsia and its subtypes. 
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iii) AIM 3: To evaluate the use of exosomal cytokines in diagnosing preeclampsia 
in HIV-positive pregnant women on HAART due to the increased prevalence 
of the comorbid state (HIV and PE). 
 
Objectives 
 To isolate and characterise exosomes objectively in HIV-positive pregnant 
woman on HAART. 
 
 To determine the expression levels of total and placental-derived exosomes in 
maternal circulation of HIV-positive preeclamptic pregnant women on 
HAART. 
 
 To determine the levels of exosomal Th1 and Th2 cytokines in HIV-positive 
preeclamptic pregnant women on HAART. 
 
 To evaluate the biomarker potential of exosomal cytokines in diagnosing PE in 
HIV-positive pregnant women on HAART. 
 
The outcomes from this study are novel and will hopefully contribute to the global 
understanding of the pathophysiology of preeclampsia and preeclampsia/HAART, which may 
lead to the subsequent development of biomarkers for the diagnosis of preeclampsia, within 
the FDA approved guidelines. 
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2. Chapter Two: Manuscript One 
Placenta-Derived Exosomes: Potential Biomarkers of Preeclampsia  
(Published: International Journal of Nanomedicine. 2017:12. Pages 8009-8023) 
 
This publication critically reviews the current state of PE biomarkers within the context of their 
specific sensitivity, specificity and shortcomings in diagnostic/prognostic potential, that 
subsequently formed the ‘needs assessment’ of the current biomarker status.  This formed the 
‘constitutional matrix’ to evaluate exosomes as potential biomarkers of PE in terms not only 
of the specific FDA biomarker criterion but also of any unmet clinical considerations. 
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Abstract: Preeclampsia remains a leading cause of maternal and fetal mortality, due to ineffective 
treatment and diagnostic strategies, compounded by the lack of clarity on the etiology of the 
disorder. Although several clinical and biological markers of preeclampsia have been evaluated, 
they have proven to be ineffective in providing a definitive diagnosis during the various stages 
of the disorder. Exosomes have emerged as ideal biomarkers of pathological states, such as 
cancer, and have more recently gained interest in pregnancy-related complications, due to their 
role in cellular communication in normal and complicated pregnancies. This occurs as a result 
of the specific placenta-derived exosomal molecular cargo, which may be involved in normal 
pregnancy-associated immunological events, such as the maintenance of maternal–fetal toler-
ance. This review provides perspectives on placenta-derived exosomes as possible biomarkers 
for the diagnosis/prognosis of preeclampsia. Using keywords, online databases were searched 
to identify relevant publications to review the potential use of placenta-derived exosomes as 
biomarkers of preeclampsia.
Keywords: placenta-derived exosomes, preeclampsia, biomarkers
Introduction
Preeclampsia (PE) is a multiorgan systemic hypertensive disorder of pregnancy 
(HDP) that is a leading cause of maternal and fetal mortality.1–3 The exact etiology of 
PE is difficult to establish, due to the multifactorial nature of the disorder; however, 
the general theoretical framework underlying the etiology of PE centers on abnormal 
placentation due to inadequate spiral-artery remodeling caused by poor trophoblast 
invasion.4,5 Moreover, it is now understood that increased placental oxidative stress is 
triggered by a predisposing condition, which stimulates the release of microvesicles 
from the syncytial layer of the placenta.6,7 These extracellular vesicles (EVs), termed 
syncytiotrophoblast microvesicles (STBMs), may bind to monocytes and stimulate the 
production of proinflammatory cytokines, which results in altered maternal systemic 
inflammatory response (MSIR) in normal and preeclamptic pregnancies.8–11 In addition, 
ex vivo studies have shown that STBMs have a key role in maternal immunomodu-
lation that results in regulation of T-helper 1 (T
h
1)/T
h
2 immunoresponses in normal 
pregnancy,8 and may thus be responsible for the T
h
1 skewness in PE.12
It is now recognized that the exact nature and composition of STBMs has yet 
to be defined with regard to proportion of exosomes, apoptotic bodies, and other 
vesicles. In light of this, recent literature has indicated that the constituents of STBMs 
should be classified as EVs and thus be termed STBEVs.13 Though prior knowledge 
of STBEVs indicates that these vesicles in their entirety can be used as circulating 
STB biopsies,14 they cannot be clearly defined as biomarkers of PE, as studies have 
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not demonstrated the objective isolation and detection of 
PE-specific biomarkers. In addition, studies conducted by the 
Obstetrics and Gynaecology Unit at the University of Oxford 
have shown that exosomes may be a key constituent of 
STBMs involved in the pathogenesis of the disorder.7,8,10,12–19 
These fundamental observations support the potential of 
placenta-derived exosomes as a biomarker of PE. Therefore, 
this review aims to evaluate the potential application of 
exosomes as a biomarker of PE.
Understanding the spectrum of 
pregnancy-related hypertensive 
disorders
HDPs are classified into four groups: 1) PE and eclampsia, 
2) chronic hypertension (of any cause), 3) chronic hyperten-
sion with superimposed PE, and 4) gestational hypertension. 
Clinical classification of the types of HDP is based primarily 
on gestational age, blood pressure, and compounding com-
plications (Figure 1). PE is defined as an HDP that has been 
characterized extensively in clinical practice, as it is associ-
ated with an increased risk of fetal and maternal morbidity 
and mortality.20 Without early-detection strategies, PE 
is clinically diagnosed as new-onset hypertension with 
proteinuria,20,21 and can be further subcategorized into early- 
and late-onset PE.21–24 Based on gestational age, early-onset 
PE is defined by new-onset hypertension at ,33 weeks plus 
6 days of gestation and late-onset PE defined by new-onset 
hypertension .34 weeks of gestation.22–24 However, the 
severity of PE pregnancies can be differentiated by their 
clinical manifestations, as outlined by clinical practice guide-
lines that present the adverse conditions and severe complica-
tions of PE according to the end organs affected.25
Adverse conditions in PE are associated with risks that 
increase the odds of severe maternal and fetal complica-
tions, and when exaggerated complications lead to severe 
(that warrant delivery).25 Diagnosis of these complications is 
primarily based on clinical maternal symptoms and laboratory 
tests. In addition, gestational hypertension, superimposed PE, 
and PE can progress to severe PE if one or more severe com-
plications manifest, which thus necessitates improved clinical 
monitoring-management systems using defined prognostic 
and diagnostic methods. Thus far, the only known cure of 
PE is the early delivery of the fetus and placenta to prevent 
worsening of disease progression and associated maternal 
complications, which leads to prematurity and its subsequent 
complications.25,26 All these complications emphasize the 
need for a biomarker that would enable early diagnosis and 
development of a treatment method for PE to prevent the 
inherent distress induced by it.
Biomarkers of PE: the current state
Biomarkers are universally defined as biochemical altera-
tions that can be objectively detected and quantified in 
Figure 1 Classification of hypertensive disorders in pregnancy.
Notes: Hypertensive disorders with preeclampsia subclassified into early- and late-onset preeclampsia. Adverse conditions are defined as conditions that increase the risk of 
severe complications. Adverse conditions and severe complications are categorized into the organ system affected (ie, central nervous system, cardiorespiratory, hematological, 
renal, hepatic, and fetoplacental), as described by Magee et al.25 aHypertension present either at prepregnancy or that developed at 20 weeks prior to gestation.
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human tissue, cells, or fluids and evaluated as an indicator 
of normal biological processes, pathogenic processes, or 
pharmacological responses to therapeutic intervention.27 It is 
thus imperative that these criteria are met when identifying 
potential biomarkers of PE to develop an efficient clinical 
test for early diagnosis and differentiation of the severity of 
PE. However, this is a challenge, due to the complex etiology 
and pathology of PE.
Clinical markers, such as maternal factors, blood pres-
sure, proteinuria, and uterine-artery Doppler velocimetry 
remain the most reliable methods in PE monitoring and sup-
portive care of the mother and fetus. However, they cannot 
be used in the early diagnosis of PE,21,28 but may still serve 
as useful markers when used in combination with other PE 
biomarkers. Previous studies (Table 1) have shown that 
combined clinical and biological markers have improved 
detection rates in overt PE, which could be incorporated into 
clinical care for early screening and assessment of patient-
specific risks of PE.29–31 However, the limitation of combined 
clinical markers and biological markers is the inability of 
these markers to provide definitive differentiation of the 
severity of PE and assessment of the PE-disease pathway. 
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gestational phases enhanced the diagnostic potential of the 
sFlt1:PGF ratio.38 This study, however, did not show false-
positive or false-negative values, due to the high constructed 
incidence of PE and variability of the disorder. Therefore, 
validation of the sFlt1:PGF ratio in a clinical setting with 
a larger, homogeneous population is required. sEng, a key 
antiangiogenic factor implicated in PE, has been found to 
be elevated in maternal circulation in the second trimester 
in PE-predisposed patients.43–45 Although sEng values alone 
or in combination with other pro- and antiangiogenic factors 
are significantly altered in PE serum, it has proven to be a 
poor biomarker of the disorder.46
Cell-free fetal DNA
cfDNA and cffDNA are also probable combined biomarkers of 
PE, mainly due to their sensitivity and specificity in biological 
fluids.47,48 The identification of the methylated RASSF1A 
promoter gene, which is elevated in early-PE pregnancies,49–51 
offers a promising alternative to the quantification of cffDNA, 
using Y-chromosome-specific sequences.52 Notably, high 
doses of human cffDNA did not induce PE-like symptoms 
in a murine in vivo model,53 reinforcing the notion that the 
increase in RASSF1A methylation is a consequence rather 
than a cause of PE. Nevertheless, when used in combination 
with other markers, cffDNA RASSF1A methylation may 
have potential in monitoring PE development in the second 
trimester.49–51
Cytokines
Cytokines are significantly involved in the pathophysiology 
of PE, as they are instrumental in the maintenance of the 
T
h
1–T
h
2 balance in normal pregnancy.9 During normal 
pregnancy, there is a shift toward T
h
2 immunity that results 
in the synthesis of IL4, IL5, IL6, and IL10, whereas in PE 
there is a distinct shift toward T
h
1 immunity, resulting in the 
production of IL2, TNFα, and IFNγ.54 It is this shift toward 
T
h
1-associated immunity in PE that results in the exagger-
ated MSIR. Therefore, T
h
1- and T
h
2-associated cytokines 
have gained interest as potential PE biomarkers. Research 
conducted in patients in the early second trimester of preg-
nancy has indicated that IL10-, TNFα-, and IFNγ-expression 
levels were significantly altered in PE during weeks 14–18 
of gestation.55–58 Therefore, these cytokines in combination 
may serve as potential early biomarkers of PE if validated 
in a larger sample population. In addition, GDF15, a 
macrophage-inhibiting cytokine possessing cardioprotective 
and biomarker potential in cardiovascular disease, has been 
found to be significantly reduced in PE women.59 However, 
GDF15 cannot be used as a biomarker of PE in the first 
trimester of pregnancy, as no marked differences between 
normotensive and PE pregnancies have been observed. 
Although cytokines may be involved in the pathophysiology 
of PE, their application as possible biomarkers is question-
able, since key cell-mediated factors are involved in their 
regulation during pregnancy.
High-temperature-requirement 
A3 enzyme
HTRA3, a pregnancy-related serine protease expressed by 
placental extravillous trophoblast cells, may have biomarker 
potential in the early detection of PE.60 It has been found to be 
associated with altered placental oxygen transfer and blood-
vessel remodeling in the first trimester.61 Elevated levels of 
HTRA3 in weeks 13–14 of gestation have been observed in 
PE-predisposed patients.62 Although the potential application 
of HTRA3 as a biomarker is promising, it has limited applica-
tion, since factors responsible for altered expression of this 
enzyme in PE are still unclear. Additionally, this enzyme is 
not a specific marker of placental function, and thus cannot 
be used an indicator of placental maladaptation in PE.
Pregnancy-associated plasma protein A
PAPPA, a more relevant, pregnancy-related protease involved 
in early placental development, has been found to be dys-
regulated in intrauterine growth restriction, PE, placental 
abruption, and premature birth.63 PAPPA is responsible for 
the cleavage of IGFBP4, hence regulating the synthesis of 
IGF, a key growth factor in the regulation of placental and 
fetal growth.64 Dysregulation of this enzyme may be linked 
to a variety of pregnancy-related complications associated 
with generalized placental function. Due to the aspecificity 
of this enzyme, it cannot be used as a marker of PE, but may 
have diagnostic application in combination with other clinical 
measurements and biomarkers.65
Neutrophil gelatinase-associated lipocalin
NGAL, a lipocalin-type glycoprotein involved in iron seques-
tration normally associated with inflammation, neoplastic 
transformation, and renal damage, has been found to be 
linked to PE.66 Increased serum NGAL is proportional to the 
severity of PE in the late second trimester of pregnancy, with 
sensitivity and specificity of 75% and 94.5%, respectvely.67 
However, NGAL is not linked exclusively to placental 
maladaptation, and its role in PE is unclear. Additionally, 
maternal serum AFP, in combination with maternal factors, 
the uterine-artery pulsatility index, and mean arterial pressure, 
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has shown potential in the diagnosis of PE in weeks 19–24 
of gestation in combination with other biomarkers.68
Placental protein
PP13 has been reported extensively in early placental 
development,69,70 and may be involved in T-cell and mac-
rophage apoptosis, regulation of maternal immunoresponses, 
and maternal–fetal immunomodulation.70,71 Due to its asso-
ciation with early placental development, it may be useful in 
detecting PE during early pregnancy.72 A significantly lower 
concentration of PP13 in weeks 6–10 of gestation has been 
found in PE-predisposed patients, which was attributed to 
impaired trophoblastic regulation and spiral-artery remodel-
ing in PE.72 Studies involving PP13 as a biomarker are limited, 
due to the lack of sample-population homogeneity and poor 
detection sensitivity; in addition, sensitivity and specificity 
for detection has to be determined using predefined cutoff 
values. Interestingly, STBEVs have been shown to be immu-
nopositive for PP13,70 suggestive of an immunomodulatory 
role. Therefore, future studies must evaluate PP13-biomarker 
potential in association with STBEVs and exosomes.
Syncytiotrophoblast extracellular vesicles
STBEVs may play a role in maternal–fetal immunoadap-
tation.73 In addition, in vitro research has indicated that 
PE-derived STBEVs differentially affect immune cells, 
endothelial cells, and platelet activation, suggesting a key role 
in maintenance of the MSIR.74 STBEVs have been identi-
fied in maternal circulation in the first trimester of normal 
pregnancy and also found to be significantly elevated in 
early-onset PE.75 Moreover, it is known that STBEVs contain 
subpopulations of EVs.16 As such, it is difficult to utilize the 
entire STBEV population as a biomarker of PE solely, as 
there are a multitude of biological factors associated with 
each EV subtype.
Lipids
New developments in lipidomic research have led to the 
identification of multimarker lipid biomarkers of PE. Lipid 
biomarkers with a mass:charge ratio (m/z) of 383, 784, 796, 
798, and 920 were able to identify PE with sensitivity of 91% 
and specificity of 82%. Lipids with an m/z of 383 have been 
identified as oxidized cholesterol, which has been shown to 
contribute to vascular atherosclerosis in PE.76 However, lipids 
with an m/z of 784, 796, 798, and 920 belong to the glycer-
ophosphocholine-lipid class, which may be elevated in PE 
pregnancies due to enhanced cellular apoptosis.76 Although 
lipidomics provide a new avenue for the identification of PE 
biomarkers, further studies are needed to determine if these 
markers are specific for PE.
In summary, biomarkers of PE can be described as 
angiogenic and antiangiogenic factors involved in pla-
cental maladaptation, improper spiral-artery remodeling, 
and immune factors that are synthesized as a result of the 
predominant T
h
1 immunoshift in PE (Figure 2). The dys-
regulation of these factors in PE indicates that they may be 
involved in the etiopathogenesis of the disorder. However, 
the upregulation of proangiogenic factors, AFP, and HTRA3 
indicates that these factors are consequences of the disorder, 
rather than the cause. Consolidation of the current state of 
biomarkers in PE indicates that there is no single biomarker 
of the disorder that can be objectively utilized as a defini-
tive early biomarker of PE. However, placenta-derived 
exosomes, a key constituent of STBEVs, may best fit the 
required biomarker criterion of PE and provide key evidence 
supporting the etiology and pathogenesis of the disorder. 
This review thus aims to evaluate the potential of placenta- 
derived exosomes as biomarkers of PE within the approved 
US Food and Drug Administration (FDA) biomarker-criterion 
framework.
Placenta-derived exosomes as 
potential biomarkers of PE
Placenta-derived exosomes are synthesized by STB cells 
via the lysosomal pathway, whereby multivesicular bodies 
fuse with the cell membrane via exocytosis, resulting in the 
release of placental exosomes into maternal circulation. 
During the process of exosome biogenesis, selective packag-
ing of molecules into exosomes occurs within the originating 
cell. These native molecules contained within the exosome 
thus consist of genetic and proteomic information that could 
serve as direct markers of pregnancy-related complications/
placental function. However, the rationale for presenting exo-
somes as a candidate biomarker of PE is yet to be evaluated 
in terms of the FDA-approved biomarker criterion.27 In this 
review, we thus incorporate the FDA-biomarker criterion in 
evaluating placenta-derived exosomes as biomarkers of PE, 
whereby placenta-derived exosomes were evaluated in view 
of the following criteria. Can they be objectively isolated, 
detected, and quantified from biological fluids? Have they 
been shown to increase with an increase in gestational age in 
normal pregnancy? Have they been shown to be significantly 
altered in PE? Do they contain key molecular markers that 
can improve biomarker sensitivity and specificity? Can they 
be used as a biotherapeutic agent to reprogram the dysfunc-
tional placenta?
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Isolation, detection, and quantification of 
placenta-derived exosomes in maternal 
circulation
Blood is the biofluid of choice when isolating exosomes for 
research and diagnostic purposes; however, various factors, 
such as the choice of anticoagulant, venipuncture, blood 
handling, circadian systems, time of draw, fasting status, 
platelet activation, and hemolysis, affect the composition and 
characteristics of exosomes in downstream sample processing 
and may result in inaccurate results.77 It is thus a requirement 
that when investigating the use of placenta-derived exosomes 
as biomarkers of PE that standardized blood-collection 
protocols as recommended by the International Society for 
Extracellular Vesicles be considered to prevent the artificial 
release of exosomes, which would result in false positives and 
negatives.77 Exosomes from maternal circulation are generally 
isolated based on their buoyant density of 1.13–1.19 g/mL 
using density-gradient or static-gradient ultracentrifugation 
and characterized by microscopic morphology and proteomic 
identification of exosome-associated tetraspanins, such 
as CD63, CD9, CD81, and HSP70.78 Furthermore, PLAP 
is used as a placenta-specific marker for the isolation and 
α
γ
Figure 2 Potential biomarkers involved in the pathogenesis of preeclampsia (Pe).
Notes: (A) Proangiogenic and (B) anti-angiogenic factors associated with improper spiral-artery remodeling in Pe. (C) Immune factors associated with the pathogenesis of 
Pe as a result of the predominant Th1 immunity of the disorder. 
+Significantly increased expression in comparison to normal pregnancy; -significantly lowered expression in 
comparison to Pe pregnancies.
Abbreviations: MSIR, maternal systemic inflammatory response; Th, T-helper.
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quantification of placenta-derived exosomes.79–81 Alternative 
technologies, such as analytical size-exclusion chroma-
tography and immunoaffinity capture,82,83 for the isolation 
of PLAP+ exosomes from maternal circulation have been 
shown elsewhere; however, these methods, especially the 
latter, result in analytical challenges with regard to the repro-
ducibility and precision of the quantification of placenta-
derived exosomes in maternal circulation. Alternatively, 
the direct quantification of placenta-derived exosomes from 
total purified exosomes using PLAP as a placenta-specific 
marker has been achieved.79–85 In contrast to immunocapture 
methods, this method eliminates inaccuracies attributed to 
the lower exosomal yield obtained using immunocapture 
techniques. However, the direct quantification of placenta-
derived exosomes in maternal circulation is largely dependent 
on the purity of the exosomal fraction. It is thus advisable 
that density-gradient ultracentrifugation and analytical 
size-exclusion exosome-isolation methods be utilized in 
combination to improve the purity and yield of maternal 
exosomes, thus enhancing the objective identification of 
placenta-derived exosomes.
The objective isolation of exosomes in maternal circula-
tion coupled with recent advancements in nanotechnology, 
such as nanoparticle-tracking analysis, enables the accurate 
characterization and quantification of exosomal populations 
based on particle-size distribution using dynamic light scatter-
ing and Brownian motion.80,85,86 Additionally, this technology 
enables the use of placenta-specific fluorescent probes, such 
as PLAP and other exosome-specific protein markers, for 
the quantification of placenta-derived vesicles.86,87 With 
advances in exosome-isolation and -detection technologies, 
the expected challenges would not only include the dis-
covery of specific PE exosomal markers but also how to 
incorporate these markers into regulatory decision-making 
and clinical practice.
Placenta-derived exosomes in normal and 
complicated pregnancies
Altered levels of circulating placenta-derived 
exosomes in Pe
Previously, studies have focused on supraphysiologi-
cal levels of enriched STBEVs in ex vivo systems.12,19,88 
These studies have demonstrated an increase in STBEVs 
in ex vivo placental perfusates in PE in comparison to 
normal pregnancies. Furthermore, it has been established 
that STBEVs have a key role in immunomodulation during 
normal and complicated pregnancies,12,83,89 and not as purified 
populations of constituent vesicles, such as exosomes. Exo-
somes are regarded as a key constituent of STBEVs, due 
to their ability to reprogram cells and consequently alter 
normal cellular physiology, which thereby contributes to 
various pathological states. Although STBEVs in normal 
pregnancies have been shown to play a role in immunoregu-
lation12 and placenta-derived exosomes have been shown to 
increase with gestational age and alter in vitro endothelial 
cell migration,80,90 there is a lack of knowledge in understand-
ing the role of placenta-derived exosomes in complicated 
pregnancies, such as those with PE, as well as the relative 
proportion of these vesicles in relation to other STBEVs.
Role of placenta-derived exosomes in maternal 
immunomodulation
Placenta-derived exosomes were initially identified from 
placental tissue by Frängsmyr et al, and have been shown 
to contain the transmembrane protein FasL, which suggests 
that placenta-derived exosomes are involved in immuno-
regulation during pregnancy by initiating the local deletion 
of activated maternal lymphocytes that identify placental 
paternal antigens.91 In addition, a similar study by Abrahams 
et al indicated that exosome-mediated secretion of FasL 
promotes immunoprivilege of semi-allograph invading tro-
phoblastic cells by inducing apoptosis in Fas-bearing immune 
cells during implantation and pregnancy.92 However, a more 
recent study showed that B7 immunomodulatory molecules 
and HLAG5 are secreted via exosomes from early and term 
placentas.93 This study offered a novel perspective in which 
human placenta-derived exosomes may have served directly 
as key mediators of maternal immunotolerance to the semial-
logeneic fetus. The identification of these key immunoregula-
tory proteins bound to placenta-derived exosomes supports 
the fact that exosomes have an immunomodulatory role in 
preventing the degradation of invading trophoblastic cells by 
inducing maternal T-cell apoptosis, which could play a key 
role in maternal complications, such as PE, fetal rejection, 
and intrauterine growth restriction.
MSIR and placenta-derived exosomes in maternal 
circulation
According to Redman and Sargent, in PE, placental oxida-
tive stress as a result of abnormal placentation induces the 
release of STBEVs that may control cellular apoptotic and 
necrotic events in circulation, thus resulting in an exagger-
ated MSIR.7,15 In addition, these authors postulated that in 
normal pregnancy, the process of regeneration of placental 
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STB cells is dependent on cellular apoptosis, which is 
modulated by STBEVs.7,15 In PE, the increase in STBEVs 
results in an exaggerated MSIR,7,10,86 which is induced 
when the maternal immune system reacts adversely in an 
exaggerated manner upon exposure to STBEVs.17 Since 
placenta-derived exosomes are a key constituent of STBEVs, 
we and others16,94 thus hypothesize that the marked differ-
ences in magnitude of placenta-derived and total exosomes 
in PE in comparison to normal pregnancies may control 
T
h
1/T
h
2 immunity during pregnancy, which in turn has a 
direct relationship with the size of the MSIR (Figure 3). 
In particular, this model proposes that a possible alteration 
in magnitude of placenta-derived and total exosomes during 
the pathological progression of early- or late-onset PE may 
cause adverse conditions or severe complications, which 
manifest in either severe PE or eclampsia, respectively. 
Additionally, this hypothesis can be authenticated by the 
incorporation of a mathematical algorithm whereby the 
rate of change of placenta-derived exosomes, in relation 
to total exosomes, within a specified gestational age would 
enable accurate and reliable diagnosis of PE throughout 
gestation. This is based on the theory that placenta-derived 
and total exosomes increase throughout gestation in normal 
pregnancy,80,81 which have been found to be altered in early- 
and late-onset PE.85 This model represents the classification 
of early- and late-onset PE based on the ratio of the rate of 
change of total exosomes to placenta-derived exosomes 
within a specified gestational age range represented by the 
following elementary formulae:
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∆
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where PLAP+ exosomes are placenta-derived exosomes, 
CD63+ total exosomes, and G gestational age.
With this hypothetical model, at any specified time period 
during pregnancy, the calculation of the rate of change in 
total exosomes to placenta-derived exosomes can be used to 
assess placental function, impending PE, and the severity of 
the complication. The model presents the rate of change of 
∆PLAP+ exosomes/∆CD63+ exosomes as a relative measure 
of impending PE during the preclinical and clinical phases 
of PE. However, this model is still to be evaluated in a 
clinical setting, in order to determine the appropriate rate of 
change for diagnosis/prognosis.
Figure 3 Hypothetical model of exosomes in relation to immunological and clinical outcomes in eOPe, LOPe, and normal pregnancy.
Notes: (A) In eOPe, an increase in placenta-derived and total exosomes in comparison to normal pregnancy mediates a shift toward Th1 immunity and thus results in an 
exaggerated MSIR. (B) In normal pregnancy, there is a balance between placenta-derived and total exosomes that mediates a shift toward Th2 immunity, thereby maintaining 
a balanced MSIR, a requirement for successful pregnancy. (C) In LOPe, the increase in total and decrease in placenta-derived exosomes in comparison to normal pregnancy 
mediates a shift toward Th1 immunity, which exaggerates the MSIR to a degree that does not exceed the MSIR in eOPe. (A, C) Alteration in the magnitude of placenta-
derived and total-exosomes during the manifestation of LOPe or eOPe results in adverse conditions or severe complications that lead to the clinical manifestation of severe 
Pe or eclampsia.
Abbreviations: EOPE, early-onset preeclampsia; LOPE, late-onset PE; MSIR, maternal systemic inflammatory response; Th, T-helper.
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Molecular markers of placenta-derived 
exosomes in normal and preeclamptic 
pregnancies
Exosomes contain cargo, such as mRNA, miRNA, cytosolic 
proteins, membrane-bound proteins, and lipids, which are 
selectively packaged during exosomal biogenesis. Exosomes 
usually contain a variety of molecules that are native to the 
originating cell and enriched with endosome-associated 
protein markers, such as tetraspanins (CD63, CD81, CD82, 
CD9, CD37), HSP70, RAB proteins, ALIX, TSG101, 
endocytic proteins, and cell-specific proteins, which provide 
information regarding their cellular origin.95 Pregnancy-
associated exosomes have been found to contain a number 
of membrane-bound protein markers, such as NKGD2 
ligands,96 FasL,82,83 TRAIL,82 and syncytin 1,97 which sug-
gests that placenta-derived exosomes play a key role in 
maintaining maternal–fetal tolerance (Figure 4). Other 
specific pregnancy-associated exosomal proteins, such 
as TGFβ, indicate that placenta-derived exosomes are 
involved in the control of STB growth, proliferation and 
differentiation.98 Although these exosomal membrane-bound 
proteins are associated with pregnancy, they cannot be used 
as definitive markers of placenta-derived exosomes, due to 
their lack of placental specificity; therefore, placental ALP 
remains the marker of choice when isolating and identifying 
placenta-derived exosomes.79–81,85,90,99,100 Even though it 
is known that exosomes contain mRNA and miRNA, 
which are key molecular mediators in translational and 
posttranscriptional modification, the exact composition 
of these exosomal constituents has not been elucidated in 
placenta-derived exosomes. Therefore, future studies should 
incorporate identification of novel nucleic acid sequences in 
placenta-derived exosomes in normal and PE pregnancies 
to enhance the specificity and sensitivity of these vesicles 
as biomarkers of PE.
Perspectives on engineered 
exosomes in PE therapeutics
Stem cell (SC)-derived exosome therapy is of emerging clinical 
importance as an alternative to other gene therapies, since 
exosomes have no risk of aneuploidy and a lower rate of 
immunorejection following allogeneic administration.101 
In addition, they serve as ideal vectors for the reprogramming 
of diseased cells in various pathological states, such as PE, 
since they have the ability to change the phenotype of the 
target cell though various signaling cascades and transfer 
of RNA.102,103 Mesenchymal SCs (MSCs) are rich in their 
application as regenerative agents of damaged or diseased 
β
β
Figure 4 Schematic representation of key pregnancy-associated exosomal molecular cargo and their function.
Notes: This figure highlights key transmembrane and cytosolic proteins involved in immunomodulation during normal pregnancy. Key pregnancy-associated exosomal nucleic 
acids have not been identified to date. Common exosomal markers are not shown.
Abbreviation: PBMCs, peripheral blood mononuclear cells.
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cells, due to their unique complement of proteins, which 
promote biological processes and pre-miRNA that facilitate 
intercellular communication.104–106 MSC-derived exosomes 
have been shown to act as promising therapeutic agents 
in cardiovascular disease,107,108 kidney injury,109 immune 
disease,110 tumor growth,111 and neurological diseases.112,113 
However the use of MSC-derived exosomes to treat PE has 
its challenges, due to the complexity of the pathogenesis of 
the disease. It is thus a prerequisite to determine the role 
of placenta-derived exosomes in the pathogenesis of PE 
through isolation and characterization of exosomal cargo 
and functional activity, and to understand the mechanism 
of biogenesis of placenta-derived exosomes in normal and 
PE pregnancies.
Engineering MSC-derived exosomes for the specific 
treatment of PE has potential, based on the understanding that 
exosomes may be primary-role players in the etiopathogen-
esis of PE. This process would involve the in vitro genetic 
manipulation of isolated MSCs using plasmid-based vectors 
to package dsRNA selectively during in vitro MSC-exosome 
biogenesis to enable the silencing of specific genes involved 
in the pathogenesis of PE and to engineer the surface proteins 
of MSC exosomes to result in their specific delivery to STB 
cells, allowing for more targeted exosome-cargo delivery. 
This would enable the effective targeted delivery of RNAi 
for reprogramming of the diseased placenta.
Conclusion
The future of the diagnosis of PE is dependent on the 
identification of novel biomarkers, which in turn may lead 
to personalized medicine during pregnancy in the form of 
liquid biopsies. Exosomes are the future of liquid biop-
sies, as they contain molecular cargo that can be used to 
diagnose such diseases as cancer without the need for a 
conventional biopsy. Although there is much controversy 
regarding the collection, isolation, and characterization of 
exosomes, the concept of these vesicles as novel biomarkers 
of the disease remains promising. We project that these 
shortcomings will be resolved with the implementation of 
carefully regulated exosomal standardization and validation 
methods. Additionally, rapid advances in such technolo-
gies as nanoparticle-tracking analysis, immunocapture, and 
next-generation sequencing would improve the efficiency 
of exosomal isolation and characterization and lead to the 
identification of novel placenta-derived exosomal protein and 
nucleic acid markers. The development of algorithms based 
on the model presented would add value in creating a person-
alized approach in managing PE and other pregnancy-related 
complications. These perspectives form the fundamental 
basis for the use of placenta-derived exosomes in liquid 
biopsies of the diseased placenta in PE.
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3. Chapter Three: Manuscript Two  
Exosomal microRNA profiling in early and late onset pre-eclamptic pregnant women 
reflects pathophysiology. (Accepted: International Journal of Nanomedicine. 2019) 
 
The theoretical framework outlined in manuscript one (chapter 2) supports the scientific role 
of exosomes in the pathogenesis of PE and consequently its future biomarker potential and 
‘context of use’ in the clinical setting.  Therefore, this publication focused on the purpose and 
nature of exosomal miRNA in PE, enabling a clearer understanding of their specific role in the 
pathophysiology of PE.  This was determined within the contextual framework of the FDA 
biomarker criterion [92] by: 
(1) Using a technology platform that directly detects miRNAs, and offers fast and reliable 
detection of small amounts of miRNA; 
(2) Using validated computational merging and meta-analytical algorithms in identifying 
specific exosomal miRNA biological pathway interactions related to the pathology of 
preeclampsia; and   
(3) Identifying specific exosomal miRNA signatures, which may serve as candidate 
biomarkers. 
The findings from this study are significant as they highlight the context of use of exosomes as 
biomarkers of PE. 
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Background: Preeclampsia is the leading cause of maternal and fetal mortality due to the
inability to diagnose and treat the disorder early in pregnancy. This is attributed to the
complex pathophysiology and unknown etiology of the disorder, which is modulated by
several known and unknown factors. Exosomes have recently been implicated as possible
mediators of the pathogenesis of preeclampsia, with, however, no evidence linking these
nanovesicles to the pathophysiology of preeclampsia and its subtypes.
Methods: To better understand the pathophysiological role of exosomes in preeclampsia, we
have analyzed the exosomal microRNA in early and late onset preeclamptic women in
comparison to their gestationally matched normotensive controls using Digital Direct
Detection (NanoString Technologies).
Results: For the first time, distinct exosomal microRNA signatures in early and late onset
preeclampsia have been identified. Moreover, these signatures indicate that exosomes are
involved in key pathological features associated with preeclampsia and differentiate between
the subtypes.
Conclusion: This study forms the basis for the diagnostic and functional validation of the
identified signatures as biomarkers of preeclampsia and its subtypes.
Keywords: biomarkers, preeclampsia, exosomes, microRNA
Introduction
Preeclampsia (PE), a hypertensive disorder of pregnancy (HDP), remains one of the
leading causes of maternal and neonatal mortality and morbidity, affecting 5–8% of
pregnancies globally.1–3 The clinical management of this disorder is complicated,
partly due to the heterogeneity of the disease which is attributed to its complex
etiopathophysiology, caused by the dysregulation of a host of unknown and known
factors. Even though the exact etiology of PE remains unknown, the placenta is
central in the pathogenesis of PE. The functional unit of the placenta, the chorionic
villous, is a vascular projection of fetal tissue surrounded by the chorion. The
embryonic-derived chorion consists of an inner cytotrophoblast layer and outer
syncytiotrophoblast layer which, importantly, forms the interface between maternal
blood from the fetal vasculature and may be a potential source of circulating
factors.
Preeclampsia is commonly categorized into early onset-PE (EOPE) and late
onset-PE (LOPE), which can manifest with or without clinical features, such as
epigastric pain, visual disturbances, persistent headache, nausea and vomiting,
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culminating in eclampsia if untreated.4 Notably, early
onset-PE occurs at ≤33 weeks of gestation and is asso-
ciated with greater risk of maternal and fetal complications
in comparison to late onset-PE,5–7 which is reflective of
the differences in the pathogenesis between the subtypes.
The pathophysiology of early onset-PE is characterised as
a two-stage disorder, namely, (1) improper placentation
due to shallow trophoblast invasion, impacting upon spiral
artery remodelling leading to decreased uteroplacental
blood flow (due to the under-perfused placenta) and
oxygenation,5 which results in (2) enhanced placental oxi-
dative stress which is a precursor to the maternal systemic
inflammatory response observable later in pregnancy6 with
lasting effects. Late onset PE occurs at ≥34 weeks of
gestation and manifests as a result of villous overcrowding
at term, leading to competitive inhibition of cellular
growth due to limited gaseous exchange and nutrient sup-
ply which culminates in placental oxidative stress,7 lead-
ing to the clinical disease state. Late onset-PE is often not
associated with significant fetal involvement, but com-
monly, in both early and late onset-PE, there are two
principle features: (1) syncytiotrophoblast stress occurring
in the placenta and (2) systemic endothelial dysfunction
affecting the mother.
Although the key events and factors initiating the patho-
physiology of PE remain largely unclear, biologically-
derived nanovesicles, termed exosomes, have emerged as
potential mediators of this process8-11 partly due to their
increased levels in maternal circulation.8 Furthermore, in a
recent study, we identified differences between early and
late onset-PE in the levels of total and placenta-derived
exosomes in maternal circulation,12 alluding to the possible
role of exosomes in the pathophysiology of early and late
onset-PE and their subsequent application as biomarkers.8
Exosomes (20–130 nm) derived from multivesicular
bodies contain nucleic acids, proteins and lipid rafts,
which have been reported to promote physiological func-
tion through autocrine, paracrine and endocrine signaling
mechanisms.8,13 Exosomes can bind to target cells or
organs, reprogramming them, either by direct signaling
via surface proteins or by depositing their vesicular cargo
intracellularly.14 Hence, in disease states, it is this property
which confers the ability for these vesicles to directly
mediate end-organ damage; forming ideal candidate bio-
markers for early disease diagnosis/prognosis. More
recently, exosomal microRNAs (exomiRNA), in particu-
lar, have emerged as key biomarkers of several other
disease states, as they are selectively packaged into
exosomes15 and are subsequently released by the cell,
destined to participate in cellular reprogramming.16,17 A
few studies have described the key physiological role of
miRNAs in regulating normal placental development, as
well as the pathogenesis of PE,18–22 leading to our propo-
sal that a comprehensive understanding of exosomal
miRNA will provide key functional insights into the role
of these nanovesicles in the pathophysiology of PE.
Evidence of miRNA as a constituent of exosomal RNA
cargo has been reported in PE using next-generation
sequencing (NGS).23 However, there is still a lack of
information regarding the pathophysiological role of
exomiRNA in early and late onset-PE, especially given
its powerful role in the modification of gene expression.
Importantly, the analysis of exomiRNA is complicated by
the limitations of this technology given the small amounts
of exomiRNA present. Therefore, studies involving the
detection and quantification of exomiRNA would require
more specific, rapid analytical strategies for easy clinical
application. NanoString technology fulfils this criterion
because of its digital precision, enhanced sensitivity,
reproducibility and technical robustness using small
amounts of starting RNA, without the need for further
validation.24,25 Importantly, standard assessment of small
amounts of RNA involves amplification which can skew
the relative abundance of short RNA sequences.24
NanoString technology does not utilise amplification pro-
cesses thus enabling a more accurate representation of
resident miRNA expression levels. Therefore, in this
study, we aimed to identify exomiRNA signatures asso-
ciated with the pathophysiology of early and late onset-PE
using the NanoString nCounter platform (Seattle, WA,
USA). We highlight the contrasting exomiRNA profiles
associated with the pathophysiology of early and late
onset-PE as well as the possible overlapping miRNA tar-
get-related pathways linked to preeclampsia pathology.
Methods
Ethics statement
Regulatory ethical and institutional approval were obtained
from the Biomedical Research Ethics Committee of the
University of KwaZulu-Natal (BE310/15), South Africa.
Patients were recruited from the Prince Mshiyeni
Hospital, Kwa-Zulu Natal, South Africa. All participants
were recruited via written informed consent, and the study
was conducted in accordance with the Declaration of
Helsinki.
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Study group
Controls [Gestationally matched normotensive pregnant
woman (N)] and experimental groups [Early onset-PE
(EOPE) and late onset-PE patients (LOPE)], were enrolled
in this study (n=15 per group). Normotensive patient controls
were gestationally matched to the EOPE and LOPE groups
(Table 1), and, identified as blood pressure of 120±10/80±5
(systolic/diastolic mm Hg) with absent proteinuria as
detected by a rapid urine dipstick test (Markomed®, South
Africa). Early onset preeclampsia was classified as new-
onset hypertension (diastolic blood pressure of ≥90 mm Hg
and systolic blood pressure of ≥140 mm Hg) and proteinuria
(≥300 mg) at ≤33 weeks. Late onset-preeclampsia was
defined by new-onset hypertension (diastolic blood pressure
of >90 mm Hg and systolic blood pressure of >140 mm Hg)
and proteinuria (≥300 mg) at ≥34 weeks gestational age. All
recruited women had singleton pregnancies with no evidence
of any infections or medical, surgical or other obstetric
complications. Blood from maternal circulation was col-
lected at the time of clinical diagnosis of PE as specified
above together with gestationally matched normotensive
[BD Vacutainer Tubes (EDTA), Becton Dickinson and
Company, South Africa] and the plasma samples were stored
at −80 °C for analyses.27,28 Samples were processed accord-
ing to the accepted guidelines pertaining to exosomes.24
Exosome isolation
Exosomes were isolated using the exosome miRCURY
isolation kit (Qiagen, USA) according to the manufac-
turer’s instruction with modifications. Briefly, plasma
was centrifuged at 300 g for 10 min the supernatant was
then centrifuged at 2000 g for 30 min to remove dead
cells. Thereafter the recovered supernatant was centrifuged
at 12,000 g for 45 min to remove cell debris. To ensure
removal of all unwanted cells and debris the supernatant
was further purified using a 0.22 µm spin column
(Corning, USA). Thrombin was then added to the filtrate
for de-fibrination. This was followed by centrifugation at
10 000 g for 5 min. Precipitation buffer was thereafter
added to the recovered supernatant and incubated at 4 ºC
for 4hrs. Post incubation the exosomes were recovered by
centrifugation at 500 g for 5min at 20 ºC. The exosomal
pellet was resuspended in exosome resuspension buffer as
prescribed by the total exosomal Protein and RNA isola-
tion kit (Life Technologies).
Exosomal protein and RNA isolation
Exosomal RNAwas isolated using the total exosome RNA
and protein isolation kit (Life Technologies) as per the
manufacturer’s instructions. The total RNA concentration
was measured using the NanoDrop 2000 spectrophot-
ometer (Thermo Scientific, Waltham, MA, USA).
Isolated exosomes were re-suspended in exosome resus-
pension buffer as per the total exosomal protein and RNA
isolation kit (Life Technologies). The total protein concen-
tration was determined using the RC DC Protein Assay as
per manufacturer’s instructions (Bio-Rad Laboratories,
Hercules, CA, USA).
Exosome characterization
Nanoparticle tracking analysis
Quantification and size distribution of exosomes were
determined using Nanoparticle Tracking Analysis as
described in our previous publication (NanoSight500
Table 1 Clinical characteristics of participants
Variables Normotensives Preeclampsia
≤33 weeks (n=15) ≥34 weeks (n=15) Early onset (n=15) Late onset (n=15)
Age (years) 28.43±2.23 26.12±3.62 25.25±5.13 27.11±5.23
Weight (kg) 59.88±3.25 67.57±5.22 71.12±7.85 87.21±9.21
Height (cm) 151.91±4.89 158.33±5.61 159.12 3±3.11 155.82±5.23
BMI 26.14±3.24 27.91±3.66 28.24±2.11 35.14±6.12†††
Gestational Age (weeks) 31.21±1.56 (26–33) 37±1.9 (34–38) 32.42±2.19 (28–33) 38.14±3.41 (34–39)
Systolic/diastolic blood pressure
(mm Hg)
121/79±3.47/2.54
(90–120/50–80)
118/81±8/5
(90–120/50–80)
162/98±6/8
(>140/90)***
157/95±7/5
(>140/90)†††
Urine Protein (mg/dl) ND ND 491±71.54 381±68.99
Notes: All values are represented by mean ± SEM. All pregnancies were singleton without intrauterine infection or any other medical condition. The patients recruited had
a parity of 1±1. In systolic/diastolic blood pressure early onset-PE versus N (≤33 weeks), ***p<0.001 and late onset-PE versus N (≥34 Weeks), p<0.001. In BMI late onset-PE
versus early onset-PE, †††p<0.05.
Abbreviations: ND, not detected; N, normotensive pregnancies; PE, preeclampsia.
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NTA 3.0 Nanoparticle Tracking Analysis Release, Version
Build 0069).12 In Brief, samples were diluted with PBS in
order to obtain particle distribution of between 10 and 100
particles per image (optimal, 50 particles per image).
Samples were introduced into the instrument using the
following script: PUMPLOAD, REPEATSTART, PRIME,
DELAY 10, CAPTURE 60, REPEAT 5. Videos were
recorded at a camera level of 10, a camera shutter speed
of 20 ms and camera gain of 600, these settings were kept
constant between samples. Each video was then analyzed
to give the mean particle size together with the concentra-
tion of particles. The size of the exosomes was represented
as the mean particle size ± SEM.
Western blotting
Exosomes isolated from plasma samples were lysed with
RIPA buffer (1X) at room temperature and the protein content
determined using the RC DC Protein Assay (Bio-Rad
Laboratories, Hercules, CA, USA). Laemmli buffer (2X)
was added to the samples and incubated at 95 °C for 5 min.
Thirty micrograms of exosomal protein per well were sepa-
rated by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and transferred onto polyvinylidene
fluoride membranes. Polyvinylidene fluoride membranes
were probed with the primary antibody, CD63 (ExoAB,
System Biosciences, Mountain View, CA) and Placental
Alkaline Phosphatase (PLAP) monoclonal antibody (5B1)
(Thermo Fisher Scientific). Post incubation at room tempera-
ture for 1 h, membranes were washed in Tris buffer saline (pH
7.6) and incubated for 1 h at room temperature with the
exosome validated secondary conjugated horseradish peroxi-
dase antibody (System Biosciences, Mountain View, CA).
Membranes were incubated with the chemiluminescent sub-
strate and visualised with the ChemiDoc® Gel Documentation
System (Bio-Rad Laboratories, Hercules, CA, USA).
Transmission electron microscopy
Exosomes were placed onto a continuous carbon grid and
negatively stained with 2% uranyl acetate. The morphol-
ogy of the particles was examined using a JEOL 1010
transmission electron microscope (JEOL, Peabody,
MA, USA).
Quantification of total and placenta-
derived exosomes
Total and placenta-derived exosomes were determined as
per our previous publication.12 Total exosomes in maternal
circulation were determined by the quantification of total
immunoreactive exosomal CD63 via an enzyme-linked
immune absorbency assay (ExoELISA™, System
Biosciences, Mountain View, CA), as per manufacturer’s
instructions. In brief, 30 µg of isolated exosomal protein
was immobilised onto a microtiter plate overnight at 37 °C
using exosome binding buffer supplied the manufacturer
(System Biosciences). Plates were washed and incubated
at room temperature for 1 h with exosome specific primary
antibody (CD63), followed by a wash step and incubation
with secondary antibody (1:5000) at room temperature for
1 h with agitation. Plates were thereafter washed and
incubated with Tetramethylbenzidine ELISA substrate at
room temperature for 45 min with agitation. The reaction
was thereafter terminated using stop buffer and the absor-
bance was measured at 450 nm. The number of exosomes/
ml, (ExoELISA™ kit) was obtained using an exosomal
CD63 standard curve that was generated using the cali-
brated exosome standard that was supplied.
The relative concentration of placenta-derived exo-
somes was determined by the quantification of human
placental alkaline phosphatase in the exosomal fraction
using a commercial ELISA kit (Elabscience, E-EL-
H1976, WuHan, P.R.C), as per manufacturers instruction.
In brief, 30 µg of exosomal protein was allowed to bind to
the primary PLAP specific antibody coated plates by incu-
bation at 37 °C for 90 min. Plates were washed with buffer
and 50 μl of HRP-conjugate was added to each well and
incubated at 37 °C for 20 min. Plates were washed and
incubated with 50 μl of substrate A and 50 μl of substrate
B at 37 °C for 15 min. The incubation was terminated
using 50 μl of stop solution at room temperature for 2 min
under agitation. Absorbance was measured at 450 nm.
Exosomal PLAP was expressed as pg/ml plasma. The
quantification of PLAP in the exosomal fraction indicates
the relative concentration of placenta-derived exosomes
(PLAP+ exosomes) in maternal circulation.
Nanostring ncounter system miRNA
assay
One hundred nanograms of exosomal RNA from each sample
group (n=15 per group, pooled into 3 technical replicates) was
analyzed using the NanoString nCounter SPRINT Profiler
(NanoString Technologies®, Inc., Seattle, WA, USA).
Briefly, miRNAs were ligated to a species-specific tag
sequence (nCounter miRtag) through a thermally controlled
splinted ligation. Un-ligated miRtags was removed by enzy-
matic purification, and the miRtagged mature miRNAs were
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then hybridized with the nCounter Human (V3) miRNA
Expression Assay Code Set overnight at 65 °C. Samples
were then injected into the nCounter SPRINTTM cartridge
and read using the nCounter® SPRINT Profiler (NanoString
Technologies®, Inc., Seattle, WA, USA). The instrument per-
formed the necessary magnetic bead separation, liquid trans-
fers and immobilization of molecular labels on the sample
surface before being finally analyzed by the system. The
counts of the reporter probes were documented for each sam-
ple by the nCounter Digital Analyzer, which was subsequently
analyzed using the nSolver Software (V 4.0). Before data
normalization was performed, the nCounter data imaging
QC metrics were assessed using the nSolver program, using
the following parameters; imaging, binding density, positive
control linearity, and positive control limit of detection. No
significant discrepancy between the fields of view attempted
and the fields of view counted were obtained. The binding
density for the samples ranged between 0.20 and 0.74 within
the recommended range. The normalisation factor by the
nSolver program accounts for technical noise such as; varia-
tions in hybridization, purification, binding efficiency. The
geometric mean of the positive controls was utilised for code
count normalization, and the background was estimated using
themean of the negative controls. Input amounts of RNAwere
normalized to the geometric mean of five housekeeping
miRNA controls (RPLP0, RPL19, B2M, GAPDH, and
ACTB) and spike-in miRNA (osa-miR422, osa-miR414,
osa-miR254, osa-miR248 and osa-miR159a) included in the
assay, which was finally normalised to total miRNA count.
Statistical data analysis
All data analyses and graphical representations were per-
formed and generated in GraphPad Prism 6.0 (CA, La
Jolla) and nSolver Analysis Software 4.0.7 (NanoString
Technologies Inc, USA). Exosomal miRNA ratio analysis
between groups was selected based on an arbitrary |fold
change|≥1 and False Discovery Rate (FDR) ≤0.05 with
all expression data represented in Log2 scale using the
nSolver analysis software. Subsequently, advanced ana-
lysis of the data was done using average-linked hierarch-
ical clustering of a Spearman’s Rank correlation
similarity matrix of the PE and normotensive samples
using the nSolver analysis software. All functional
Kyoto Encyclopedia of Genes and Genomes (KEGG)
and Gene Ontology (GO) analysis was performed using
Descriptive Intermediate Attributed Notation for Ada
(DIANA) miRPATH (V 3.0) together with DIANA-
microT-CDS 5.0 algorithms (interactions with a p-
value<0.00001 was considered).
Results
Participant clinical characteristics
Early and late onset-PE groups were gestationally matched
as shown in Table 1 below. Proteinuria was elevated in
EOPE (491±71.54 mg/dl) and LOPE (381±68.99mg/dl).
As expected, a significant increase in blood pressure was
observed in EOPE (162/98±6/8 mm Hg) and LOPE (157/
95±7/5 mm Hg) in comparison to the N groups
(≤33 weeks: 121/79±3.47/2.54, ≥34 weeks: 118/81±8/5,
p<0.001, Table 1) respectively. However, there was no
significant difference in blood pressure and proteinuria
between the N (≤33 weeks) and N (≥34 weeks) groups.
It is notable that the BMI of the early onset-PE group was
significantly greater than the late onset-PE group (35.14
±6.12 vs 28.24±2.11 p<0.001).
Isolation and characterization of
exosomes in maternal circulation
Isolated exosomes from each group were analyzed for size
distribution using Nanoparticle Tracking Analysis and
transmission electron microscopy. Isolated exosomes
were within the accepted exosomal size range (20–
130 nm, Figure 1E–G). The total number of exosomes in
maternal circulation was quantified using an exosome
validated ELISA kit which detected the exosome CD63
marker. Total exosomes in EOPE (8.9±0.5×1010 total exo-
somes/ml) and LOPE (5.3±0.5×1010 total exosomes/ml)
were significantly higher than total exosomes in N
(≤33 weeks: 1.06±0.2×1010 total exosomes/ml, p<0.0001)
and N (≥34 weeks: 2.54±0.32×1010 total exosomes/ml,
p<0.0001) respectively. Additionally, the exosome concen-
tration in EOPE was significantly higher in comparison to
LOPE (Figure 1A, p<0.0001). In conjunction with the
ELISA, the Western blot analysis was positive for the
exosomal CD63 marker (Figure 1B).
In order to determine the contribution of placenta-
derived exosomes present in maternal plasma, the
PLAP content per exosome was determined using
ELISA (Figure 1C). Placental alkaline phosphatase is
a marker of the syncytiotrophoblast and therefore its
presence confirms placental origin.26 A significant
increase in placenta-derived exosomes was observed
in early onset-PE in comparison to N (≤33 weeks)
(427.1±8.9 vs 231±10.92 pg/ml, p<0.0001).
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Figure 1 Identification and Characterization of Exosomes from Maternal Circulation. Exosomes from early onset-PE, late onset-PE and normotensive pregnant women
were isolated and characterized. (A) Total exosome concentration was determined by the quantification of exosomal CD63 marker per ml of plasma using ELISA. (B)
Western blot analysis for the CD63 exosome enriched marker. (C) Placenta-derived exosomes (ie exosomal placental alkaline phosphatase (PLAP) was quantified per ml of
plasma by ELISA. (D) Western blot analysis for the exosomal PLAP marker. (E) Nanoparticle Tracking Analysis (NTA) illustrating the representative vesicle size distribution
(nm). (F) Representative NTA video frame of the isolated exosomes. (G) Electron micrograph of isolated exosomes, scale bar 100 nm. In A and C the data is expressed as
aligned dot plot and values are mean ± SEM. ***p<0.0001 early onset-PE vs N (≤33 weeks), p<0.0001 late onset PE vs N (≥34 weeks), †††p<0.001 early onset-PE vs late
onset-PE, ‡‡‡p<0.0001 N (≤33 weeks) vs N (≥34 weeks).
Abbreviations: N - Normotensive Pregnant Women, PE - Preeclampsia, ELISA - Enzyme-Linked Immunosorbent Assay.
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Additionally, a significant decrease in placenta-derived
exosomes in LOPE compared to N (≥34 weeks) was
observed (323.6±8.01 vs 101.4±6.22 pg/ml, p<0.0001).
Moreover, a significant decrease in placenta-derived
exosomes in LOPE in comparison to early onset-PE
was observed (427.1±8.9 vs 101.4±6.22 pg/ml,
p<0.0001). Furthermore, isolated exosomes were posi-
tive for membrane-bound PLAP marker by Western
blot analysis (Figure 1D).
Exosomal miRNA expression profiles in
early and late onset preeclampsia
In order to determine the profile of exomiRNA detected by
the NanoString Human miRNA reference panel, we per-
formed hierarchical clustering using all detected miRNAs
within the specified range (FDR ≤0.05) in the EOPE vs N
(33≤weeks, Figure 2) and LOPE vs N (≥34 weeks, Figure 3)
groups. Average-linked hierarchical clustering of a
Figure 2 Comparison of exomiRNA expression profiles of Early onset Preeclamptic (EOPE) vs Normotensive derived exosomes. (A) Heatmap representing hierarchical
clustering of differentially expressed miRNAs in EOPE (n=15, pooled into three technical replicates) and normotensive (n=15, pooled into three technical replicates) derived
exosomes using average linkage clustering and Spearman Rank as distance metrics. miRNA profiles are clustered in 7 different subgroups (as indicated by the color bar on
the right of the heatmap) defined by the miRNA expression patterns. Samples are shown in columns, miRNA in rows. Heat map from green to red represents relative
miRNA expression as indicated in the key bar above the dendrogram. (B) KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway mapping for top canonical pathways
represented by the differentially expressed miRNA within each cluster, as determined by Descriptive Intermediate Attributed Notation for Ada (DIANA) miRPATH V.3.0
software.
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Spearman’s Rank correlation similarity matrix of the data
was performed using the NanoString nSolver analysis soft-
ware (Version 4.0). As expected, two distinct patient clus-
ters were identified (early and late onset-PE vs gestationally
matched controls) and distinct gene clusters indicated by
the colour bar represented in the heat map (Figures 2 and 3).
In its entirety, there were 578 and 611 differentially
expressed exomiRNA in EOPE vs N (33≤weeks) and
LOPE vs N (≥34 weeks) respectively. Moreover, the
KEGG pathway enrichment analysis of each cluster was
performed using DIANA miRPath (V 3.0) together with
DIANA-microT 5.0 algorithms. Significantly enriched
KEGG pathways (p-value <0.00001), indicated that differ-
entially expressed exomiRNA are involved in key signaling
pathways associated with PE pathophysiology (Rap1,
ErbB, TGF-β, Ras, Hippo, FOX, adrenergic cardiomyocyte
and Thyroid hormone signaling, Figures 2 and 3).
Interestingly, the differential expression of exomiRNA
Figure 3 Comparison of exomiRNA expression profiles of Late onset Preeclamptic (LOPE) vs Normotensive derived exosomes. (A) Heatmap representing
hierarchical clustering of differentially expressed miRNAs in LOPE (n=15, pooled with three technical replicates) and normotensive (n=15, pooled with three
technical replicates) derived exosomes using average linkage clustering and Spearman Rank as distance metrics. miRNA profiles are clustered in 8 different
subgroups (as indicated by the color bar on the right of the heatmap) defined by the miRNA expression patterns. Samples are shown in columns, miRNA in rows.
Heat map from green to red represents relative miRNA expression as indicated in the key bar above the dendrogram. (B) KEGG (Kyoto Encyclopedia of Genes
and Genomes) pathway mapping for top canonical pathways represented by the differentially expressed miRNA within each cluster determined using microT-CDs
target predicting with (Descriptive Intermediate Attributed Notation for Ada) DIANA miRPATH V.3.0 software.
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mirrors the molecular pathways associated with cancer
biology (glioma, renal cell carcinoma, pancreatic cancer,
proteoglycans and pathways in cancer, Figures 2 and 3)
which links placental development with cancer biology.27
Further analysis of the significantly dysregulated
exomiRNA in each comparison explores these relationships
in more detail.
Dysregulated exomiRNA in early and late
onset preeclampsia in comparison to
gestationally matched normotensive
pregnant women
Differential expression of exomiRNA was identified using
the nSolver Analysis Software (V 4.0). All fold changes (FC)
are represented in log 2 scale (log FC). Statistically signifi-
cant exomiRNAs were selected based on an arbitrary |FC|≥1
and FDR ≤0.05 (Figure 4B–D). To evaluate the function of
the significantly dysregulated exomiRNAwithin the comple-
mentary and intersecting group comparisons (Figure 4A),
KEGG pathway and GO: Biological process target enrich-
ment analysis was done using DIANA mirPATH together
with DIANA-microT-CD 5.0 algorithms (Figure 5A and B
respectively). These findings directly linked the identified
exomiRNAs to validated pathways and biological functions
involved in the pathophysiology of preeclampsia.
Complement analysis
In [EOPE vs N (≤33 weeks)] and [LOPE vs N (≥34 weeks)],
59 and 30 exomiRNAs in total were differentially expressed
respectively, of which 39 were unique to EOPE and 19
LOPE with 3 common miRNAs between the groups
(Figure 4, Supplementary file 1). In EOPE vs N
(≤33 weeks), of the 39 uniquely expressed exomiRNA,
KEGG pathway enrichment of the 14 upregulated
exomiRNA (Figure 4, Supplementary file 1) represented
involvement in lipid metabolism (Fatty acid biosynthesis),
endocrine system functioning (Thyroid signaling pathway)
and biological processes associated with tumor progression
(Proteoglycans in cancer and Glioma) (Figure 5A,
p<0.00001). Furthermore, GO: biological process target
enrichment indicated that the upregulated EOPE
exomiRNA is involved in several key biological processes
associated with the pathophysiology of EOPE, these
include; platelet activation, blood coagulation, cell death
and protein modification, Figure 5B, p<00001). In contrast,
KEGG enrichment of the downregulated exosomal
miRNAs in EOPE in comparison to N (≤33 weeks) indicate
dysregulation in key signaling pathways (Hippo, TGF-beta,
Wnt, ErbB, FoxQ signaling pathways), cellular processes
(Endocytosis, Adherens junction, Regulation of the pluri-
potency of stem cells) and organismal systems (Axon gui-
dance, Glutamatergic synapse) (Figure 5A, p<00001).
Of the 19 exclusively dysregulated exomiRNA in [LOPE
vs N (≥34 weeks)], KEGG enrichment of the 7 upregulated
exomiRNAs (Figures 4 and 5, Supplementary file 1) repre-
sented involvement in lipid metabolism (Fatty acid metabo-
lism and fatty acid biosynthesis), signaling pathways (Hippo
signaling pathway and signaling pathways regulating pluripo-
tency of stem cells) and cancer biology (Glioma) (Figure 5A,
p<0.00001). GO target enrichment of the upregulated
exomiRNA in LOPE indicates involvement in several signal-
ing pathways (phosphatidylinositol-mediated, fibroblast
growth factor receptor, epidermal growth factor, Fc-epsilon
receptor and Neurotrophin TRK signaling pathways) and cel-
lular processes (Cellular lipid metabolism, biological process,
synaptic transmission, cellular protein metabolism, cellular
component assembly, catabolism, blood coagulation, small
molecule metabolism, gene expression, biosynthesis and cel-
lular protein modification) associated with EOPE with how-
ever no involvement in cell death, platelet activation, response
to stress and Toll-like receptor signaling pathways as displayed
in EOPEwhich distinguishes the pathology of EOPE vs LOPE
(Figure 5B, p<0.00001). KEGG pathway enrichment of the
downregulated exomiRNA in LOPE vs N (≥34 weeks) indi-
cates dysregulation in cell survival, migration and invasion
associated with tumor progression (proteoglycans in cancer)
and signaling pathways (Hippo and regulation of pluripotency
of stem cells) (Figure 5A, p<0.00001).
Intersect analysis
In the intersect between [EOPE vs N (≤33 weeks)] and
[LOPE vs N (≥34 weeks)] exosomal miR-2113 (logFC
−1.69 vs −1.12 respectively) and miR-374c-5p (logFC −1.7
vs −1.21) were downregulated. KEGG enrichment indicated
that exosomal miR-2113 regulates fatty acid biosynthesis
which is a key biological process in lipid metabolism and
miR-374c regulates inflammation (KEGG pathways: TGF-
beta signaling, Hippo andWnt signaling pathway) which are
key biological processes commonly linked to the pathophy-
siology of EOPE and LOPE (Figure 5A, p<00001).
In [EOPE vs LOPE] vs [LOPE vs N (≥34 weeks)] and
[EOPE vs LOPE] vs [EOPE vs N (≤33 weeks)] 6 and 15
commonly dysregulated exomiRNA (Figure 4,
Supplementary file 1) were identified between the groups
respectively, suggesting the pathophysiological role of
Dovepress Pillay et al
International Journal of Nanomedicine 2019:14 submit your manuscript | www.dovepress.com
DovePress
5645
exosomes in EOPE and LOPE in comparison to their respec-
tive normotensive controls. In EOPE vs LOPE and EOPE vsN
(≤33 weeks), KEGG pathway enrichment (Figure 5A) of the
15 dysregulated exomiRNAs (Figure 4, Supplementary file 1)
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Figure 4 Differential expression analysis of exosomal miRNA in early and late onset preeclampsia. (A) Venn diagram representing differentially expressed exomiRNA
observed in the comparisons amongst Early-onset Preeclampsia (EOPE), Late-onset Preeclampsia (LOPE) and the respective gestationally matched controls (|fold-change| ≥
1.0, FDR ≤ 0.05). (B) Log FC values of differentially expressed miRNA in EOPE in comparison to N (≤33 Weeks). (C) Log FC values of differentially expressed miRNA in
LOPE in comparison to N (≥34 Weeks). (D) Log FC values of differentially expressed miRNA in EOPE in comparison to LOPE. In B, C and D the x-axis represents the
LogFC of differentially expressed miRNA. In B, C and D, respective colors indicate the common miRNA between intersecting groups: commonly deregulated exosomal
miRNAs in the LOPE vs N (≥34 Weeks) and EOPE vs to N (≤33 Weeks) comparisons, commonly deregulated exosomal miRNAs in the LOPE vs N (≥34 Weeks) and
EOPE vs LOPE comparisons, commonly deregulated exosomal miRNAs in the EOPE vs LOPE and EOPE vs N (≤33 Weeks) comparisons, commonly deregulated
exosomal miRNAs in all comparisons.
Abbreviations: FC - Fold Change, N - Normotensive pregnant women.
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Figure 5 Pathway andGeneOntologyenrichment analysis of the exosomalmiRNA targets differentially expressed in early and late onset preeclampsia. (A) KEGG (Kyoto Encyclopedia
of Genes and Genomes) pathway mapping for top canonical pathways and (B) Biological process of Gene Ontology (GO) enrichment analysis represented by the differentially up and
downregulated exosomal miRNAs within each group determined using microT-CDs target predicting with Descriptive Intermediate Attributed Notation for Ada (DIANA) miRPATH
V.3.0 software. Each group is represented by the following respective colors: uniquely dysregulated exosomal miRNA in the EOPE vs N (≤33 Weeks) comparisons, uniquely
dysregulated exosomal miRNA in the LOPE vs N (≥34 Weeks) comparisons, commonly deregulated exosomal miRNAs in the LOPE vs N (≥34 Weeks) and EOPE vs to N
(≤33Weeks) comparisons, commonly dysregulated exosomalmiRNAs in theLOPEvsN (≥34Weeks) and EOPEvs LOPE comparisons, commonly deregulated exosomalmiRNAs
in the EOPE vs LOPE comparison, commonly deregulated exosomal miRNAs in the EOPE vs LOPE and EOPE vs N (≤33Weeks) comparisons, commonly deregulated exosomal
miRNAs in all comparisons.
Abbreviations:N - Normotensive PregnantWomen, EOPE - Early -onset Preeclampsia, LOPE - Late -onset Preeclampsia
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specifies participation of exosomes in the dysregulation of;
protein glycosylation (Mucin type O-Glycan biosynthesis
pathway), lipid metabolism (Biosynthesis of unsaturated
fatty acids pathway) and signal transduction during cell pro-
liferation and migration (Wnt signaling pathway). This is
related to GO biological process targets (Figure 5B) which
regulate key cellular (cellular nitrogen compound metabolism,
cellular protein modification) and signaling processes (Fc-
epsilon receptor signaling pathway, Neurotrophin TRK recep-
tor signaling pathway, Epidermal growth factor receptor sig-
naling pathway, cell-cell signaling) (Figure 5, p<0.00001).
Intersecting exomiRNAs (hsa-miR-451a and hsa-379-5p) in
the EOPE vs LOPE and LOPE vs N (≥34 weeks) comparisons
indicate exosomal involvement in cardiomyocyte adrenergic
signaling; a direct association with impaired cardiac function
which is a key feature of PE.
Importantly in all comparisons 2 distinct exomiRNAs
were identified, both of which indicated involvement in
mucin-type O-Glycan biosynthesis pathway (KEGG
enrichment p<0.00001, Figure 5A). Coupled to this finding
these exomiRNAs were linked to posttranslational protein
modification and cellular protein metabolic processes (GO:
Biological process target enrichment p<0.00001).
Exosomal miRNA signatures associated
with the pathophysiology of early and late
onset preeclampsia
In addition to the KEGG and GO enrichment analysis we
further analyzed the differentially expressed exomiRNA in
each comparison (Figure 4A), for their biological function
and gene targets using NCBI gene databases (Tables 2 and 3).
This linked the identified exomiRNAs to the validated patho-
physiological functions involved in preeclampsia.
Complement analysis
In the complement analysis of EOPE vs N (≤33 weeks)
and LOPE vs N (≥34 weeks) and EOPE vs LOPE,
exomiRNA with an arbitrary |fold change|≥1.0 and FDR
≤0.05 were selected for further evaluation. It was con-
firmed that the significantly dysregulated exomiRNA
unique to the EOPE vs N (≤33 weeks) comparison is
associated with key pathophysiological features related to
the more severe clinical outcomes of EOPE, such as
angiogenesis, cell proliferation, inflammation, vasocon-
striction, cell invasion, myogenesis and lipid metabolism
(Table 2). Furthermore, in LOPE vs N (≤33 weeks) the
dysregulated exomiRNA indicates the role of exosomes in
the misregulation of angiogenesis and glucose homeostasis
(Table 2), which is associated with the decreased prob-
ability of adverse maternal and fetal complications when
compared to EOPE. Exosomal miRNA in the EOPE vs
LOPE comparison indicated a physiological role in inflam-
mation, angiogenesis, cell proliferation, blood pressure
regulation and electrolytic homeostasis, which are features
associated with the pathology of PE (Table 2).
Intersect analysis
In the intersect analysis of comparisons, exomiRNAwith an
arbitrary |fold change|≥1.0 and FDR ≤0.05 were selected for
further evaluation of their physiological function and tar-
gets (Table 3). Intersecting exomiRNA in the EOPE vs N
(≤33 weeks) and LOPE vs N (≥34 weeks) comparisons
indicated three statistically significantly dysregulated
exomiRNA which have confirmed biological roles in cell
proliferation, invasion and inflammation (Table 3).
Intersecting exomiRNA in the EOPE vs N (≤33 weeks)
and EOPE vs LOPE comparisons indicated a downregula-
tion of the identified exomiRNA in EOPE in comparison to
LOPE and N (≤33 weeks) (Table 3). These exomiRNA play
a role in the dysregulation of cell migration and invasion,
cell proliferation apoptosis, mesenchymal transition, multi-
ciliogenesis and angiogenesis. Furthermore, the enhanced
downregulation of exomiRNAs in EOPE in comparison to
LOPE and N (≤33 weeks) suggests that exosomes contri-
bute to the more severe maternal and fetal complications
associated with EOPE in comparison to LOPE.
In contrast, intersecting exomiRNA between the LOPE
vs N (≥34 weeks) and EOPE vs LOPE comparisons indicate
that the pathological association between LOPE in compar-
ison to EOPE and N (≥34 weeks) (Table 3) is linked to cell
survival, glucose secretion, angiogenesis, autophagy, cell
proliferation and migration and trophoblast invasion.
Moreover, the dysregulation of hsa-miR-379-5p in LOPE
exosomes in comparison to EOPE and N (≥34 weeks)
(Log2: 3.93 vs 2.79 and 2.71 respectively) signifies a possi-
ble association with the maternal metabolic syndrome in
LOPE through the suppression of glucose-induced insulin
secretion. In all intersecting comparisons [EOPE vs N
(≤33 weeks) and LOPE vs N (≥34 weeks) and EOPE vs
LOPE] two exomiRNA; hsa-miR-122-5p and has-miR-
3605-3p were common (Table 3). hsa-miR-122-5p has been
confirmed to have a function in cholesterol metabolism by
targeting CAT1 which directly links to dyslipidemia in PE.
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Discussion
Whilst studies have supported the role of exomiRNA as
potential biomarkers of PE, their role in the etiopathophy-
siology of PE and its subtypes remains unclear. Therefore,
for the first time, this study has profiled exomiRNA and
determined the pathophysiological role of dysregulated
exomiRNA in early and late onset-PE using Direct
Digital Detection and computational algorithms.
The data observed from the characterisation and quan-
tification of total and placenta-derived exosomes are con-
sistent with our previous study12 reinforcing that
differential levels of placenta-derived exosomes in mater-
nal circulation are attributed to the differences in the
pathophysiology of the disease subtypes. Moreover, the
significant increase of placenta-derived exosomes in
EOPE vs N (≤33 Weeks) and decrease in LOPE vs N
(≥34 Weeks), which may reflect the role of the placenta
in the pathogenesis of PE.
Exosomal miRNA expression profiles in EOPE vs N
(≤33 weeks) and LOPE vs N (≥34 weeks) indicate a
clear dysregulation and difference in exomiRNA
expression between the PE subtypes and the matched
normotensive controls. KEGG pathway enrichment of
clusters of dysregulated exomiRNA (Figures 2 and 3)
reveal top canonical pathways which are associated
with cellular signaling, cancer biology, metabolism,
cellular processes, cardiovascular disease and organis-
mal systems. Further analysis of highlighted KEGG
target genes indicates that exomiRNA in maternal cir-
culation are likely to be involved in modulating key
biological processes involved in cell proliferation,
invasion, migration and apoptosis, which are known
to be dysregulated in PE. Our findings, therefore, sup-
port the role of exosomes in reprogramming adjacent
or distant cells through autocrine and paracrine signal-
ing mechanisms thereby facilitating the pathogenesis of
preeclampsia. Moreover, we identified specific clusters
of exomiRNA in both EOPE and LOPE, which are
linked to arrhythmogenic right ventricular cardiomyo-
pathy (Figures 2 and 3) indicating that exosomes in
maternal circulation may be involved in the dysregula-
tion of cardiac function – a known complication of the
disease.60
Computational analysis of statistically significant fold
changes in exomiRNA (LogFC ≥1, FDR ≤0.05) between
the EOPE vs N (≤33 weeks), LOPE vs N (≥34 weeks) and
EOPE vs LOPE groups supports the pathophysiological role
of exomiRNA in PE. Enrichment of exclusively upregulated
exomiRNA in EOPE vs N (≤33 weeks) indicates that the
dysregulation of exomiRNA in EOPE in comparison to N
(≤33 weeks) is responsible for the irregular expression of
proteoglycans (KEGG pathway: Proteoglycans in cancer, p-
value ≤0.00001), which concomitantly contribute to placen-
tal proteoglycan deficiency, resulting in placental thrombotic
lesions: a key morphological feature of PE placentas.61
Additionally, this pathway interaction indicates that the upre-
gulated exomiRNA in EOPE induces a micro-environment
which favours abnormal metastatic-related properties result-
ing in abnormal cell growth, adhesion, migration and inva-
sion. Moreover, the pathway interactions of significantly
upregulated exomiRNA in EOPE are associated with dysre-
gulation of the thyroid hormone signaling pathway by target-
ing the thyroid hormone receptor-β (THRE), a regulator of
calcineurin 1(RCAN1) and Ca2+ transporting ATPase
(ATP2A2), which controls cardiac muscle contraction and
angiogenesis. Therefore, our findings highlight the potential
cardiovascular involvement of exomiRNA in preeclampsia
which we are further investigating.
In contrast, the enrichment of exclusively upregulated
exomiRNA in LOPE (LogFC ≥1, FDR ≤0.05) indicated a
dysregulation in lipid metabolism by targeting fatty acid
synthase (FASN) expression which indicates that LOPE
exosomes enhance a state of adipogenic trans-differentia-
tion which promotes oxidative stress, chronic inflamma-
tion, and, potentially, insulin resistance in LOPE; which
are key metabolic features which may be linked to patho-
physiology of LOPE or reflective of the increased BMI in
LOPE in comparison to EOPE (38.14±3.41 vs 32.42±2.19,
p<0.001).62 Moreover, KEGG enrichment of upregulated
exomiRNA in EOPE vs N (≤33 weeks) and LOPE vs N
(≥34 weeks) indicates a significant involvement in the
glioma cancer pathway (p<0.00001), suggesting that
EOPE- and LOPE-derived exosomes have the ability to
target glial cells through a network of genes responsible
for signaling in glial progenitor cells (KEGG highlighted
target genes: TGFA, PDGFA, SOS1, AKT3, PTEN and
IGF1R) which may provide the possible links to placental
branching and vasculogenic, abnormalities that occur dur-
ing the development of EOPE and LOPE.63
Intersecting exomiRNA hsa-miR-122-5p and hsa-miR-
3605-3p were common in [EOPE vs N (≤33 weeks)],
[LOPE vs N (≥34 weeks)] and [EOPE vs LOPE].
Exosomal hsa-miR-122-5p expression in all groups may
target the polypeptide N-acetylgalactosaminyltransferase
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gene which regulates the biosynthesis of mucin-type O-
glycosylated antigen (Tn antigen); a tumor-associated car-
bohydrate antigen which is not normally expressed in
peripheral tissues or blood cells.64 It is possible that exo-
somal mediated dysregulation of Tn antigen synthesis may
be an important recognition element, mediating cell-cell
interactions involved in placental organotrophic
metastasis.27,64 Additionally, the upregulation of exosomal
hsa-miR-122-5p in EOPE vs LOPE (LogFC 5.72 vs 0.76)
could indicate that this exomiRNA in EOPE is associated
with the aberrant glycosylation of the Tn antigen which is
linked to the enhanced maternal systemic inflammatory
response which is commonly observed in PE with severe
features.59 Moreover, recent studies have identified that
the aberrant glycosylation of proteins in PE is linked to
the synthesis of novel proteins involved in hepatic and
renal dysfunction65 which suggests that total and pla-
centa-derived exosomes may be involved in causing end-
organ complications associated with severe forms of PE.
The identification of unique signatures of exomiRNA
in [EOPE vs N (≤33 weeks)], [LOPE vs N (≥34 weeks)]
and [EOPE vs LOPE]; revealed key pathophysiological
differences between the groups. Significantly dysregulated
exomiRNA (LogFC ≤1.4) in [EOPE vs N (≤33 weeks)]
were confirmed to have a pathophysiological role in cel-
lular maintenance, inflammation, vasoconstriction, myo-
genesis and lipid metabolism, all of which are associated
with the more adverse pathological features of EOPE in
comparison to LOPE.65 In contrast, since significantly
dysregulated exosomal hsa-miR-297 and hsa-miR-375
(LogFC ≤1.0) in LOPE vs N (≥34 weeks) has been pre-
viously shown to negatively regulate VEGFA expression
and glucose homeostasis36,38 suggests that this could con-
tribute to more favourable maternal and neonatal outcomes
in comparison to EOPE.66 Furthermore, dysregulated
(LogFC ≤1.0) exomiRNAs in EOPE vs LOPE but not in
comparison to their physiologic controls (Table 3) indicate
that differential severity of EOPE compared to LOPE is
mediated by exomiRNAs which modulate cell prolifera-
tion and migration, angiogenesis, inflammation and blood
pressure regulation. These events and factors are central to
the pathogenesis of PE. Interestingly even though no con-
firmed targets are available for hsa-miR-3605-3p, it has
been shown to be linked to Multiple System Atrophy
(MSA), a sporadic neurodegenerative disorder character-
ized by a combination of various degrees of Parkinson
cerebellar ataxia and autonomic dysfunction, which
might provide a link to the autonomic nervous system
control of key physiological processes such as blood pres-
sure regulation in EOPE and LOPE.
Moreover, we found that the exomiRNAs in normoten-
sive and preeclamptic maternal circulation is linked to
biological pathways associated with cancer biology. This
concurs with a current theory that placental trophoblast
and cancer cells can develop a microenvironment which
supports immunologic privilege and angiogenesis through
molecular mechanisms which regulate hyper-proliferation,
invasion, angiogenesis and immunoevasion.27 Therefore,
our future studies would seek to compare and integrate the
pathophysiological role of exomiRNA in pregnancy, PE
and cancer biology to identify possible interrelated
mechanisms to better understand the intriguing and natural
phenomenon of pregnancy.
This study highlights the possible roles of exomiRNA
in the pathophysiology of preeclampsia and its subtypes
which warrants further validation of their biomarker
potential with a larger and dynamic patient cohort.
Furthermore, this study is limited by the unknown cellular
origin of the exosomal miRNA identified therefore it
becomes challenging to understand the diverse exosome-
mediated interactions involved in the pathophysiology.
The NanoString Direct Digital Detection technology used
in this study has proven to be valuable in a clinical setting
due to rapid detection, precision and accuracy. Therefore,
future studies will focus on (1) identifying the specific
origin of the sub-populations of exosomes for in-depth
analysis and (2) validating exosomes and their molecular
cargo as biomarkers of preeclampsia and their subtypes.
Conclusion
This novel study identifies exomiRNA signatures in
EOPE and LOPE which are implicated in the dysregu-
lation of key physiological processes associated with
the etiopathology of PE. Importantly, the interconnect-
edness of cancer biology and PE is revealed through
pathway associations which supports the notion that
exomiRNAs in pregnancy and its associated complica-
tions, including PE, is related to the “pseudo-malignant
like” physiological processes. Furthermore, the discov-
ery of distinct exomiRNA signatures in EOPE and
LOPE support the existence of the differential patho-
physiology between the subtypes. Therefore, the obser-
vations made in this study warrant the diagnostic and
functional validation of the signatures as biomarkers of
PE and its subtypes.
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4. Chapter Four: Manuscript Three  
Exosomal Th1/Th2 Cytokines in Preeclampsia and HIV-positive Preeclamptic Women on 
Highly Active Anti-Retroviral Therapy. (Under Review: Cytokine CYTO-19-358) 
 
Our previous studies presented in Chapters 2 and 3 have contextualised the basis of exosomes 
as a biomarker of PE.  Defined conditions of use must be characterised when evaluating 
potential biomarkers. This must incorporate the intent-to-diagnose the disease in combination 
with other conditions which increase the susceptibility/risk of the disease. We, therefore, 
evaluated the biomarker potential of exosomes in diagnosing PE in HIV-positive pregnant 
women on HAART.  Highly Active Anti-Retroviral Therapy has been closely associated with 
the increased risk of PE due to maternal immune reconstitution [93], which alters the Th1/Th2 
immune balance as represented by the variations in cytokine levels in circulation [94]. 
Therefore our findings of altered exosomal cytokines in PE and PE in HIV-positive pregnant 
women on HAART lends greater significance to the role of exosomes as biomarkers of PE. 
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A B S T R A C T
Preeclampsia (PE) is a hypertensive disorder of pregnancy which is a leading cause of maternal and foetal
morbidity and mortality. Furthermore, HIV/Highly Active Anti-Retroviral Treatment has been associated with
the increased risk of preeclampsia due to maternal immune reconstitution, which complicates the clinical di-
agnosis of PE in these patients. It is therefore necessary to identify biomarkers involved in the pathology of both
disorders with the intent to diagnose. Exosomal cytokines represent ideal biomarkers of PE and inflammatory
conditions due to their immunomodulatory role in pregnancy. We therefore quantified exosomal Th1 (IL-2 and
TNF-α) and Th2 cytokines (IL-10) in maternal circulation. A significant dysregulation in total exosomes, pla-
cental-derived exosomes and exosomal cytokines in PE and HIV-positive PE pregnant woman on Highly Active
Antiretroviral Treatment (HAART) was observed (p < 0.01). Additionally, we observed a significant shift to-
wards Th1 immunity in PE which becomes amplified in HIV-positive PE pregnant woman on HAART
(p < 0.01). Moreover, we show the potential application of exosomal Tumor necrosis factor alpha (TNF-α) as a
biomarker of PE and PE in HIV-positive pregnant women on HAART (CI: 95%, LHR > 10, sensitivity of 100%
and specificity of 90%). These findings are in support of exosome release and exosome cytokine encapsulation as
a tightly regulated process in favour of maintaining the immune microenvironment, which can orchestrate either
normal pregnancy, or the pathogenesis of preeclampsia and preeclampsia in HIV/HAART pregnancies.
1. Introduction
Preeclampsia (PE) remains a leading cause of maternal and foetal
morbidity [1] which is further complicated in HIV-positive pregnant
women receiving Highly Active Anti-Retroviral Therapy (HAART) who
are at a greater risk of developing PE [2]. Therefore, definitive bio-
markers of PE and PE in HIV-positive pregnant women are required
within the clinical setting.
Pregnancy is a well-coordinated immune state regulated by a net-
work of cytokines which modulate a balance between both pro-in-
flammatory (Th1) and anti-inflammatory (Th2) immune responses
[3,4]. In order for the mother to tolerate the semi-allogenic foetus a Th2
mediated immune response modulated by cytokines such as IL-10 is
essential [3,4], whereas the Th1 mediated pro-inflammatory immune
state modulated by cytokines such as TNF-α and IL-2 is essential for
trophoblast invasion, parturition and defense against infections [5,6].
Therefore, the balance between Th1/Th2 immune response is a critical
requirement for successful pregnancy. Conversely, the dysregulation in
Th1/Th2 immune balance during pregnancy results in complications
such as PE. Preeclampsia is associated with a shift from Th2 to Th1
dominant immunity [7] due to cell-mediated immune responses acti-
vated by known and unknown factors, which induce an enhanced
maternal systemic inflammatory response (MSIR). Similar to normal
pregnancy, a shift from Th1 to Th2 immunity has been observed during
the progression of HIV infection [8]. However, the immune status is
reversed with HAART [9,10] which increases the risk of PE. It has been
established that circulating cytokines are key immunomodulating fac-
tors involved in HIV-associated immune activation [11] and PE [12].
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Recent reports have established that most circulating cytokines are
encapsulated in extracellular vesicles (viz. 70%-IL-2, 50% TNF-α and
100% IL-10) in comparison to the soluble form [13].
Extracellular vesicle (EV) cytokine encapsulation is described as a
regulated property of the immune system, whereby, T-cells and
monocytes predominantly release IL-2, IL-10 and TNF-α in EVs [13].
This emphasises the significant role of cytokine EV-entrapment: (1) as a
mechanism to dispose of over-produced cytokines; (2) as protection
from degradation, enhancing their half-lives in circulation and (3) to
facilitate delivery to distant targets [13–16]. Therefore, cytokine EV-
encapsulation can be viewed as a carefully regulated process, involving
cell-cell communication which facilitates and is reflective of adaptation
to specific physiological and pathophysiological immune requirements
[15–17].
Exosomes (20–130 nm) are important sub-constituents of circu-
lating EVs due to their role in key physiological and pathophysiological
processes [14]. However, their immunomodulatory role in PE and PE in
HIV/HAART remains unexplored therefore the presented study ex-
amined exosomal levels of pro-inflammatory Th1 cytokines (IL-2 and
TNF-α) as well as anti-inflammatory Th2 cytokine (IL-10) in maternal
circulation [12,18]. Moreover, to identify biomarkers and therapeutic
targets in PE and PE in HIV-positive women on HAART, the complex
immune interactions in these disease states needed to be understood.
Therefore, the present study focused on elucidating: (1) the con-
centration of exosomes in maternal circulation and (2) exosomal Th1
and Th2 cytokine levels in preeclamptic and HIV-positive preeclamptic
women on HAART.
2. Materials and methods
2.1. Ethics statement
Regulatory ethical and institutional approval was obtained from the
Biomedical Research Ethics Committee of the University of KwaZulu-
Natal, South Africa (BE310/15). Patients were recruited from the Prince
Mshiyeni Hospital, KwaZulu Natal, South Africa. All participants gave
written informed consent, and the study was conducted in accordance
with the Declaration of Helsinki.
2.2. Study groups and samples
HIV-positive and HIV-negative pregnant women with PE (early
onset and late onset), in the third trimester, were recruited (n=30 per
group). HIV-positive and HIV-negative normotensive pregnant women
recruited and matched to PE groups based on their gestational (n=30
per group). HIV was detected using a rapid test kit and confirmed using
an Enzyme-linked immunosorbent assay (ELISA) performed by the
South Africa National Health Laboratory Services (Prince Mshiyeni
Hospital, Kwa-Zulu Natal, South Africa). All HIV-infected patients were
on HAART (tenofovir, emtricitabine, efavirenz) as per the CDC guide-
lines. Normotensive patients were classified by a blood pressure of
120 ± 10/80 ± 5 (systolic/diastolic mm Hg) and absent proteinuria
as detected by a rapid urine dipstick test (Markomed®, South Africa).
Early onset pre-eclampsia was classified as new-onset hypertension
(diastolic blood pressure of ≥90mm Hg and systolic blood pressure of
≥140mm Hg) and proteinuria (≥300mg) at ≤33weeks. Late onset-
pre-eclampsia was defined by new-onset hypertension (diastolic blood
pressure of> 90mm Hg and systolic blood pressure of> 140mm Hg)
and proteinuria (≥300mg) at ≥34weeks gestational age. Gestational
age matching was done on all samples collected. All patients had sin-
gleton pregnancies and those with evidence of any infections or med-
ical, surgical or other obstetric complications were excluded. Blood
samples were collected [BD Vacutainer Tubes ethylenediamine tetra-
acetic acid (EDTA), Becton Dickinson and Company, South Africa] and
the plasma samples were stored at −80 °C for analyses. All samples
analysed were not stored for more than 1month.
2.3. Isolation and characterisation of exosomes from the plasma of HIV-
positive and HIV-negative pregnant women
2.3.1. Exosome isolation
Total exosomes were isolated according to the method described by
Théry et al. [19]. Plasma (1ml) was diluted with an equal volume of
phosphate buffered saline (PBS; pH 7.4). Exosomes were isolated and
purified by differential ultracentrifugation using a 30 per cent sucrose
cushion. In brief, centrifugation was initially performed at 2000g at 4 °C
for 30min, the supernatant was collected and then centrifuged at
12,000× for 45min. Thereafter the collected supernatant was cen-
trifuged at 110,000g at 4 °C for 120min (Optima™ MAX-XP Ultra-
centrifuge, fixed angle MLA-55 rotor, Beckman Coulter Inc., Brea, CA,
USA). The pellet was suspended in Phosphate Buffered Saline (PBS) and
filtered through a 0.22 µm filter (Cellulose acetate, GVS™, Europe). The
filtrate was centrifuged at 110,000g at 4 °C for 70min, the pellet re-
suspended in PBS (pH 7.4) and centrifuged at 110,000g for 70min, 4 °C.
The exosome pellet was suspended in 1ml of PBS and subsequently
purified from contaminating HIV using a 6–18% iodixanol gradient
(Opti-prep, Sigma) [20,21]. One millilitre of the solution was then
placed on top of the 11ml gradient and was centrifuged at 200 000g for
120min at 4 °C. Thereafter twelve 1ml fractions were collected for
further characterisation.
2.3.2. Acetylcholinesterase (AChE) assay
Acetylcholinesterase activity was measured according to the
method described by Ellman et al. [22]. This assay was used to de-
termine the fractions which segregate the exosomes from the HIV
particles [20,21]. In Brief, 100 µl of each exosomal fraction was sus-
pended in 100 µl of substrate solution (1.25mM acetylthiocholine in
PBS, pH 8, mixed with 0.1mM 5,5-dithio-bis(2-nitrobenzoic acid) in
PBS pH 7 in a final volume of 200 µl). The solution was then incubated
in pre-warmed (37 °C) substrate solution for 10min and thereafter ab-
sorption was measured at 450 nm. Fractions with high AchE activity
were considered to have a high concentration of exosomes which was
confirmed using ELISA, immunoblot identification, electron microscopy
and nanoparticle tracking analysis.
2.3.3. Nanoparticle tracking analysis
Quantification and size distribution of exosomes was determined
using the NS500 equipped with a 405 nm laser and a sCMOS camera as
previously described (NanoSight NTA 3.0 Nanoparticle Tracking and
Analysis Release, Version Build 0069) [23]. Samples were diluted with
PBS prior to analysis in order to obtain particle distribution of 10 and
100 particles per image before analysis with the NTA system. Samples
were introduced into the sample chamber using the following script:
PUMPLOAD, REPEATSTART, PRIME, DELAY 10, CAPTURE 60, RE-
PEAT 5. Videos were recorded at a camera level of 10, a camera shutter
speed of 20ms and camera gain of 600, these settings were kept con-
stant between samples. Each video was then analysed to give the mean
particle size together with the concentration of particles.
2.3.4. Exosomal protein quantification
Isolated exosomes were re-suspended in PBS and the total protein
concentration determined using the RC DC Protein Assay (Bio-Rad
Laboratories, Hercules, CA, USA). The bovine γ-globulin protein stan-
dard was used.
2.3.5. Western blotting
Isolated exosome pellets were lysed with radioimunoprecipitation
assay (RIPA) buffer (1X) at room temperature for 5min and the protein
content determined using the RC DC Protein Assay (Bio-Rad
Laboratories, Hercules, CA, USA). Laemmli buffer (2X) was added to the
samples and incubated at 95 °C for 5min. Twenty micrograms of exo-
somal protein per well were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto
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polyvinylidene fluoride (PVDF) membranes which were probed with
CD63 primary antibody (ExoAB, System Biosciences, Mountain View,
CA) post-incubation at room temperature for 60min. Membranes were
washed in Tris buffer saline (pH 7.6) and incubated for 60min at room
temperature with the exosome validated secondary conjugated goat
rabbit horseradish peroxidase antibody (ExoAB, System Biosciences,
Mountain View, CA). Membranes were incubated with chemilumines-
cent substrate and visualised using the ChemiDoc® Gel Documentation
System (Bio-Rad Laboratories, Hercules, CA, USA).
2.3.6. Transmission electron microscopy
Exosomes were applied to a continuous carbon grid and negatively
stained with 2% uranyl acetate. The size and morphology of the par-
ticles were examined using a JEOL 1010 transmission electron micro-
scope (JEOL, Peabody, MA, USA) at the Electron Microscopy Unit,
University of KwaZulu-Natal.
2.4. Quantification of total and placental-derived exosomes
2.4.1. Quantification of total exosomes in maternal circulation
The concentration of total exosomes in maternal circulation was
determined by the quantification of total immunoreactive exosomal
CD63 via an enzyme-linked immune absorbency assay (ExoELISA™,
System Biosciences, Mountain View, CA), as per manufacturer’s in-
structions. In brief, 30 µg of isolated exosomal protein was immobilised
on microtiter plates overnight at 37 °C using exosome binding buffer
supplied by the manufacturer (System Biosciences). Plates were washed
and incubated at room temperature for 60min with exosome specific
primary antibody (CD63), followed by a wash step and incubation with
secondary antibody (1:5000) at room temperature for 60min with
agitation. Plates were thereafter washed and incubated with tetra-
methylbenzidine ELISA substrate at RT for 45min with agitation. The
reaction was thereafter terminated using stop buffer and the absorbance
was measured at 450 nm. The number of exosomes, (ExoELISA™ kit)
was obtained using an exosomal CD63 standard curve that was gener-
ated using the calibrated exosome standard that was supplied.
2.4.2. Quantification of placental-derived exosomes in maternal circulation
The relative concentration of placental-derived exosomes was de-
termined by the quantification of human Placental-Like Alkaline
Phosphatase (PLAP) in the exosomal fraction using a commercial ELISA
kit (Elabscience, E-EL-H1976, WuHan, P.R.C), as per manufacturer’s
instruction. In brief, 30 µg of exosomal protein was allowed to bind to
the primary PLAP specific antibody coated plates by incubation at 37 °C
for 90min. Plates were washed and 50 μl of HRP-conjugate was added
to each well and incubated at 37 °C for 20min. Plates were washed and
incubated with 50 μl of substrate A and 50 μl of substrate B at 37 °C for
15min. The reaction was terminated using 50 μl of stop solution at RT
for 2min under agitation. Absorbance was measured at 450 nm.
Exosomal PLAP was expressed as pg/ml plasma. The quantification of
PLAP in the exosomal fraction indicates the relative concentration of
placental-derived exosomes (PLAP+ exosomes) in maternal circulation.
2.5. Quantification of exosomal cytokines
2.5.1. Multiplex quantification of cytokines IL-2, IL-10 and TNF-α
Exosomal IL-2, IL-10 and TNF-α were analysed using the Milliplex
MAP Human Cytokine Panel (Merck, Germany) according to manu-
facturer’s instructions. Exosomes were solubilised by incubating the
intact exosomes with Triton X (1% v/v). The protein concentration was
then determined using the RC DC Protein Assay (Bio-Rad Laboratories,
Hercules, CA, USA). In brief, the microtiter plate was pre-wet with
200 µl assay buffer. Fifty micrograms of sample and standards were
added to the appropriate wells followed by the addition of the magnetic
beads. The plate was incubated for 240min with agitation at room
temperature, the fluid was then removed, and the wells washed twice
with wash buffer. Detection antibodies (anti-IL-2, IL-10 and TNF-α)
were then added to each well and incubated for 60min at room tem-
perature. Thereafter the fluorescent Streptavidin-Phycoerythrin con-
jugate was added to each well and incubated for 30min at room tem-
perature. The fluid was then removed, and the wells were washed twice
with buffer. The analytes were then resuspended in sheath fluid and
analysed using the Luminex 100 instrument (Bio-Rad). Data were
analysed using the Bio Manager Analytical software (BioRad) with the
lower detection limit at 3.2 pg/ml for all analytes with an intra-assay
variability of less than 10%.
2.6. Statistical analysis
All data analyses and graphical representations were performed and
generated using GraphPad Prism 6.0 (CA, La Jolla). Data distribution
was determined using the Kolmogorov-Smirnov normality test with
Dallal-Wilkinson-Lilliefor P-value, all data were found to be normally
distributed. One-way Analysis of Variance (ANOVA) followed by Tukey
post-hoc testing was done to determine the level of significance of
differences between groups. Statistical significance was defined as
p < 0.05. Where applicable data are represented as the mean ± SEM.
Graphical representation of data is summarised using box and whisker
plots including median and interquartile range. Cut-off values for exo-
somal markers, cytokines and ratios which diagnose PE and its subtypes
were conducted using receiver operating characteristics analysis
(GraphPad Prism 6.0). Cut-off values of diagnostic relevance were de-
fined as having a sensitivity of 100% and a specificity of 90% with a
positive likelihood ratio (LHR) of 10 at a CI of 95%.
3. Results
The focus of the analysis was conducted on PE and PE in HIV-po-
sitive pregnant women on HAART vs. their respective controls. The
differentiation between EOPE and LOPE is of clinical importance irre-
spective of HIV status. All significant findings between each of the
groups described above was summarised in Table 1.
3.1. Participant clinical characteristics
There was no significant difference in blood pressure and protei-
nuria between the N (≤33weeks) and N (≥34weeks) groups. All CD4
counts were above 400 cells/mm3 with no significant differences be-
tween groups (p > 0.05). A significant increase in blood pressure was,
however, observed in PE vs. N [HIV-positive (EOPE: 177/99 ± 4.23/
6.66 vs. 118/77 ± 4.71/3.66 and LOPE: 166/96 ± 4/3 vs. 128/
85 ± 2.77/3.11 mm Hg) and HIV-negative (EOPE: 166/96 ± 4/3 mm
Hg vs. 124/75 ± 2.11/1.56 and LOPE: 165/91 ± 3.2/5.42 vs. 123/
80 ± 2/4 mm Hg) total exosomes/ml, Table 2, p < 0.001].
Proteinuria was significantly elevated in EOPE in comparison to
LOPE (HIV-positive 466 ± 64.99 vs. 345 ± 54.21 and HIV-negative
495 ± 66.41 vs. 389 ± 60.90mg/dl, Table 1). It is notable that the
BMI of the early onset-PE group was significantly greater than the late
onset-PE group [(HIV-positive: 36.80 ± 3.32 vs. 28.10 ± 2.08) and
(HIV-negative: 36.10 ± 4.41 vs. 28.0 ± 1.08 p < 0.001)].
3.2. Isolation and characterisation of exosomes from HIV-infected and non-
infected pregnant women
Exosomes were isolated using density gradient ultracentrifugation
and were distinguished from HIV particles by acetylcholinesterase
(AChE) activity. The fractions with a lower-density collected from the
top of the iodixanol gradient were enriched for exosomes as confirmed
by AChE activity (1–5, Fig. 1). Discarded HIV particles were segregated
in the higher-density fractions (at the bottom of the iodixanol gradient)
and were confirmed to have no AChE activity (6–12, Fig. 1). These
results are in accordance with previous studies [20,21]. The presence of
P. Pillay, et al. Cytokine 125 (2020) 154795
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exosomes was further confirmed by western blot analysis using the
CD63 exosomal marker, transmission electron microscopy and nano-
particle tracking analysis (Fig. 1). Isolated exosomes were within the
accepted exosomal size range of 20–130 nm (Fig. 1).
3.3. Quantification of total and placental-derived exosomes in maternal
circulation
3.3.1. Quantification of total exosomes
Significantly increased levels of total exosomes were observed in
HIV-positive vs. negative normotensive pregnant women
[(N≤ 33weeks: 9.96 ± 0.04×109 vs. 6.16 ± 0.05×109) and
(N≥ 34weeks: 1.22 ± 0.04× 1010 vs. 8.45 ± 0.05× 109) total
exosomes/ml plasma, p < 0.001, Fig. 2A]. Similarly, a significantly
higher total exosome concentration in HIV-positive in comparison to
HIV-negative PE pregnant women was observed [EOPE:
3.71 ± 0.06× 1010 vs. 2.73 ± 0.01×1010 and LOPE:
2.15 ± 0.07× 1010 vs. 1.71 ± 0.06×1010 total exosomes/ml
plasma, p < 0.001].
The total exosome concentration in [HIV-positive PE vs. N] and
[HIV-negative PE vs. N] pregnant women was significantly higher [HIV-
positive: (EOPE: 3.710 ± 0.6×1010 vs. 9.96 ± 0.4× 109 and LOPE:
2.15 ± 0.05× 1010 vs. 1.22 ± 0.05×109) and HIV-negative (EOPE:
2.273 ± 0.05×1010 vs. 6.16 ± 0.4×109 and LOPE:
Fig 1. Isolation and Characterisation of Exosomes from HIV-infected and non-infected pregnant woman. Exosomes from preeclamptic and normotensive pregnant
women were isolated and characterised. (A) Nanoparticle Tracking Analysis (NTA) illustrating the representative vesicle size distribution (nm). (B) Representative
NTA video frame of the isolated exosomes. (C) Enzymatic assay for acetylcholinesterase (AChE) and (D) Western blot analysis for exosomal CD63. (E) Electron
micrograph of isolated exosomes, scale bar 100 nm.
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1.71 ± 0.05×1010 vs. 8.45 ± 0.05× 109) total exosomes/ml
plasma, p < 0.001].
The total exosome concentration was significantly higher in HIV-
positive EOPE (3.71 ± 0.06×1010/ml plasma) vs. LOPE
(2.15 ± 0.07× 1010/ml plasma) (p < 0.001). Additionally, the total
exosome concentration in HIV-negative EOPE (2.27 ± 0.08×1010/ml
plasma) vs. LOPE (1.71 ± 0.05×1010/ml plasma) was significantly
higher (p < 0.001).
3.3.2. Quantification of placental-derived exosomes
The relative concentration of the placental-derived exosomes was
determined by quantifying the exosomal PLAP concentration (Fig. 2B).
Placental-derived exosome concentration in HIV-positive pregnant
women was significantly higher in comparison to HIV-negative nor-
motensive pregnant women [(N≤ 33 weeks: 557.7 ± 5.63 vs.
412.3 ± 4.91 pg/ml) and (N≥ 34weeks: 501.8 ± 4.48 vs.
270.4 ± 6.64) pg/ml, Fig. 2B p < 0.001]. Significantly increased
placental-derived exosomes were observed in HIV-positive
(662.8 ± 7.3 pg/ml) vs. HIV-negative (179.8 ± 7.39 pg/ml), LOPE
was observed (p < 0.001). On the other hand, the concentration of
placental-derived exosomes was significantly decreased in HIV-positive
(107.5 ± 8.39 pg/ml) compared to HIV-negative EOPE
(384.3 ± 6.01 pg/ml), p < 0.001.
Significantly increased placental-derived exosomes was observed in
HIV-positive LOPE (662.8 ± 7.3 pg/ml) in comparison to N
[≥34weeks, (557.7 ± 5.63 pg/ml)] (p < 0.001). However, a sig-
nificant decrease in the concentration of placental-derived exosomes in
HIV-positive EOPE (107.5 ± 8.39 pg/ml) vs. N [≤33weeks,
(501.8 ± 4.48 pg/ml)] was observed (p < 0.001).Significantly in-
creased placental-derived exosomes was observed in HIV-negative
EOPE (384.3 ± 6.01 pg/ml) in comparison to N [≤33weeks,
(270.4 ± 6.64 pg/ml)] (p < 0.001). On the other hand, a significant
decrease in the concentration of placental-derived exosomes in HIV-
negative LOPE (179.8 ± 7.39 pg/ml) vs. N (412.3 ± 4.91 pg/ml) was
observed (p < 0.001).
A significant decrease in placental-derived exosomes in HIV-positive
EOPE (107.5 ± 8.39 pg/ml) vs. LOPE (662.8 ± 7.3 pg/ml) was ob-
served (p < 0.001). We also observed a significant increase in pla-
cental-derived exosomes in HIV-negative EOPE (384.3 ± 6.01 pg/ml)
vs. LOPE (179.8 ± 7.39 pg/ml) (p < 0.001).
3.3.3. The relative contribution of placental-derived exosomes to total
exosomes in maternal circulation
The contribution of placental-derived (PLAP+) exosomes to total
exosomes in maternal circulation was determined by calculating the
ratio of PLAP content per exosome (Fig. 2C). Significant differences in
the ratio of PLAP+ exosomes to total exosomes were observed (Fig. 2C).
Significantly decreased ratio of PLAP+ exosomes to the total number of
exosomes was identified in HIV-negative EOPE (1.69 ± 0.04× 10−8)
in comparison to N [≥33weeks, (5.55 ± 0.05×10−8)]. Similarly a
decreased ratio of PLAP+ exosomes to the total number of exosomes
was identified in HIV-negative LOPE (1.05 ± 0.08×10−8) in com-
parision to N [≥34weeks, (4.59 ± 0.06×10−8)], Fig. 2C,
p < 0.001. Additionally, a significant decrease in the ratio of PLAP+
Fig 2. Quantification of total and placental-derived exosomes in maternal cir-
culation. Total and placental-derived exosomes were quantified in HIV-positive
and -negative preeclamptic and normotensive pregnant women. (A) Total
exosome concentration was determined by the quantification of exosomal CD63
marker per ml of plasma using ELISA. (B) Placental-derived exosomes (i.e.
exosomal placenta alkaline phosphatase (PLAP) was quantified per ml of
plasma by ELISA. (C) The ratio of placental-derived exosomes (PLAP+) to total
exosomes (CD63+). In A, B and C the horizontal bars indicate the level of
significance of the difference between two groups at either end of the bar tails,
*p < 0.01, **p < 0.001, ***p < 0.0001 using one-way ANOVA followed by
Tukey post-hoc testing. Red horizontal bars indicate ROC cut-off values at a
sensitivity of 100% and specificity of 90% with a positive LHR≥ 10 (CI: 95%).
Data are presented as box and whisker plots including mean and interquartile
range. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
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exosomes per number of total exosomes in HIV-positive PE vs.N was
observed [EOPE: (3.49 ± 0.04×10−9 vs. 4.73 ± 0.08×10−8) and
LOPE: (3.09 ± 0.08×10−8 vs.4.93 ± 0.06×10−8), Fig. 2C,
p < 0.001].
Moreover, a significant decrease in the ratio of PLAP+ exosomes to
the total number of exosomes was identified in [HIV-positive
(3.49 ± 0.041×10−9) vs. HIV-negative (1.69 ± 0.04× 10−8)
EOPE] whereas a significant increase in [HIV-positive
(3.09 ± 0.04×10−8) vs. HIV-negative (1.05 ± 0.04× 10−8) LOPE]
was observed (Fig. 2C, p < 0.001).
A significantly decreased ratio of PLAP+ exosomes to total exo-
somes between HIV-positive EOPE (3.49 ± 0.041×10−9) vs. LOPE
(3.09 ± 0.06×10−8) was observed (Fig. 2C, p < 0.001). On the
other hand, a significant increase in the ratio between HIV-negative
EOPE (6.40 ± 0.1× 10−9) vs. LOPE (4.59 ± 0.6×10−8) was ob-
served (Fig. 2C, p < 0.001).
3.4. Quantification of exosomal cytokines
3.4.1. IL-10 (Th2 anti-inflammatory cytokine)
Significantly decreased exosomal IL-10 was observed in [HIV-posi-
tive PE vs. N, (EOPE: 48 ± 0.7 vs. 56.85 ± 1.25 and LOPE:
41.82 ± 1.4 vs. 53.02 ± 1.65) pg/ml] and [HIV-negative PE vs. N,
EOPE: 56.23 ± 0.93vs.68.81 ± 1.12 and LOPE: 50.80 ± 1.25 vs.
66.59 ± 1.64) pg/ml], Fig. 3C, p < 0.001. Similarly, a significant
decrease in exosomal IL-10 was observed in HIV-positive vs. HIV-ne-
gative normotensive pregnant women [N: ≤33weeks (56.83 ± 1.24
vs. 63.8 ± 1.12) and N: ≥34 weeks (53 ± 1.65 vs. 66.6 ± 1.64) pg/
ml, p < 0.01, Fig. 3A]. Moreover, a significant decrease in exosomal
IL-10 in HIV-positive vs. HIV-negative PE was observed [EOPE:
48 ± 0.71 vs. 56.23 ± 0.93 and LOPE: 41.83 ± 1.48 vs
50.66 ± 1.25 pg/ml, p < 0.001, Fig. 3A].
3.4.2. IL-2 and TNF-α (Th1 pro-inflammatory cytokines)
Significantly increased exosomal TNF-α was observed in HIV-posi-
tive PE vs. N, (EOPE: 90.26 ± 2.85 vs. 53.86 ± 4 and LOPE:
65.38 ± 1.4 vs. 44.71 ± 2.03 pg/ml) and HIV-negative PE vs. N,
(EOPE: 67.85 ± 1.05 vs.46.37 ± 1.41 and LOPE: 66.84 ± 1.15 vs.
49.03 ± 1.41 pg/ml), Fig. 3C, p < 0.001. Moreover, a significant in-
crease in exosomal TNF-α was observed in HIV-positive
(90.26 ± 2.85 pg/ml) vs. HIV-negative (67.85 ± 1.05 pg/ml) EOPE,
Fig. 3C, p < 0.001.
Significantly increased exosomal IL-2 was observed in HIV-positive
vs. HIV-negative normotensive pregnant women [N≤ 33weeks
(76.14 ± 1.45 vs. 30.70 ± 1.37) and N≥ 34weeks (65.87 ± 3.43
vs. 25.08 ± 2.78) pg/ml, p < 0.01, Fig. 3B].
Similarly, a significant increase in exosomal IL-2 in HIV-positive PE
vs. N, (EOPE: 103.5 ± 2.86 vs. 76.14 ± 1.45 and LOPE: 130 ± 2.9
vs. 66 ± 3.43 pg/ml) and HIV-negative PE vs. N, (EOPE:
62.73 ± 1.91 vs. 30.70 ± 4.12 and LOPE: 40.80 ± 3.62 vs.
25.08 ± 2.78 pg/ml) was observed, Fig. 3B, p < 0.01. Moreover, a
significant increase in exosomal IL-2 in HIV-positive vs. HIV-negative
PE was observed [EOPE: 103.5 ± 2.86 vs. 62.73 ± 1.91, p < 0.001
and LOPE: 130.7 ± 2.9 vs. 40.8 ± 3.62 pg/ml, Fig. 3B, p < 0.01].
Significantly increased exosomal IL-2 was observed in HIV-negative
EOPE (62.73 ± 1.91 pg/ml) in comparision to LOPE (40.8 ± 3.62 pg/
ml), Fig. 3B, p < 0.001. Moreover, a significant increase in exosomal
TNF-α in HIV-positive EOPE (90.28 ± 2.85 pg/ml) in comparison to
LOPE (65.38 ± 1.40 pg/ml) was observed, Fig. 3C, p < 0.001. On the
other hand, a significant decrease in exosomal IL-2 was observed in
HIV-positive EOPE (103.5 ± 2.86 pg/ml) in comparision to LOPE
(130.7 ± 2.9 pg/ml), Fig. 3B, p < 0.001.
3.5. Th1/Th2 exosomal cytokine ratio in maternal circulation
3.5.1. TNF-α (Th1)/IL-10 (Th2)
The ratio of exosomal TNF-α (Th1) to IL-10 (Th2) in maternal
(caption on next page)
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circulation was calculated (Fig. 4A). A significantly increased exosomal
TNF-α/IL-10 ratio was observed in HIV-positive PE vs. N (EOPE:
1.88 ± 0.1 vs. 0.95 ± 0.03, p < 0.01, and LOPE: 1.58 ± 0.07 vs.
0.85 ± 0.04, p < 0.001) and HIV-negative PE vs. N (EOPE:
1.07 ± 0.03 vs. 0.82 ± 0.05 and LOPE: 1.32 ± 0.03 vs.
0.74 ± 0.02, pg/ml, Fig. 4A, p < 0.01). Similarly, a significant in-
crease in exosomal TNF-α/IL-10 ratio was observed in HIV-positive
(1.88 ± 0.1, pg/ml) incomparision to HIV-negative PE
(1.07 ± 0.03 pg/ml) EOPE, Fig. 4A, p < 0.001. No significant in-
tragroup associations were observed (p > 0.05).
3.5.2. IL-2 (Th1)/IL-10 (Th2)
The ratio of exosomal IL-2 (Th1) to IL-10 (Th2) in maternal circu-
lation was calculated (Fig. 4B). A significantly increased exosomal IL-2/
IL-10 ratio was observed in HIV-positive vs. HIV-negative normotensive
pregnant women [N≤ 33 weeks (1.34 ± 0.03 vs. 0.54 ± 0.03) and
N≥ 34weeks (1.25 ± 0.07 vs. 0.38 ± 0.04) pg/ml, p < 0.01,
Fig. 3B].
Significantly increased exosomal IL-2/IL-10 ratio was observed in
HIV-positive in comparison to HIV-negative pregnant women [EOPE:
(2.16 ± 0.06 vs. 1.0 ± 0.04) and LOPE: (3.16 ± 0.13 vs.
0.82 ± 0.1), Fig. 4B, p < 0.001]. Moreover, a significant increase in
the exosomal IL-2/IL-10 ratio in HIV-positive PE in comparision to N
was observed [EOPE: 2.16 ± 0.06 vs. 1.34 ± 0.03, and LOPE:
3.16 ± 0.13 vs. 1.25 ± 0.07 pg/ml, Fig. 4B, p < 0.001)]. On the
other hand a significant decrease in the exosomal IL-2/IL-10 ratio in
HIV-positive EOPE vs. LOPE was observed (2.16 ± 0.06 vs.
3.16 ± 0.13, Fig. 4B, p < 0.001).
3.6. The relative contribution of exosomal cytokines to placental-derived
exosomes in maternal circulation
A significant increase in the ratio of exosomal cytokines to PLAP+
exosomes was observed in HIV-positive in comparison to HIV-negative
EOPE [IL-10/PLAP: (0.47 ± 0.04 vs. 0.14 ± 0.01), IL-2/PLAP:
(1.02 ± 0.08 vs. 0.16 ± 0.01) and TNF-α/PLAP: (0.9 ± 0.09 vs.
0.17 ± 0.01), pg/ml, Fig. 5, p < 0.001]. Similarly, a significant in-
crease in the ratio in HIV-positive EOPE vs. N (≤33weeks) was ob-
served [IL-10/PLAP: (0.47 ± 0.04 vs. 0.11 ± 0.01), IL-2/PLAP:
(1.02 ± 0.08 vs. 0.15 ± 0.01) and TNF-α/PLAP: (0.9 ± 0.09 vs.
0.1 ± 0.01), pg/ml, Fig. 5, p < 0.001]. Moreover, a significant in-
crease in the ratio in HIV-negative LOPE vs. N (≥34weeks) was ob-
served [IL-10/PLAP: (0.29 ± 0.01 vs. 0.16 ± 0.01), IL-2/PLAP:
(0.22 ± 0.02 vs. 0.06 ± 0.005) and TNF-α/PLAP: (0.38 ± 0.02 vs.
0.12 ± 0.01), pg/ml, Fig. 5, p < 0.001].
Significantly increased ratio of exosomal cytokines to PLAP+ exo-
somes in HIV-positive EOPE incomparision to LOPE was observed [IL-
10/PLAP: (0.47 ± 0.05 vs. 0.06 ± 0.001), IL-2/PLAP: (1.02 ± 0.08
vs. 0.2 ± 0.01) and TNF-α/PLAP: (0.9 ± 0.09 vs. 0.09 ± 0.005),
Fig. 5, p < 0.001]. On the contrary, a significantly decreased ratio of
exosomal TNF-α to PLAP+ exosomes in HIV-positive EOPE in com-
parison to LOPE was observed [TNF-α/PLAP: (0.18 ± 0.01 vs.
0.37 ± 0.02), Fig. 5, p < 0.001].
3.7. Diagnostic value of exosomes in preeclampsia in HIV-Positive and HIV-
Negative pregnant women
3.7.1. Total and placental-derived exosomes
The ratio of placental derived to total exosomes suggests diagnostic
potential in determining PE but it cannot differentiate between the
subtypes. The ratio predicted PE in HIV-positive and -negative preg-
nancies with a cut-off value of 4.51× 108 at a sensitivity of 100% (95%
CI: 69.15–100.0%) and specificity of 90% (95% CI: 55.50–99.75%)
with a positive LHR of 10.
Fig 3. Quantification of Exosomal Cytokines in maternal circulation. Exosomal
(A) IL-10, (B) IL-2 and (C) TNF-α was quantified in HIV-positive and -negative
preeclamptic and normotensive pregnant women (pg/ml plasma). Horizontal
bars indicate the level of significance of the difference between two groups at
either end of the bar tails, *p < 0.01, **p < 0.001, ***p < 0.0001 using one-
way ANOVA followed by Tukey post-hoc testing. Data are presented as box and
whisker plots including mean and interquartile range. In B and C the red hor-
izontal lines indicate the significant ROC cut-off values in distinguishing be-
tween experimental and control groups whereas the blue horizontal line dis-
tinguishes the significant ROC cut-off values between HIV-positive EOPE and
LOPE at a sensitivity of 100% and a specificity of 90% with a positive LHR≥ 10
(CI: 95%). No significant cut-off values between HIV-positive EOPE and LOPE
were observed (p > 0.05). (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
Fig 4. Th1/Th2 ratio analysis of exosomal cytokines. The Th1/Th2 ratio of
exosomal (A) TNF-α/IL10 and (B) IL2/IL10 and was determined in HIV -posi-
tive and -negative preeclamptic and normotensive pregnant women. Horizontal
bars indicate the level of significance of the difference between two groups at
either end of the bar tails, *p < 0.01, **p < 0.001, ***p < 0.0001 using one-
way ANOVA followed by Tukey post-hoc testing. Data are presented as box and
whisker plots including mean and interquartile range.
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3.7.2. Exosomal cytokines
It is important to note that exosomal IL10, Th1/Th2 cytokine ratios
& exosomal cytokine/placental-derived exosome ratios do not indicate
any strong application in diagnosing PE in comparison to controls
(LHR < 10). However individual exosomal cytokines IL-2 and TNF-α
showed promising potential in diagnosing PE (Table 3).
3.7.2.1. IL-2. Exosomal IL-2 levels predicted PE in the HIV-positive
EOPE, HIV-positive LOPE and HIV-negative EOPE in comparison to
their controls with cut-off values of 82, 36 and 83 pg/ml respectively at
a sensitivity of 100% (95% CI: 69.15–100.0%) and specificity of 90%
(95% CI: 55.50–99.75%) with a positive LHR of 10. Additionally, it was
only able to differentiate EOPE from LOPE in the HIV-positive patient
cohort with a cut-off value of 117 pg/ml at a sensitivity of 100% (95%
CI: 69.15–100.0%) and specificity of 90% (95% CI: 55.50–99.75%)
with a positive LHR of 10.
3.7.2.2. TNF-α. Exosomal TNF-α levels predicted PE in the HIV-
positive EOPE, HIV-positive LOPE, HIV-negative EOPE and HIV-
negative LOPE in comparison to their controls with cut-off values of
59, 53, 58 and 52 pg/ml respectively at a sensitivity of 100% (95% CI:
69.15–100.0%) and specificity of 90%(95% CI: 55.50–99.75%) with a
positive LHR of 10. Additionally, it was only able to differentiate EOPE
from LOPE in the HIV-positive patient cohort with a cut-off value of 79
117 pg/ml at a sensitivity of 100% (95% CI: 69.15–100.0%) and
specificity of 90% (95% CI: 55.50–99.75%) with a positive LHR of 10.
4. Discussion
The present study demonstrates alterations in levels of total exo-
somes, placental-derived exosomes and exosomal cytokines (IL-10, IL-2
and TNF-α) in preeclamptic pregnant women as well as HIV-positive
preeclamptic pregnant women on HAART. The findings obtained sup-
port the probable role of exosomes in the pathogenesis of preeclampsia
and preeclampsia in HIV-positive women on HAART. Importantly,
these findings support the clinical application of exosomes in diag-
nosing PE and PE in HIV-positive pregnant woman.
4.1. Total and placental-derived exosomes and their relative contribution
The significant increase in total and placental-derived exosomes
observed in PE which is consistent with our previous study where we
associated this finding with the pathophysiology of PE and its subtypes
[23]. Moreover, the observations made in this study indicated a similar
increase in HIV-positive pregnant woman on HAART. This could pos-
sibly be attributed to the enhanced maternal immune response induced
by the HAART reconstituted maternal immune system.
We also observed a significantly lower ratio of placental derived to
total exosomes in PE. Since, exosomes are known to regulate foeto-
maternal immune tolerance in normal pregnancy [24], this may be a
consequence of the foeto-maternal immune imbalance which negatively
affects placental development. Moreover, the significantly lower ratio
of placental-derived to total exosomes in HIV-positive EOPE suggests
that HAART may be responsible for the augmentation of the more se-
vere clinical outcomes associated with EOPE in HIV-positive pregnant
women on HAART. The implication is that HAART immune recon-
stitution may contribute to the foeto-maternal immune maladaptation,
contributing to the improper placental development, which culminates
in the clinical manifestation of PE.
Fig 5. The relative contribution of exosomal cytokines to placental-derived
exosomes in maternal circulation. The ratio of (A) IL-10/placental-derived
exosomes, (B) IL-2/placental-derived and (C) TNF-α/placental-derived exo-
somes from maternal circulation was determined in HIV -positive and -negative
preeclamptic and normotensive pregnant women. Horizontal bars indicate the
level of significance of the difference between two groups at either end of the
bar tails, **p < 0.001, ***p < 0.0001 using one-way ANOVA followed by
Tukey post-hoc testing. Data are presented as box and whisker plots including
mean and interquartile range.
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4.2. Quantification of pro- and anti-inflammatory exosomal cytokines
4.2.1. IL-2 and TNF-α (Th1 pro-inflammatory cytokines)
The increase in exosomal IL-2 and TNF-α observed in PE and in PE
in HIV-positive pregnant women on HAART may contribute to the
systemic pro-inflammatory state commonly associated with PE patho-
physiology [25]. Moreover, the significant increase in exosomal IL-2 in
HIV-negative EOPE vs. LOPE suggest that exosomal IL-2 may contribute
to the more severe clinical symptoms associated with EOPE. These re-
sults imply that exosomes may be directly involved in the pathophy-
siology of PE since increased IL-2 and TNF- α expression has been as-
sociated with endothelial cell injury [26,27].
A significant increase in exosomal IL-2 and TNF-α was observed in
HIV-positive preeclamptic women on HAART. These proinflammatory
cytokines are known to have a role in maintaining CD4+ T cell pro-
liferation and differentiation [28,29] we therefore speculate that the
dysregulation of exosomal proinflammatory cytokines occurs due to the
HAART reconstituted maternal immune system, whereby the improper
restoration of specific T-cell memory phenotypes result in immune ac-
tivation [30,30–32]. This could further enhance maternal immune ac-
tivation in response to the allogenic foetus, subsequently leading to the
immune pathogenesis associated with PE. Importantly, from these
findings we postulate that the link between the pathogenesis of PE and
HAART-induced maternal immune reconstitution occurs through an
exosomal microenvironment, which modulates immune activity and
enhances the potency of pro-inflammatory cytokines in maternal cir-
culation.
4.2.2. IL-10 (Th2 anti-inflammatory cytokine)
The significant decrease in exosomal IL-10 observed in PE may be
reflective of the role of exosomes in the immune pathogenesis of PE
[33]. IL-10 is considered a master regulator of immunity in pregnancy
and sufficient levels are required to suppress active maternal immunity
to allow for the acceptance of the foetal allograft [34]. Reports indicate
that extracellular vesicle IL-10 encapsulation is representative of ap-
proximately 100% of circulating IL-10 [13]. We therefore hypothesise
that the decreased exosomal encapsulation of IL-10 in PE promotes a
pro-inflammatory phenotype, resulting in an immune and angiogenic
imbalance [35], which leads to endothelial dysfunction and subsequent
hypertension, organ damage and proteinuria [36].
Similarly, we identified a decrease in exosomal IL-10 in HIV-positive
PE women on HAART. This may occur as a result of inappropriate
immune reconstitution, whereby, decreased levels of memory CD4+ T
cells and increased reconstitution of naïve CD4+ T-cells commonly
associated with HAART [32,37], alter the immune microenvironment,
which contributes to the pathogenesis of PE.
4.2.3. Th1/Th2 ratio analysis of exosomal cytokines in maternal
circulation
In order for the mother to tolerate the semi-allogenic foetus a shift
towards Th2 immunity is essential to achieve positive obstetric out-
comes [3], whereas Th1 dominant immunity results in subsequent PE
and foetal abortion [4]. Therefore, the Th1/Th2 cytokine ratio is an
indicator of the normal or compromised immune state of pregnancy. In
this study, exosomal Th1/Th2 cytokine ratios (TNF-α/IL-10 and IL-2/
IL-10) in all normotensive pregnancies favoured a Th2 type immunity,
thereby signifying the role of exosomes in maternal-foetal tolerance in
HIV-positive and HIV-negative normotensive pregnancies. On the other
hand, the increased exosomal Th1/Th2 ratios (TNF-α/IL-10 and IL-2/
IL-10) in PE, indicate a shift towards Th1 immunity which is commonly
associated with exaggerated inflammatory responses in PE. These
findings support the possible role of exosomes in mediating foeto-ma-
ternal immune balance in normal pregnancy, and the immune dysre-
gulation in PE.
Importantly the significantly higher exosomal Th1/Th2 ratios in
HIV-positive PE woman on HAART indicate an exosome-mediated Th1
skewness, which may be as result of the overactive maternal immune
system to foetal antigens, caused by disproportionate maternal immune
reconstitution by HAART [9]. Although the exact mechanisms involved
in immune reconstitution remain unknown, we speculate that the HIV
proviral latent state may contribute to the irregular activation of the
maternal immune system through a network of exosomal cytokines
which control viral replication.
4.2.4. Ratio of exosomal cytokines to placental-derived exosomes
The significant increase in the ratio of exosomal cytokines to
Table 3
The sensitivity and specificity of exosomal cytokines in preeclamptic and HIV-positive preeclamptic pregnant woman.
Exosomal Cytokine Comparison Cut-off Value Sensitivity (%) 95% CI Specificity (%) 95% CI Likelihood Ratio
IL10 HIV-positive
EOPE vs. N >51 100 69.15–100.0% 90 55.50–99.75% 10
LOPE vs. N >49 70 34.75–93.33% 90 55.50–99.75% 7
EOPE vs. LOPE <45 70 34.75–93.33% 90 55.50–99.75% 7
HIV-negative
EOPE vs. N >60 90 55.50–99.75% 90 55.50–99.75% 9
LOPE vs. N >56 100 69.15–100.0% 90 55.50–99.75% 10
EOPE vs. LOPE <52 60 26.24–87.84% 90 55.50–99.75% 6
IL2 HIV-positive
EOPE vs. N >82 100 69.15–100.0% 90 55.50–99.75% 10
LOPE vs. N >83 100 69.15–100.0% 90 55.50–99.75% 10
EOPE vs. LOPE >117 100 69.15–100.0% 90 55.50–99.75% 10
HIV-negative
EOPE vs. N >36 100 69.15–100.0% 90 55.50–99.75% 10
LOPE vs. N <44 70 34.75–93.33% 90 55.50–99.75% 7
EOPE vs. LOPE <82 90 55.50–99.75% 80 44.39–97.48% 4.5
TNF-α HIV+
EOPE vs. N >58 100 69.15–100.0% 90 55.50–99.75% 10
LOPE vs. N >52 100 69.15–100.0% 90 55.50–99.75% 10
EOPE vs. LOPE <79 100 69.15–100.0% 90 55.50–99.75% 10
HIV−
EOPE vs. N >59 100 69.15–100.0% 90 55.50–99.75% 10
LOPE vs. N >53 100 69.15–100.0% 90 55.50–99.75% 10
EOPE vs. LOPE <64 30 6.674–65.25% 90 55.50–99.75% 3
N=normotensive pregnancies; EOPE= early onset pre-eclampsia; LOPE= late onset pre-eclampsia.
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placental-derived exosomes observed in HIV-positive vs. HIV-negative
EOPE suggests that the more severe outcomes commonly associated
with preeclamptic pregnant women on HAART [2,38] may be related to
the maternal immune maladaptation caused by HAART and not due to
its toxicity. Moreover, the increase in the ratio in HIV-positive EOPE vs.
LOPE, suggests that circulating exosomes may reflect the variations in
placental and maternal immune-related stress response pathways be-
tween the sub-types in HIV-positive pregnant woman on HAART. From
these findings we hypothesise that, irrespective of the comorbidity,
EOPE and LOPE occur due to differences in their eitopathogensis which
clarifies their differences in severity.
4.3. Diagnostic value
4.3.1. The ratio of placental-derived to total exosomes
It is important to note that total or placental-derived exosomes in-
dependently do not possess clinical diagnostic utility (LHR < 10),
which is possibly due to their diverse roles in modulating immune re-
sponses in normal pregnancy and PE. However, the ratio of placental-
derived to total exosomes suggests potential diagnostic application in
determining PE in HIV-positive and HIV-negative pregnant women.
4.3.2. Ant-inflammatory cytokines
The data analysis showed no clinical significance in the potential of
IL-10 (LHR < 10).
4.3.3. Pro-inflammatory cytokines
Pro-inflammatory IL-2 and TNF-α have shown potential clinical
significance in diagnosing EOPE and LOPE in HIV-positive women on
HAART (CI: 95%, LHR > 10, sensitivity of 100% and specificity of
90%). More importantly, we demonstrate the potential clinical utility of
exosomal TNF-α in diagnosing PE in both HIV-positive and -negative
pregnant women with a definitive distinction between EOPE and LOPE
in only HIV-positive pregnant women on HAART (CI: 95%, LHR > 10,
sensitivity of 100% and specificity of 90%).
4.4. Limitations
Due to ethical considerations, untreated HIV-positive pregnant
women could not be included in this study. Future in-vivo and in-vitro
functional studies would also aid in elucidating the biological me-
chanism of action of exosomes in the pathophysiology of PE in HIV-
positive pregnant women. A larger prospective observational study
together with validation strategies is underway to qualify exosomal
cytokines as candidate biomarkers in PE (non-infected) and PE in HIV-
positive pregnant women on HAART in early pregnancy.
5. Conclusion
This study investigated the potential use of exosomes and its asso-
ciated cytokines as biomarkers of PE and PE in HIV/HAART. The
findings from this study highlight the immune-related pathophysiolo-
gical implications of HAART immune reconstitution on pregnancy
outcomes, which may be modulated by exosomes. Moreover, the ob-
served alterations in the Th1/Th2 ratio in HIV/HAART pregnancies
complicated with EOPE and LOPE implicates exosomes as central fa-
cilitators of PE and HIV pathogenesis. Importantly, we have shown that
exosomal pro-inflammatory cytokines have promising clinical applica-
tion in diagnosing preeclampsia and preeclampsia in HIV-positive
pregnant women on HAART.
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5. Chapter Five: Synthesis 
5.1 Synthesis 
 
The scientific understanding of disease pathogenesis involves the integration of information 
from numerous, complex physiological systems. Preeclampsia, a debilitating pregnancy-
related disorder, is complicated by its unknown etiopathogenesis [95].  Therefore, 
identification of definitive, early biomarkers of preeclampsia is a challenging area of research. 
Exosomes have been reported to have numerous roles in normal pregnancy per se, especially 
with regard to immunomodulation [70], endothelial function [96] and placental development 
[97]. However, exosomes have also been implicated in abnormal pregnancies. In particular, we 
were the first to have reported altered levels of total and placental-derived exosomes in early 
and late onset preeclampsia [11], suggesting their involvement in the pathophysiology of 
preeclampsia which formed the rationale for the evaluation of exosomes as biomarkers of 
preeclampsia.  Therefore the data presented in this study are a progression from our initial 
findings with the aim of providing evidence further supporting the potential use of exosomes 
as biomarkers of PE in compliance with FDA criteria. 
 
In publication one (Chapter Two), the theoretical ‘context of use’ of exosomes as biomarkers 
of PE was developed, based on the FDA Biomarker Framework [92]. From the perspective of 
the current state of PE biomarkers, we critically reviewed and evaluated the potential biomarker 
application of exosomes based on the following criteria: (1) Can exosomes in preeclampsia be 
isolated and quantified using standardised methods from maternal circulation? (2) Are 
exosomes distinctly dysregulated in preeclampsia in comparison to normotensive pregnancies? 
and (3) Do exosomes contain specific and distinct molecular markers, which can improve 
biomarker sensitivity and specificity for the disease in question?  From this review, it was 
evident that exosomes do have potential in diagnosing preeclampsia which formed the basis 
for our subsequent experiments. 
 
We have shown that exosomes can be isolated and quantified in maternal circulation, however, 
this criterion alone does not justify their use as biomarkers of preeclampsia.  Therefore, 
publication two (Chapter 3) subsequently focused on the role of exosomal miRNA in the 
pathophysiology of preeclampsia.  We and others have reported altered levels of microRNAs 
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in the pathophysiology of preeclampsia [63, 98]. However, these miRNAs do not qualify as 
biomarkers of preeclampsia due to their low diagnostic sensitivity and specificity [63, 99], 
which may be attributed to the unknown origin of the miRNA in maternal circulation. 
 
Current methods of miRNA quantification apply indirect techniques reliant on the 
amplification of target genes due to the small amounts of starting miRNA, which lowers the 
sensitivity and specificity of the assay.  Furthermore, we proposed that the exosomal origin of 
the miRNA would enhance the accuracy and precision of diagnosis, since these nanovesicles 
are involved in key cellular processes. The analysis of exosomal miRNA is not a 
straightforward process due to the small amounts of starting nucleic acid, and this is 
compounded by the available molecular technology. Therefore, the current conventional 
methods of analysis would not be viable, because in the modern era of precision medicine one 
requires precise and rapid analytical strategies for easy and accurate clinical application.  
NanoString technologies have emerged as a promising platform for the detection of exomiRNA 
due to its digital precision, enhanced sensitivity, reproducibility and technical robustness, using 
small amounts of starting RNA, hence there is no requirement for further validation by another 
method [100].  Additionally, the Nanostring technology does not utilise any amplification 
processes, which therefore enhances the dynamic range of the assay thus enabling a more 
accurate representation of the miRNA expression levels.  Therefore, our current study has 
provided a sound rationale for the involvement of exosomal miRNA in the pathophysiology of 
PE using the sensitive Nanostring technology platform for a survey of the entire profile and 
status of exomiRNA in PE. Using Descriptive Intermediate Attributed Notation for Ada 
(DIANA) (Web Server 5.0) computational merging and meta-analytical algorithms we 
uncovered distinct exomiRNA signatures which are involved in key pathophysiological 
processes associated with preeclampsia; which includes inflammation, cell migration, cell 
invasion, angiogenesis, apoptosis, vasoconstriction, lipid metabolism and blood pressure 
homeostasis.  Furthermore, the significantly altered expression of specific exomiRNA in 
preeclampsia indicates their direct involvement in dysregulating key biological processes such 
as platelet activation, apoptosis, cellular stress responses, blood coagulation, cardiomyocyte 
signaling, catabolic processes and gene expression; all of which are instrumental in the 
symptoms observed in preeclampsia.  Interestingly, distinct exomiRNA differences were 
observed between early- and late- onset preeclampsia.  This illustrated the clinical differences 
in severity between the subtypes based on their biological pathway enrichment analysis.  These 
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findings suggest that exosomes may well be part of the basis for the systemic manifestation of 
preeclampsia, which supports the qualification of exosomes as biomarkers of preeclampsia.  
Importantly, the distinct exomiRNA signatures identified serve as candidate biomarkers of the 
disease. 
 
The FDA biomarker definition specifies that biomarkers of disease must be validated with other 
prevalent clinical disorders associated with the increased susceptibility/risk of the disease (i.e. 
co-morbid states) [92, 101].  In South Africa, there is a high prevalence of the co-morbid state 
of HIV and preeclampsia, and importantly there have been reports of an increased risk of 
preeclampsia in HIV/HAART pregnant woman (all HIV infected pregnant women in this study 
were on HAART as per the Center for Disease Control and Prevention guidelines, 2016) [3, 
93, 102].  Therefore to satisfy the FDA biomarker criterion we have included the treated HIV 
cohort to validate the biomarker potential of exosomes. 
 
In Chapter four (manuscript 3) we explored the biomarker potential of exosomes in the two 
cohorts namely preeclampsia and HIV positive preeclamptic women on HAART. Notably, 
both HIV and preeclampsia represent hyperinflammatory states and circulating cytokines are 
key mediators of these states. Extracellular vesicle cytokine encapsulation represents a 
powerful system which may explain the dysfunctional immune responses involved in 
pathological states such as PE. Exosomal cytokines were selected for two reasons (1) both HIV 
and preeclampsia are immune-related disorders and (2) a large percentage of cytokines were 
found to be encapsulated in extracellular vesicles (viz. 70%-IL-2, 50% TNF-α and 100% IL-
10) [103].  This suggests that exosomal cytokine encapsulation may be a regulated property of 
the immune system, which is yet to be fully understood. Although there is a substantial amount 
of literature supporting the general role of cytokines in preeclampsia [104] and HIV [105], 
there is no scientific evidence linking exosomal cytokine encapsulation in HIV-positive women 
on HAART and in preeclampsia. The quantification of exosomal IL-2, TNF-α (pro-
inflammatory) & IL-10 (anti-inflammatory), was selected for investigation since these 
cytokines are known to have a significant immuno-modulatory role in the pathophysiological 
state of both HIV and preeclampsia [106].  Our data indicate that exosomal IL-2 and TNF-α 
levels are increased, whereas IL-10 levels are decreased in preeclampsia and in HIV-positive 
preeclamptic women on HAART, suggesting the immuno-modulatory role of exosomes in both 
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disease states.  The ratio between these pro- and anti- inflammatory exosomal cytokines 
indicates a  predominant shift towards Th1 (pro-inflammatory) immunity in preeclampsia 
which implicates exosomes as factors involved in the exaggerated MSIR commonly associated 
with the clinical manifestation of preeclampsia.  Furthermore, we speculate that the maternal 
immune reconstitution by HAART may be responsible for the increase in exosomal pro-
inflammatory cytokines which contribute to the pathogenesis of preeclampsia.  Importantly, 
we show that exosomal TNF-α and IL-2 have potential in diagnosing preeclampsia and 
preeclampsia in HIV-positive women on HAART with high sensitivity and specificity (CI: 
95%, LHR > 10, sensitivity of 100% and specificity of 90%). Our findings suggest that 
exosomal cytokine quantification may be a better indication or marker of the pathogenesis of 
preeclampsia and preeclampsia in HIV-positive women on HAART when compared to non-
specific, non-exosomal quantification of cytokines in maternal circulation. 
 
Even though the presented research supports the use of exosomes as biomarkers of 
preeclampsia further validation in a larger patient cohort is required. Furthermore, these studies 
are limited because we are unable to pinpoint the specific cellular origin of the exosomal 
miRNA and cytokines identified. Therefore it becomes challenging to understand the diverse 
exosome-mediated cellular interactions involved in the pathophysiology of preeclampsia. 
Additionally, we could not include untreated HIV-positive women in this study due to ethical 
considerations.  Furthermore, intricate in vivo and in vitro functional studies would also aid in 
elucidating some of the exact biological mechanisms of exosomes in the pathophysiology of 
preeclampsia and preeclampsia in HIV-positive pregnant women. 
 
5.2 Conclusion 
 
The findings presented have identified novel exomiRNA signatures and exosomal cytokine 
levels in PE, which are involved in key biological processes associated with the pathology of 
the disease. The altered exosomal cytokine levels in preeclampsia and HIV/HAART highlights 
the pathophysiological implications of HAART immune reconstitution on pregnancy 
outcomes, which may be modulated by exosomes.  Importantly the discovery of distinct 
exomiRNA signatures and exosomal cytokines in early- and late- onset preeclampsia support 
the existence of a differential pathophysiology between the subtypes. Therefore, the 
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observations made in this study support the diagnostic value of exosomal cytokine and miRNA 
signatures as biomarkers of preeclampsia and its subtypes.  
 
5.3 Recommendations 
 
Our proposed future studies will seek to enhance the scientific understanding of exosomes in 
the pathogenesis of preeclampsia in order to determine its potential context of use as 
biomarkers in the clinical environment. Therefore, our future research will focus on developing 
biomarker technology. This will involve a comprehensive approach in qualifying exosomes as 
a biomarker of preeclampsia which should subsequently lead to the submission of a 
qualification package to the relevant regulatory authorities for approval of exosomes for the 
clinical diagnosis of preeclampsia. 
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Introduction and aim: Exosomes are a subtype of extracellular vesicle (20e130 nm) released by biological
cells under normal and pathological conditions. Although there have been reports of circulating exo-
somes in normal pregnancy, the relevance of placental-derived exosomes in normal and abnormal
pregnancies still needs to be elucidated. The aim of this study was to quantify total and placental-derived
exosomes in maternal plasma from normal (N), early onset- and late onset-preeclampsia (PE).
Method: Plasma samples were obtained from pregnant women in the third trimester, for the isolation of
exosomes by differential ultracentrifugation. Total exosomes were quantified using nanoparticle tracking
analysis and immuno-reactive exosomal CD63 quantification. Placental-derived exosomes were quan-
tified using placental alkaline phosphatase (PLAP) as a specific marker. The contribution of placental-
derived exosomes to total exosomes in maternal plasma was determined by the ratio of PLAPþ exo-
somes to CD63þ exosomes.
Results: The concentration of total exosomes significantly increased in early onset-PE and late onset-PE
compared to N (33 weeks) and N (34 weeks). The relative concentration of placental-derived exo-
somes significantly increased in early onset-PE but decreased in late onset-PE compared to N. The ratio of
PLAPþ exosomes to total number of exosomes significantly decreased in early onset-PE and late onset-PE.
A positive correlation between total and placental-derived exosomes were obtained in N (33 weeks:
Pearson's r ¼ 0.60, 34 weeks: Pearson's r ¼ 0.67) and early onset-PE (Pearson's r ¼ 0.51, p < 0.05) with
the inverse in late onset-PE (Pearson's r ¼ 0.62, p < 0.01).
Conclusion: The differences in the contribution of placental-derived exosomes to total exosomes in
maternal circulation suggests a possible pathophysiological role of placental-derived exosomes in pre-
eclampsia.
© 2016 Elsevier Ltd. All rights reserved.1. Introduction
Pre-eclampsia (PE) is a hypertensive pregnancy disorder unique
to human pregnancies. It is defined as new onset hypertension
(systolic blood pressure of 140 mm Hg and diastolic blood pres-
sure of 90 mm Hg), proteinuria (300 mg) [1]. Pre-eclampsia is
reported to occur in approximately 5e7% of pregnant womanglobally [2] and is a major cause of maternal and neonatal
morbidity and mortality [3].
The recent classification of hypertensive disorders of pregnancy,
recommends that the categorization of PE is categorised into mild
to moderate PE, severe preeclampsia, eclampsia and early onset-PE
& late onset-PE [1]. Early onset-PE is associatedwith greater risks of
maternal and fetal complications than late onset-PE [4e6]. The
distinction in severity between early onset-PE and late onset-PE
may reflect the differences in the etiopathogenesis of the sub-
types of PE which adds a new dynamic to a disorder with existing
complexities. The exact etiology of PE is not known, however, the
P. Pillay et al. / Placenta 46 (2016) 18e25 19pathophysiology is thought to be a two-stage disorder originating
in the placenta [7]. The first stage is theorised to be due to defective
trophoblastic invasion of the uterine spiral arterioles, which leads
to decreased uteroplacental blood flow and a reduction in
oxygenation [7]. Subsequently, the second stage is one in which
decreased cellular oxygenation results in the release of proangio-
genic factors and an imbalance between pro- and anti-angiogenic
factors leading to widespread endothelial damage and the clinical
manifestations of PE [7e10]. The placenta, therefore, plays an
important role in the pathophysiology of PE. Both early onset-PE
and late onset-PE are of placental origin with early onset-PE
believed to be superimposed on underlying medical conditions
such as diabetes [11,12]. Therefore the severity of placental changes
and maladaptation in the uterine spiral arterioles may be greater
than that which occurs in late onset-PE.
The aetiology of preeclampsia still remains unknown due to the
multifactorial nature of the disorder. Angiogenic, antiangiogenic,
cffDNA, cfDNA, proteins and vasoactive factors have been impli-
cated in the pathogenesis PE [13e15]. More recently, studies have
identified syncytiotrophoblast microparticles (STBM) as factors
that are immune-stimulatory, antiangiogenic, pro-coagulant and
involved in endothelial dysfunction, a key pathological feature of
preeclampsia [16e18]. Syncytiotrophoblast microparticles are
directly released from the placenta into maternal circulation and
consist of vesicles ranging from 20 to 3000 nm in size [19].
Exosomes are a key constituent of STBMs which fall within the
smaller size spectrum of 20e130 nm and have a latent role in fetal-
maternal immune tolerance and endothelial cell migration
[20e22]. Exosomes are formed as products of the lysosomal
pathway and secreted by most cell types due to the fusion of
intracellular multivesicular bodies with the plasma membrane.
These vesicles consist of a bi-lipid membrane containing a variety
of signalling molecules including cell adhesion molecules and
growth factor receptors [23]. In addition, exosomes contain mRNA
andmiRNA [24], which are involved in immune function [21,25,26].
Exosomes function primarily by communicating with adjacent or
distal cells to re-programme their phenotype and regulate cell
function [24]. Reports suggest that placental-derived exosomes
play a role in the regulation of immune tolerance during normal
and complicated pregnancies [21,23e26]. The variations in the
contribution of placental-derived exosomes and bioactivity in
normal pregnancies are suggestive of the immune regulatory role
of exosomes in a successful pregnancy. The probable role of
placental-derived exosomes is to regulate the activity of both
proximal and distal target cells, translation, angiogenesis, prolifer-
ation, metabolism, and apoptosis [21,27e31].
Exosomes may have a potential role as activating agents in
endothelial dysfunction, a hallmark of PE [30]. It has been estab-
lished that total and placental-derived exosomes with no associ-
ated pathologies are biologically active molecules with a regulatory
role in endothelial cell migration [27]. Normally, placental exo-
somes in maternal circulation increase with gestational age which
inversely correlates to endothelial cell migration [27]. In the third
trimester of pregnancy, however, the lower contribution of
placental-derived exosomes in relation to total exosomes contrib-
utes to the inhibition of endothelial cell migration [27].
Ex-vivo and in-vitro studies have been used to examine enriched
preparations (supraphysiological levels) of placental exosomes
from placental perfusates [31]. However, the relevance of placental-
derived exosomes in pathological pregnancies has not yet been
elucidated. Therefore the aim of this study was to determine the
levels of placental-derived exosomes from maternal plasma in
normal, early onset-PE and late onset-PE pregnancies.2. Materials and methods
2.1. Ethics statement
Regulatory ethical and institutional approval were obtained
from the Biomedical Research Ethics Committee of the University of
KwaZulu-Natal (BE310/15), South Africa.
2.2. Study group and samples
Normotensive (N), early onset-PE and late onset-PE patients, in
the third trimester were recruited (n ¼ 15 per group). Normoten-
sive patients were classified by a blood pressure of 120 ± 10/80 ± 5
(systolic/diastolic mm Hg) and absent proteinuria as detected by a
rapid urine dipstick test (Markomed®, South Africa). Normotensive
patients were matched for gestational age according to early onset-
PE and late onset-PE patients. Early onset pre-eclampsia was
defined by new onset hypertension (diastolic blood pressure of
90 mm Hg and systolic blood pressure of 140 mm Hg) and
proteinuria (300 mg) at < 33 weeks plus 6 days of gestation. Late
onset-pre-eclampsia was defined by new onset hypertension
(diastolic blood pressure of >90 mmHg and systolic blood pressure
of >140 mm Hg) and proteinuria (300 mg) at > 34 weeks gesta-
tional age. All patients had singleton pregnancies and those with
evidence of any infections or medical, surgical or other obstetric
complications were excluded. Blood samples were collected [BD
Vacutainer Tubes (EDTA), Becton Dickinson and Company, South
Africa] and the plasma samples were stored at 80 C for analyses
[27,28].
2.3. Isolation and purification of exosomes from maternal
circulation
Exosomes were isolated according to the method described by
Thery et al., 2006 (Fig. 1) [32]. Plasma (1 ml) was diluted with an
equal volume of phosphate buffered saline (PBS; pH 7.4). Exosomes
were isolated and purified by differential ultracentrifugation using
a 30% sucrose cushion. In brief, centrifugation was initially per-
formed at 2000  g at 4 C for 30 min, followed by 12 000  g at
4 C for 45 min. The supernatant was centrifuged at 110 000  g at
4 C for 120 min (Optima™ MAX-XP Ultracentrifuge, fixed angle
MLA-55 rotor, Beckman Coulter Inc., Brea, CA, USA). The pellet was
suspended in PBS and filtered through a 0.22 mm filter (Cellulose
acetate, GVS™, Europe). The filtrate was centrifuged at 110 000  g
at 4 C for 70 min, the pellet re-suspended in PBS (pH 7.4) and
centrifuged at 110 000 g for 70 min, 4 C. The exosome pellet was
suspended in 1 ml of PBS and subsequently purified using a 30%
sucrose cushion as described by Thery et al., 2006 [32]. The final
pellet was resuspended in 100 ml of PBS and stored at 80 C. The
exosomal protein concentration was determined as described by
Salomon et al. (2014) using the RC DC Protein Assay (Bio-Rad
Laboratories, Hercules, CA, USA) [27].
2.4. Nanoparticle tracking analysis
Quantification and size distribution of exosomes were deter-
mined using the NS500 equipped with a 405 nm laser and sCMOS
camera (NanoSight NTA 3.0 Nanoparticle Tracking and Analysis
Release, Version Build 0069). Samples were diluted with PBS prior
to analysis in order to obtain particle distribution of 10 and 100
particles per image (optimal, 50 particles per image) before the
analysis with NTA system. Samples were introduced into the
sample chamber using the following script: PUMPLOAD, REPEAT-
START, PRIME, DELAY 10, CAPTURE 60, REPEAT 5. Videos were
recorded at a camera level of 10, camera shutter speed of 20ms and
Fig. 1. Flow chart for the exosome purification. Procedure used is based on differential ultracentrifugation methods as described by Thery et al., 2006. The figure illustrates the
differential centrifugal steps followed for the removal of contaminants and isolation of purified exosomes.
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samples. Each video was then analysed to give the mean particle
size together with the concentration of particles. The size of the
exosomes was represented as the mean particle size ± SD.2.5. Quantification of placental-derived exosomes
The concentration of total exosomes in the maternal circulation
was determined by the quantification of total immunoreactive
CD63 enzyme-linked immune absorbency assay (ExoELISA™, Sys-
tem Biosciences, Mountain View, CA), as described by Salomon
et al. (2014) [27]. CD63 is not an exosome specific marker but is
commonly bound to the exosomal membrane, and hence the
method employed uses isolated and purified exosomes which
contain the CD63 marker. The kit used consists of an exosome
specific primary CD63 antibody developed by the manufacturer.
Briefly, exosomes were immobilised on microtiter plates overnight
at 37 C using exosome binding buffer supplied the manufacturer
(System Biosciences). Plates were washed and incubated at room
temperature for 1 h with exosome specific primary antibody
(CD63), followed by a wash step and incubation with secondary
antibody (1:5000) at RT for 1 h with agitation. Plates were there-
after washed and incubated with Super-sensitive TMB ELISA sub-
strate at RT for 45 min with agitation. The reaction was terminated
using Stop Buffer solution. Absorbance was measured at 450 nm.
The number of exosomes/ml, (ExoELISA™ kit) was obtained using
an exosomal CD63 standard curve that was generated using the
calibrated exosome standard that was supplied.
The relative concentration of placental-derived exosomes was
determined by the quantification of human placental alkaline
phosphatase in the exosomal fraction using a commercial ELISA kit
(Elabscience, E-EL-H1976, WuHan, P.R.C), as described by Salomon
et al. (2014) [27]. Briefly, exosomes were allowed to bind to the
primary PLAP specific antibody coated plates by incubation at 37 C
for 90 min. Plates were washed and 50 ml of HRP-conjugate was
added to each well and incubated at 37 C for 20 min. Plates were
washed and incubated with 50 ml of substrate A and 50 ml of sub-
strate B at 37 C for 15 min. The incubation was terminated using50 ml of stop solution at RT for 2 min under agitation. Absorbance
was measured at 450 nm. Exosomal PLAP was expressed as pg/ml
plasma. The quantification of PLAP in the exosomal fraction in-
dicates the relative concentration of placental-derived exosomes
(PLAPþ exosomes) in maternal circulation.
2.6. Western blotting
Exosome pellets isolated from the normal pregnant and pre-
eclamptic plasma samples were lysed with RIPA buffer (1X) at
room temperature for 5 min and the protein content determined
using the RC DC Protein Assay (Bio-Rad Laboratories, Hercules, CA,
USA). Laemmli buffer (2X) was added to the samples and incubated
at 95 C for 5 min 20 mg of exosomal protein per well was separated
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred onto polyvinylidene fluoride (PVDF)
membranes. Polyvinylidene fluoride membranes were probed with
primary antibody, CD63 (ExoAB, System Biosciences, Mountain
View, CA). Post incubation at room temperature for 1 h membranes
was washed in Tris buffer saline (pH 7.6) and incubated for 1 h at
room temperature with the exosome validated secondary conju-
gated goat rabbit horseradish peroxidase antibody (ExoAB, System
Biosciences, Mountain View, CA). Membranes were incubated with
chemiluminescent substrate and visualised using the ChemiDoc®
Gel Documentation System (Bio-Rad Laboratories, Hercules, CA,
USA).
2.7. Transmission electron microscopy
Exosomes were applied to a continuous carbon grid and nega-
tively stained with 2% uranyl acetate. The size and morphology of
the particles were examined using a JEOL 1010 transmission elec-
tron microscope (JEOL, Peabody, MA, USA) at the Electron Micro-
scopy Unit, University of KwaZulu-Natal.
2.8. Statistical analysis
The data is presented as mean ± SEM, with n ¼ 15 per patient
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PLAPþ exosome concentration between N (33 weeks), N (34
weeks), early onset-PE and late onset-PE groups were determined
using ANOVA with posthoc analyses (Tukey-Kramer). Pearson's
correlation was used to assess the relationship between placental-
derived exosomes and total exosomes in N (33 weeks), N (34
weeks), early onset-PE and late onset-PE groups. Statistical analysis
was performed using Prism 6 (GraphPad Inc, CA, USA). Statistical
significance was defined as p < 0.05.3. Results
3.1. Patient clinical data
Table 1 shows the clinical characteristics of the study groups.
The N (33 weeks), N (34 weeks), early onset-PE and late onset-
PE groups had a gestational age of 30.8 ± 2.63, 38 ± 1.7, 30.55 ± 2.68
and 36.73 ± 2.18 weeks respectively (Table 1). Proteinuria was
evident in early onset-PE (460 ± 82.80 mg/dl) and late onset-PE
(300 ± 75.59 mg/dl). As expected, a significant increase in blood
pressure was observed when early onset-PE (152/96 ± 12/6 mm
Hg) and late onset-PE (155/98 ± 13/9 mm Hg) were compared to
the N groups (33 weeks: 110/67 ± 6.32/9.29, 34 weeks: 111/
68 ± 10/7, p < 0.05, Table 1) respectively. However, there was no
significance between the early onset-PE and late onset-PE groups. It
is notable that the BMI of the early onset-PE group was significantly
greater than the late onset-PE group (31.14 ± 5.66, p < 0.05).3.2. Exosome isolation and characterisation
Fig. 2A and B shows the size distribution of the exosome-
enriched fraction viz. N  33 weeks (102.9 ± 12.16 nm), N  34
weeks (100.3 ± 7.78 nm), early onset-PE (101.8 ± 7.68 nm) and late
onset-PE (104.1 ± 7.65 nm). A particle diameter of ~100 nm was
obtained from electron microscopic analysis (Fig. 2C). The
exosome-enriched fraction was analysed for the presence of CD63
exosomal marker by western blot (Fig. 2D). Nanoparticle tracking
analysis (NTA) of exosomes demonstrated a significant increase in
total exosome concentration in early onset-PE and late onset-PE
(Fig. 3A). Total exosomes in early onset-PE (8.23 ± 1.59  109 to-
tal exosomes/ml) and late onset-PE (6.14 ± 1.45  109 total exo-
somes/ml) were significantly higher than total exosomes in N (33
weeks: 5.75 ± 2.27  108 total exosomes/ml, p < 0.05) and N
(34weeks: 3.88 ± 0.23  1010 total exosomes/ml, p < 0.05)
respectively. In addition, the total exosome concentration in early
onset-PE was significantly higher in comparison to late onset-PE
(8.23 ± 1.59  109 vs 6.14 ± 1.45  109 total exosomes/ml, Fig. 3A
p < 0.05). Plasma exosomal protein concentrationwas expressed as
mg of exosomal protein per ml of plasma (Fig. 3B). Plasma exosomalTable 1
Clinical characteristics of patients.
Variables Normotensives
33 weeks (n ¼ 15) 34 we
Age (years) 27.13 ± 4.63 25.46 ±
Weight (kg) 68.51 ± 9.51 69.93 ±
Height (cm) 157.26 ± 9.46 157.66
BMI 27.4 ± 3.24 28.14 ±
Gestational Age (weeks) 30.8 ± 2.63 (26e33) 38 ± 1.
Systolic/diastolic blood pressure (mm Hg) 110/67 ± 6.32/9.29 (90-120/50-80) 111/68
Urine Protein (mg/dl) ND ND
ND ¼ not detected; N ¼ normotensive pregnancies; early onset-PE ¼ early onset pre-e
mean ± SEM. All pregnancies were singleton without intrauterine infection or any other
blood pressure early onset-PE versus N ( 33 weeks), ***p<0.001 and late onset-PE versuprotein concentration in the early onset-PE (2.39 ± 0.11 mg exo-
somal protein/ml plasma) and late onset-PE (2.03 ± 0.14 mg exo-
somal protein/ml plasma) group was significantly higher in
comparison to N (33 weeks 0.82 ± 0.04 mg exosomal protein/ml
plasma, p < 0.05) and N (34 weeks:1.83 ± 0.11 mg exosomal
protein/ml plasma, p < 0.05) respectively. However protein con-
centration in late onset-PEwas not significantly different from early
onset-PE (2.03 ± 0.14 vs 2.39 ± 0.11 mg exosomal protein/ml
plasma, Fig. 3B p > 0.05).3.3. Quantification and contribution of placental-derived exosomes
to total exosomes from maternal plasma
In order to determine the relative contribution of placental
exosomes to total exosomes present in maternal plasma, the PLAP
content per exosome was determined. The concentration of PLAPþ
exosomes in maternal plasma is represented in Fig. 4. A significant
increase in PLAPþ exosome concentration in comparison to N (33
weeks) was observed in early onset-PE (84 ± 10.61 vs
300 ± 14.00 pg/ml, p < 0.05). However, we found significantly
decreased PLAPþ exosome concentration in late onset-PE compared
to N (34 weeks: 112 ± 7.52 vs 261 ± 10.28, p < 0.05). In addition, a
significant decrease in late onset-PE PLAPþ exosomes was obtained
in comparison to early onset-PE (112 ± 7.52 pg/ml vs 300 ± 14,
p < 0.05).
The contribution of PLAPþ exosomes to total exosomes was
determined by calculating the ratio of PLAP content per exosome
(Fig. 5B). The total number of exosomes was quantified using an
ELISA kit for the quantification of the exosomal marker CD63
(Fig. 5A). The total number of exosomes increased in early onset-PE
(1.31 ± 0.007  1010 total exosomes/ml) and late onset-PE
(1.09 ± 0.004  1010 total exosomes/ml) in comparison to N (33
weeks: 5.76 ± 0.006  109 total exosomes/ml, p < 0.05) and N (34
weeks: 9.18 ± 0.09  109 total exosomes/ml, p < 0.05) respectively.
A significant decrease in the ratio of PLAPþ exosomes per number of
total exosomes's were identified (Fig. 5B) in early onset-PE
(2.25 ± 0.13  108) and late onset-PE (1.04 ± 0.12  108) in
comparison with and N (33weeks: 3.54 ± 0.31  108, p < 0.05)
and N (34 weeks: 2.93 ± 0.13  108, p < 0.05) respectively.3.4. Relationship between total exosomes and placental-derived
exosomes
Fig. 6 represents the relationship between the concentration of
total exosomes and exosomal PLAP concentration (PLAPþ exo-
somes) in the study groups. The relationship between the con-
centration of total exosomes and PLAPþ exosomes in early onset-PE
and late onset-PE was examined by the determination of the cor-
relation of PLAPþ exosomes (exosomal PLAP pg/ml plasma) perPre-eclampsia
eks (n ¼ 15) Early onset (n ¼ 15) Late-onset (n ¼ 15)
5.85 26.93 ± 6.02 26.42 ± 6.66
11.56 75.47 ± 15.98 81.85 ± 19.21
± 8.69 161.9 3 ± 6.9 161.4 ± 7.16
3.66 26.8 ± 4.21 31.14 ± 5.66y
7 (34e38) 30.55 ± 2.68 (28e33) 36.73 ± 2.18 (34e39)
± 10/7 (90-120/50-80) 152/96 ± 12/6 (>140/90)*** 155/98 ± 13/9 (>140/90)###
460 ± 82.80 300 ± 75.59
clampsia; late onset-PE ¼ late onset pre-eclampsia. All values are represented by
medical condition. The patients recruited had a parity of 1 ± 1. In systolic/diastolic
s N ( 34 Weeks), ###p<0.001. In BMI late onset-PE versus early onset-PE, yp < 0.05.
Fig. 2. Characterisation of Exosomes from Maternal Circulation. Exosomes from normotensive pregnant woman and from those with early onset-PE and late onset-PE was
characterised using Nanoparticle Tracking Analysis. (A) Representative vesicle size distribution (nm). (B) Vesicle size distribution (C) Electron micrograph of isolated exosomes, scale
bar 100 nm. (D) Western blot analysis for the CD63 exosome enriched marker; lane 1: early onset-PE, lane 2: late onset-PE and lane 3: N. Values are presented as mean ± SEM.
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relation was obtained (33 weeks: Pearsons r ¼ 0.60, 34 weeks:
Pearsons r ¼ 0.67, p < 0.05; Fig. 6A and B respectively) which cor-
responds to the positive correlation in early onset-PE but not in the
late onset-PE group. A positive correlation was obtained between
PLAPþ exosomes (pg/ml plasma) and total number of exosomes/ml
plasma (total exosomes/ml plasma) in early onset-PE (Pearson's
r ¼ 0.51, p < 0.05; Fig. 6C) with a negative correlation in late onset-
PE (Pearson's r ¼ 0.62, p < 0.05; Fig. 6D). The correlation analysis
indicates that PLAPþ exosomes increase with the increasing total
number exosomes in N (33weeks& 34 weeks) and early onset-
PE but decreases in late onset-PE.4. Discussion
Studies have shown that exosomes increase in maternal circu-
lation during normal pregnancy. However, there is a lack of infor-
mation on exosomes in early onset-PE and late onset-PE [27,28].
Exosomes, with a mean particle size distribution of
104.5 ± 11.68 nm, were measured across sample groups using NTA.
Furthermore, western blot analysis of isolated vesicles was shown
to be positive for the CD63 exosomal marker. Characterisation data
obtained in the present study was positive for exosomes and is
consistent with previously published data [21,27e30,32]. In the
present study, we found increased total exosomes in early onset-PE
(~55e60%) together with increased PLAPþ exosomes (~25e30%,
early onset-PE) compared to N (33 weeks). However, whilst thetotal exosomes in late onset-PE increased (~45% vs N  34 weeks),
we found a decrease in PLAPþ exosomes compared to N (34
weeks) and early onset-PE groups (~50% vs N  34 weeks and ~61%
vs early onset-PE). Notably, these findings may account for the
differences in the severity between the two sub-types of PE. This
study, therefore, provides preliminary data in support for the po-
tential use of exosomes as a biomarker in PE.
In our study, we found that the concentration of PLAPþ exo-
somes increased in early onset-PE but decreased in the late onset-
PE group in comparison to N (33 weeks) and N (34 weeks)
respectively. The decrease in PLAPþ exosomes in late onset-PE
could be due to the differences in the etiology of late onset-PE in
comparison to early onset-PE. In addition, correlation analysis be-
tween PLAPþ and total exosomes indicates a significant positive
correlation in early onset-PE (Pearson's r ¼ 0.51, p < 0.05) and N
(33 weeks: Pearson's r ¼ 0.60, p < 0.05) and N (34 weeks:
Pearson's r ¼ 0.67, p < 0.05), with a negative correlation in late
onset-PE (Pearson's r¼0.62, p < 0.05). These differences could be
attributed to the differences in the pathophysiology between early
onset-PE and late onset-PE. This may provide a useful tool to
distinguish the two subtypes of PE and may assist in clinical deci-
sion making in the timing of childbirth in PE.
It has been reported that placental-derived exosomes promote
vasculogenesis and angiogenesis, which are essential for placental
vasculature development, proper fetal circulation [23,27,28] as well
as immune modulation [21]. It is, therefore, possible that the in-
crease in PLAPþ exosomes in early onset-PE in comparison to N
Fig. 3. Exosome concentration in early and late-onset pre-eclampsia. Isolated
exosomes were quantified in normotensive pregnant woman and those with early
onset-PE and late onset-PE pregnancies using NTA. (A) Number of exosomes per pa-
tient group. Data is presented as aligned dot plot and values are mean ± SD. (B) Plasma
exosomal protein concentration is expressed as mg exosomal protein per ml of plasma.
Data is presented as aligned dot plot and values are mean ± SEM. In A and B
***p < 0.0001 early onset-PE vs N (33 weeks), ###p < 0.0001 late onset-PE vs N (34
weeks); In A yyyp < 0.001 early onset-PE vs late onset-PE, zzzp < 0.0001 N (33 weeks)
vs N (34 weeks).
Fig. 4. Placental-derived exosomes in Pre-eclampsia and normotensive pregnan-
cies. Placental-derived exosomes (i.e. exosomal PLAP) was quantified in maternal pe-
ripheral plasma by ELISA. The data is expressed as aligned dot plot and values are
mean ± SEM. ***p < 0.0001 early onset-PE vs N (33 weeks), ###p < 0.0001 late onset-
PE vs N (34 weeks), yyyp < 0.001 early onset-PE vs late onset-PE, zzzp < 0.0001 N (33
weeks) vs N (34 weeks).
Fig. 5. Contribution of placental-derived exosomes to total exosomes. PLAPþ exo-
somes (i.e. exosomal PLAP) and total exosomes in N (33 weeks), N (34 Weeks), early
onset-PE and late onset-PE groups were determined by ELISA. (A) Total exosomes were
determined by the quantification of exosomal CD63 marker. (B) Ratio of PLAPþ exo-
somes to total exosomes (CD63þ). Values are represented as mean ± SEM. In A and B
***p < 0.0001 early onset-PE vs N (33 weeks), A yyyp < 0.001 early onset-PE vs late
onset-PE, ###p < 0.0001 late onset-PE vs N (34 Weeks); In A, zzzp < 0.0001 N (33
weeks) vs N (34 Weeks).
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hypoxic placenta, which is a pathological manifestation of PE. Onthe other hand, the decreased PLAPþ exosomes in late onset-PE in
comparison to N (34 weeks) and early onset-PE, may suggest that
the progression of late onset-PE is not based on a hypoperfused
placenta. This may account for the differences in the clinical
expression between the PE groups. These findings are consistent
with placental morphological dissimilarities observed in early
onset-PE and late onset-PE [33]. In addition, we have identified a
positive correlation between the number of exosomes in maternal
circulation and BMI in early onset-PE (Pearson's r ¼ 0.57, p < 0.05)
and late onset-PE (Pearson's r ¼ 0.58, p < 0.05) with no significant
correlation in N (33 weeks) and N (34 weeks). These findings
indicate that the increase in exosomes in preeclampsia is associated
with an increase in BMI which could be related to the metabolic
variations associated with PE [34,35].
Placental-derived exosomes have been reported to be involved
in immune tolerance in normal pregnancies by the suppression of
T-cell signalling [21] which is mediated by exosomal FasL and PD-L1
transmembrane proteins. These placental-derived exosomal
transmembrane proteins have been shown to suppress CD3-zeta
expression and induce apoptosis in normal pregnancies, indi-
cating that placental-derived exomes play a role in fetal-maternal
immune tolerance [21]. These findings support our study,
Fig. 6. Relationship between placental-derived exosomes and total exosomes in maternal circulation. The correlation between PLAPþ exosomes (i.e. exosomal PLAP) and total
exosomes (i.e. CD63þ exosomes) in (A) N (33 weeks), (B) N (34 Weeks), (C) early onset-PE and (D) late onset-PE. In A and B a (þ) Pearson correlation. In D a () Pearson's
correlation.
P. Pillay et al. / Placenta 46 (2016) 18e2524whereby the increase in relative placental-derived exosomes in
early onset-PE is probably responsible for the exaggeratedmaternal
immune alterations and cellular apoptosis, thus, resulting in the
clinical expression of PE.
The presented study demonstrates the contribution of PLAPþ
exosomes in relation to total exosomes by the quantification of
exosome membrane bound placental alkaline phosphatase (PLAP).
Placental alkaline phosphatase was used as a marker for the
quantification of placental-derived exosomes which has been pre-
viously utilised [21,27,28]. This marker has been detected in preg-
nant women in second and third trimesters of pregnancy at a
steadily increasing rate [36,37], which subsequently declines after
delivery [38]. In addition, sources of circulating exosomes may
originate from other tissues such as the endothelium; however, we
focussed on the possible role of placental-derived exosomes.
Moreover, standardisation of exosomal isolation and purification
methods are limited and have not been validated [23], therefore the
methods used in this study, based on published protocols requires
further validation. Additionally, it cannot be ruled out completely
that the PLAP signal could be partly attributed to other contami-
nating micro-vesicles. Notwithstanding this fact, variations in PLAP
signal would be in keeping with variations in PLAP levels from
PLAPþ exosomes in maternal circulation.
5. Conclusion
In the presented study, we have shown that the total number of
exosomes increased in early onset-PE and late onset-PE compared
to N. Notably, we also found significant differences in the relativeconcentration of placental-derived exosomes between the sub-
types. A positive correlation was found between PLAPþ exosomes
and total exosomes in early onset-PE, with a negative correlation in
late onset-PE. These findings may relate to the dissimilarities in the
etiology of the two subtypes, suggesting that placental-derived
exosomes could play a pathological role in PE. Our findings,
therefore, form the rationale for the determination of the role of
placental-derived exosomes in PE and suggests that exosomes may
be a useful tool for the prognosis/diagnosis of PE.
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A B S T R A C T
Objectives: Preeclampsia (PE) occurs as a result placental hypoxia-induced oxidative and endoplasmic
reticulum stress, and is associated with the activation of hypoxia inducible factor-1a (HIF-1a) and
apoptotic CHOP pathways with the consequential shedding of syncytiotrophoblast microvesicles which
may be central in mediating the maternal systemic immune response. The aim of this study was to
immune-localise and morphometrically analyse CHOP and HIF-1a within the placenta of normotensive
and pre-eclamptic pregnancies and concomitantly quantify syncytiotrophoblast released microvesicles
in maternal circulation.
Study design: Placental tissue and plasma were obtained from normotensive and pre-eclamptic pregnant
women. The expression of CHOP and HIF-1a was analysed using immunohistochemistry. Isolation and
size distribution of the circulating maternal microvesicles was determined using nanoparticle tracking
analysis. The concentration of syncytiotrophoblast microvesicles was determined using the placental
alkaline phosphatase ELISA.
Results: This study demonstrates a significant increase in immunohistochemical expression of HIF-1 a
and CHOP in preeclampsia compared to the normotensive women (p < 0.05). In keeping with this, a
significant increase in the mean syncytiotrophoblast microvesicles concentration was observed in PE,
compared to normotensives (p < 0.05). A positive correlation between placental expression of CHOP and
HIF-1a and STBMs was obtained.
Conclusion: This study demonstrates increased placental expression of HIF-1a and CHOP in preeclampsia
compared to normotensive pregnancies which correlate to their increased syncytiotrophoblast
microvesicles concentration in maternal circulation. These findings indicate that placental hypoxia
and ER stress are interrelated contributory factors to the pathogenesis of PE and the consequential release
of placental derived debris into the maternal circulation.
© 2017 Published by Elsevier Ireland Ltd.
Contents lists available at ScienceDirect
European Journal of Obstetrics & Gynecology and
Reproductive Biology
journal homepage: www.else vie r .com/ locat e/e jogrbIntroduction
Hypertensive disorders of pregnancy constitute the main direct
cause of maternal mortality, globally and within South Africa [1].
Preeclampsia (PE) accounts for the majority of maternal and foetal
deaths emanating from hypertensive disorders, with the global
incidence of PE ranging from 2 to 8% [2].
Preeclampsia is clinically characterised by new-onset hyper-
tension and proteinuria which manifests after the 20th week of
gestation [3]. The exact aetiology of PE still remains elusive,* Corresponding author.
E-mail address: mackraji@ukzn.ac.za (I. Mackraj).
https://doi.org/10.1016/j.ejogrb.2017.11.004
0301-2115/© 2017 Published by Elsevier Ireland Ltd.although the role of the placenta in the pathogenesis has been well
described [4,5]. Preeclampsia is believed to occur as a result of
inadequate trophoblastic invasion during pregnancy, which results
in improper remodelling of the myometrial spiral arteries, with
consequential placental hypoperfusion and an ischemic microen-
vironment [6]. This results in a hypoxic microenvironment, which
induces the expression of hypoxia-inducible factor 1 alpha
(HIF-1a) [7]. HIF-1a plays a crucial role in the transcription of
numerous oxygen-dependent genes, which encode proteins
involved in angiogenesis and cell metabolism in normal pregnancy,
promoting the establishment of the placenta. However,
overexpression is implicated in the development of several
inflammatory conditions, such as PE [7,8].
S. Verma et al. / European Journal of Obstetrics & Gynecology and Reproductive Biology 220 (2018) 18–24 19This hypoxic/ischemic microenvironment causes oxidative and
endoplasmic reticulum stress and subsequent death of placental
cells, which may lead to the exaggerated release of trophoblast-
derived factors, such as microvesicles and other debris, into the
maternal circulation, in comparison to normal pregnancies [9].
Microvesicles originate from the blebbing of membranes or
cellular apoptosis during the physiological turnover of cells [10].
The syncytiotrophoblast layer of the placenta constitutes the
maternal-fetal interface, which releases microvesicles into mater-
nal circulation, termed as syncytiotrophoblast microvesicles
(STBMs). These STBMs have been shown to be involved in maternal
and fetal cross-talk, and excessive release stimulates the maternal
systemic inflammatory response (MSIR) and endothelial dysfunc-
tion, thereby contributing to the development of PE [11].
The syncytiotrophoblast layer of the placenta has a high
endoplasmic reticulum (ER) content as it performs many impor-
tant functions [12]. In PE, ischaemic reperfusion and hypoxia
caused by diminished blood flow into the intervillous space, causes
oxidative and ER stress, thus generating and accumulating reactive
oxygen species through the mitochondrial pathway [13]. This
activates a cascade of signalling networks called the Unfolded
Protein Response (UPR). The UPR restores ER homoeostasis,
promoting cell survival and adaptation [14]. However, this
initiation of UPR also leads to a homeostatic imbalance and
activation of pro-apoptotic pathways such as CHOP (GADD153)
[15]. The apoptotic events occur as a result of the overexpression of
CHOP via the Bcl-2–inhibitor mechanism [16].
While ER stress and the release of microvesicles have been
measured in separate studies, in this study we measured both
events in a single patient (both placenta and blood from the same
women) in an effort to investigate the relationship between these
factors. To the best of our knowledge, this is the first study to try
and establish a link between the etiopathology and clinical
symptoms of PE triggered by microvesicular release.
Therefore, the aim of this study is to quantify STBMs in Black
South African PE and normotensive pregnant women, and to assess
whether ER stress in placental tissue is linked to the increased
production of these microvesicles.
Materials and methods
Ethics statement
Regulatory ethical and institutional approvals were obtained
from the Biomedical Research Ethics Committee of the University
of KwaZulu-Natal (BE364/15), South Africa.
Study group and samples
Healthy normotensive (N; n = 15) pregnant and preeclamptic
(PE; n = 7) women in the third trimester of pregnancy scheduled to
have elective caesarian deliveries for obstetric indications were
recruited. The inclusion criteria was designed to minimise any kind
of hypoxic and endoplasmic reticulum stress. Normotensive
women were classified by a blood pressure of <140/90 mmHg
(systolic/diastolic mmHg) and absent proteinuria as detected by a
rapid urine dipstick test (Markomed1, South Africa). Preeclampsia
was defined as new-onset hypertension, characterized by a blood
pressure of 140/90 mmHg, with the presence of protein in the
urine (300 mg in a 24-h urine sample or a value of 2+ on
dipstick) after the 20th week of gestation [17,18]. All women had
singleton pregnancies and those with evidence of any infection or
medical, surgical or other obstetric complications were excluded.
Blood samples were collected [BD Vacutainer Tubes (EDTA),
Becton Dickinson and Company, South Africa] and the plasma
samples were stored at 80 C for analyses (N; n = 15, PE; n = 7).Placental tissue was dissected both from central and peripheral
regions of the placenta. The placental tissue was cut, rinsed with
PBS (1X, pH 7.5) and preserved in 10% phosphate buffered formalin
within 10 min of delivery.
Immuno-histochemistry
Post fixation, the placental tissue samples were dehydrated and
paraffin embedded using the Leica automated tissue processor.
Sections of 3–4 mm were cut with a Leica RM 2135 microtome and
mounted onto coated slides (X-tra Adhesive, Leica Microsystems,
Germany). Specimens were de-waxed in xylene and rehydrated in
decreasing order of ethanol concentration. Epitope retrieval was
performed with target antigen retrieval (Envision High pH Flex
Mini Kit, DAKO) for 20 min. The monoclonal-mouse-anti-HIF-1a
[1A3] antibody (Abcam, USA; ab113642, 1:1000) and monoclonal-
mouse-anti-GADD153/CHOP [9C8] antibody (Novus Biologicals;
NB600-1335, 1:75) served as primary antibodies. Gastric adeno-
carcinoma and glioblastoma multiform tissue were used as the
positive control for HIF-1 a and CHOP, respectively. Primary
antibody substituted with buffer served as a negative control. Goat
Anti-Mouse IgG [HRP] (Abcam, USA; ab205719) served as the
secondary antibody.
Morphometric image analysis of HIF-1 a and CHOP
All specimens were viewed with an Axioscope A1 microscope
(Carl Zeiss, Germany). Image capturing, processing and analysis
were performed using the AxoVision software (Carl Zeiss, Germany
4.8.3). Auto analysis was done using four fields of view per slide
which were randomly selected and captured at an initial objective
magnification of 20X.
HIF-1 a and CHOP expression were determined as a percentage
of immunostaining (colour: brown) within the villi. Within the
placental villi (both exchange and conducting), HIF-1a immuno-
staining occurred within the cytoplasm of the syncytiotrophoblast
and cytotrophoblast cell population (Fig. 1B). Additionally, the
immunoexpression was also noted in endothelial cells lining
arteries, veins and capillaries across all villi types. The CHOP
immunostaining was nuclear and also occurred in the trophoblast
cell population in both exchange and conducting villi (Fig.1A). Four
random areas per slide were selected and immunostaining was
expressed as a percentage trophoblast area.
Isolation of microvesicles from maternal circulation
Microvesicles were isolated according to a modified method as
described by Dragovic et al. [19] on seven normotensive and seven
preeclamptic pregnancies to match the equal number of pre-
eclamptic and normal samples. Plasma (1 ml) was diluted with an
equal volume of phosphate buffered saline (PBS; pH 7.4) and
centrifuged at 1500g at 4 C for 20 min. The supernatant was
collected and centrifuged at 10 000g at 4 C for 30 min. The pellet
was re-suspended in 2 ml PBS (pH 7.4) and thereafter centrifuged
at 10 000g at 4 C for 30 min. This step was repeated to reduce
contamination by soluble proteins. Microvesicle protein concen-
tration was determined using the RC DC Protein Assay (Bio-Rad
Laboratories, Hercules, CA, USA).
Size distribution of microvesicles using nanoparticle tracking analysis
Quantification and size distribution of microvesicles were
determined using the NS500 as previously described by our group
(Nano Sight NTA 3.0 Nanoparticle Tracking and Analysis Release,
Version Build 0069) [20]. Briefly, samples were diluted with PBS
prior to analysis in order to obtain particle distribution of 10 and
Fig. 1. Placental Immune Histochemical Expression of CHOP and HIF-1a in Preeclamptic and Normal Pregnancies (n = 15). (A) CHOP expression in PE and (B) normotensive
pregnancies. (D) HIF-1a expression in PE and (E) Normotensive pregnancies. Mean area (%) of (C) CHOP and (F) HIF-1a in PE and N. In A and B arrows indicate the increased
nuclear expression of CHOP in the terminal villi. In D and E arrows indicate the increased cytoplasmic expression of HIF-1a in the terminal villi. In C indicates CHOP expression
and F HIF-1a expression, ***p < 0.0001.
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analysis with NTA system. Samples were introduced into the
sample chamber using the following script: PUMPLOAD, REPEAT-
START, PRIME, DELAY 10, CAPTURE 60, REPEAT 5. Videos were
recorded at a camera level of 10, camera shutter speed of 20 ms and
camera gain of 600, these settings were kept constant between
samples. Each video was then analysed to give the mean particle
size together with the concentration of particles. The size of the
exosomes was represented as the mean particle size  SD.
Quantification of syncytiotrophoblast microvesicles
The relative concentration of syncytiotrophoblast microvesicles
was determined by the quantification of human placental alkalinephosphatase in the isolated microvesicle fraction using a
commercial ELISA kit (Elabscience, E-EL-H1976, WuHan, P.R.C).
Briefly, microvesicles were allowed to bind to the primary PLAP
specific antibody coated plates by incubation at 37 C for 90 min.
Plates were washed and 50 ml of HRP-conjugate was added to each
well and incubated at 37 C for 20 min. Plates were washed and
incubated with 50 ml of substrate A and 50 ml of substrate B at 37 C
for 15 min. The incubation was terminated using 50 ml of stop
solution at RT for 2 min under agitation. Absorbance was measured
at 450 nm. Exosomal PLAP was expressed as pg/ml plasma. The
quantification of PLAP in the microvesicle fraction indicates the
relative concentration of syncytiotrophoblast microvesicles in
maternal circulation.
Table 1
The Clinical Characteristics of both study groups.
Variables Normotensive (N) (n = 15) Preeclampsia (PE) (n = 7)
Age (years) 30.0  5.1 25.1  7.1
BMI (kg/m2) 31.6  6.4 26.7  5.9
Nulliparous (number) 1 2
Multiparous (number and percentage) 14 5
Gestational age at sampling/delivery (weeks) 36.2  1.3 35.8  1.5
Systolic blood pressure (mmHg) 108.8  6.7 148.1  11.2*
Diastolic blood pressure (mmHg) 71.8  6.4 96.4  8.8*
Baby weight (kg) 3.4  0.3* 2.7  0.5
Baby gender (Male) 7 3
Baby gender (Female) 8 4
All values are expressed as mean  SEM. All pregnancies were singleton without any intrauterine infection or any other medical condition. In systolic/diastolic blood pressure
PE versus N, * p < 0.05. In BMI N vs PE, * p < 0.05.
Fig. 2. Characterisation of Micro-vesicles in Preeclamptic and Normotensive
(n = 15) Maternal Circulation. (A) Micro-vesicles size distribution profile (nm).
(B) Mean particle size (nm), ***p < 0.0001.
Fig. 3. Micro-vesicle concentration in maternal circulation of normotensive and
preeclamptic pregnant woman (n = 15). The data is expressed as aligned dot plot and
values are mean  SEM.***p < 0.0001 PE vs N.
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Statistical significance was defined as p < 0.05. Statistical
significance between the two groups was assessed using unpaired
t-test. Data is presented as the mean  SEM. Pearson’s correlation
analysis was done to determine the relationship between
syncytiotrophoblast microvesicles in maternal circulation and
placental protein expression. Data distribution was determined
using the combined D‘Agostino and Pearson normality test, all data
was found to be normally distributed. Statistical analyses were
performed using commercially available packages (Prism 6,
GraphPad Inc, La Jolla, CA 92037 USA).
Results
Patient clinical data
Patient demographics are presented in Table 1. The table shows
that there were no significant differences in clinical parameters
between the N and PE groups (p > 0.05) except for increased blood
pressure levels in the PE group (p < 0.05). The mean birth weight in
the N group was significantly higher than that in the PE group
(3.4  0.3 vs 2.7  0.5 kg, p < 0.05).
Expression of CHOP and HIF-1a in preeclamptic and normotensive
placenta
Immunohistochemistry showed strong reactivity for HIF-1 a
and CHOP in preeclamptic placentas compared to normotensive
controls (Fig. 1). The majority of the positive staining was found in
the syncytiotrophoblasts. In addition, the analysis of the mean
percentage area of CHOP and HIF-1a immunostaining indicated
that there was a significant increase in CHOP and HIF-1a immune-
expression in PE in comparison to N (13.1 4.1% vs 6.5  4.3% and
14.1 6.8% vs 9.24  2.4%, respectively, p < 0.0001; Fig. 1C & F).
Quantification and characterisation of microvesicles in maternal
circulation
The size distribution profiles (Fig. 2A) indicate that the
microvesicles ranged in size from 50 to 450 nm. A statistically
significant difference in the mean microvesicle particle size
between preeclamptic and normotensive groups was obtained
(127.6  7.93 nm vs 137.4  5.08 nm, p < 0.005; Fig. 2B). A signifi-
cant increase in microvesicle concentration was obtained in PE in
comparison to N pregnancies (1.38  0.34 1011 vs
5.06  0.61 1010 particles/ml plasma, p < 0.05; Fig. 3). The relative
concentration of syncytiotrophoblast (STB) microvesicles obtained
in PE plasma compared to normotensive pregnancies was greater
[574.3  55.99 pg/ml vs 218.8  29.35 pg/ml, respectively,
(p < 0.005; Fig. 4)].
Fig. 4. Syncytiotrophoblast micro-vesicles in preeclampsia and normotensive
pregnancies (n = 15). The data is expressed as aligned dot plot and values are
mean  SEM. **p < 0.005 PE vs N.
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circulation and HIF-1a & CHOP expression
Fig. 5 shows the relationship between the relative concentra-
tion of syncytiotrophoblast microvesicles and placental protein
(HIF-1a & CHOP) expression. This relationship was determined by
the correlation between the PLAP+ microvesicles (pg/ml plasma)
and protein expression (HIF-1a & CHOP, % area). A positive
correlation between the relative concentration of STBMs and
placental HIF-1a & CHOP protein expression in PE and N groups
were obtained (Pearson’s r >0.5, p < 0.05; Fig. 5).Fig. 5. Relationship between the relative concentration of STBMs in maternal circulation
vesicles and CHOP expression (% Area) in (A) PE & (B) N. PLAP+ micro-vesicles and HIFDiscussion
While increased endoplasmic reticulum stress and circulating
microvesicular concentration have been reported separately in the
pathology of preeclampsia by Burton et al. [21,22] and Sargent et al.
respectively, no study has investigated the combined relationship
between these two significant events. The rising interest in
microvesicles as biomarkers necessitates this study, whereby we
hypothesise that these two important key events may be linked.
Our findings demonstrate a significant increase in the immunoex-
pression of CHOP and HIF-1a in pre-eclamptic placental tissue in
comparison to the normotensive group, in keeping with previous
studies [23,24]. Concomitantly nanoparticle tracking analysis
indicated that microvesicles in PE maternal circulation was
significantly increased in comparison to normotensives. The size
distribution profile ranged from 50 to 450 nm which is character-
istic of microvesicles. Further quantification of the relative
concentration of STBMs from the isolated microvesicles by PLAP
ELISA indicated that there was a significant increase in STBM
concentration in PE in comparison to a normotensive woman. In
addition, we report a positive correlation between placental CHOP
& HIF-1a expression and STBMs in maternal circulation. These
findings support our assertion that the oxidatively stressed
placenta results in the expression of ER stress proteins, which
may enhance the production of placental derived STBMs.
Hypoxia is essential in the early stages of gestation for a
successful pregnancy, however, prolonged hypoxia is observed in
PE and other inflammatory conditions [7]. Hence increased
expression of placental HIF-1 a in PE could be due to an imbalance and HIF-1a & CHOP & expression (n = 15). The correlation between; PLAP+ micro-
-1a expression (% Area) in (C) PE & (D) N. In A–D (+) Pearsons correlation.
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caused by improper spiral artery remodelling in early pregnancy, a
key feature of PE [23]. Increased HIF-1-a mRNA expression in
preeclamptic placentae have also been observed by others [15]. In
addition, severe and prolonged imbalances in oxygen homoeo-
stasis could result in antiangiogenic/angiogenic imbalance induced
by HIF-1a, which acts in combination with many other factors and
potentiates the clinical manifestation of PE [24].
The syncytiotrophoblast performs many key functions such as
regulation of oxygen delivery and synthesis of a variety of proteins
and possesses abundant free ribosomes and endoplasmic reticu-
lum (ER) [25]. Oxidative stress in syncytiotrophoblast predisposes
it to ER stress. CHOP is a known marker of ER stress and is
up-regulated in PE [15,26]. Endoplasmic reticulum stress-induced
apoptosis is primarily mediated through ATF4-mediated transcrip-
tional induction of the C/EBP homologous protein CHOP [27]. The
increased expression of syncytiotrophoblast nuclear CHOP
observed in PE in comparison to normotensive placentae suggests
that ER stress may be a major contributing factor to the increased
apoptosis in PE syncytiotrophoblast. This is supported by the
findings of our study whereby the increased concentration of
circulating STBMs in PE, positively correlates to placental CHOP
and HIF-1a expression. In addition, this relationship suggests that
both the ER stress and hypoxic response pathways could potentiate
the release of STBMs in maternal circulation.
STBMs are key factors involved in mediating the maternal
systemic inflammatory response (MSIR) [28]. It is, therefore,
plausible that the increased release of STBMs into maternal
circulation, leads to the exaggeration of the MSIR, resulting in PE. In
this study, we observed that the isolated vesicles in PE were
elevated with a particle size of 60–120 nm, in comparison to the
normotensives, and notably this size profile is a key characteristic
of microvesicles. This observation is in keeping with our previous
study which showed that placental-derived microvesicles and
exosomes were increased in early and late onset preeclampsia [20].
This suggests that the cascade of cellular events induced by the
enhanced expression of placental CHOP and HIF-1a not only
results in the increased release of STBMs, but possibly also the
specific biogenesis of nanovesicles such as exosomes. These
exosomes serve as signalling vesicles which may contain key
DNA, RNA and protein factors which potentiate the MSIR [20]. It is
therefore necessary that future studies incorporate the isolation
and characterisation of the sub-classes of STBMs, in conjunction
with determining their biological relationship with ER stress and
hypoxia. Such studies are currently ongoing within our research
group.
Limitations
Oxidative stress and ER stress occurs early in complicated
pregnancies, however, it was not possible to obtain placental tissue
samples during early gestation due to ethical considerations. In
addition, the sample size was a limitation as the occurrence of HIV-
negative pregnant woman with preeclampsia delivering babies by
caesarian section were low.
Conclusion
Our findings show that the placental immunoexpression of
CHOP and HIF-1a are elevated in preeclampsia and could be a key
placental factor involved in the pathogenesis of PE. Additionally,
the correlation between placental protein expression and STBMs
indicate that ER stress and hypoxia may potentiate the release of
STBMs into the maternal circulation. In combination, these
findings form the basis for future research involving the isolationand characterisation of STBM constituents for their elucidation of
their function in ER stress and hypoxia.
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Introduction
Pregnancy is well recognised as a complex immunolog-
ical adaptation between mother and fetus [1]. There are a
multitude of factors such as placental-derived microvesi-
cles, hormones, and cytokines [2] that synergistically co-
ordinate the maternal immune adaptation in the first
trimester of pregnancy, a prerequisite for successful preg-
nancy. The exact mechanism whereby these factors regulate
this process is still unknown although more recent evidence
suggests that placental-derived microvesicles may be im-
plicated in the maternal immune adaptation, required for a
successful pregnancy [3]. 
There are distinct fetal and maternal physiological de-
velopments that occur in the first trimester of pregnancy.
These developments include placentation, embryogenesis,
organogenesis, and pregnancy-associated cellular differen-
tiation, which together form part of the co-ordinated natu-
ral phenomenon. In the first trimester of pregnancy,
trophoblast cells invade the maternal decidua to ensure
proper spiral artery remodelling, a tightly regulated process
whereby any deviations from the normal could result in
complicated or failed pregnancies [4]. These trophoblast
cells are modulated by placental factors such as cytokines,
hormones, and microvesicles. In particular, syncytiotro-
phoblast microvesicles (STBMS) are understood to play a
role in maternal immune adaptation and systemic inflam-
matory response (MSIR) during normal and complicated
pregnancies [5, 6]. 
Syncytiotrophoblast microvesicles consisting of sub-
classes of molecules ranging from 10-1000 nm in size in-
clude three main types of vesicles namely: (1) vesicles that
bud directly from the cell membrane, (2) exosomes that are
derived from multi-vesicular bodies within the cell, and (3)
apoptotic bodies [5]. These microvesicles have been shown
to have an immune regulatory role in pregnancy and are in-
volved in the acceptance of the semi-allogenic fetus [7-9].
Importantly, STBM’s have been shown to induce cytokine
release in monocytes and B-cells [5] via cellular signalling
cascades leading to the synthesis of inflammatory cytokines
such as TNF-α and IL-6 [2]. In-vitro and ex-vivo studies
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Summary
Background: The first trimester of pregnancy remains an unknown immunological adaptation. Cytokines and syncytiotrophoblast
microvesicles (STBM) have been identified as key factors involved in the maternal immune adaptation. This study therefore aims to
determine the levels of T helper cell 1 (Th1) and 2 (Th2) associated cytokines TNF-α and IL-6 in relation to the relative concentration
of STBM’s in maternal circulation. Materials and Methods: Plasma samples from normotensive pregnant women in the first trimester
of pregnancy were obtained. The concentrations of TNF-α and IL-6 were determined using ELISA. STBMs were determined by iso-
lating microvesicles in maternal circulation and quantifying the concentration of PLAP using ELISA. Results: TNF-α, IL-6 and STBMs
remained at constant levels in weeks 5-10 of gestation. In weeks 11-12 of gestation, TNF-α increased with a decrease in IL-6 and
STBMs. Ratio of TNF-α/IL-6 remained constant in weeks 5-6 and significantly increased in weeks 11-12 of gestation. A positive cor-
relation between TNF-α and IL-6 was obtained in weeks 6-10 and a negative correlation in weeks 11-12 of gestation. In addition, a pos-
itive correlation between STBMs & TNF-α was obtained and negative correlation between STBMs and IL-6. was observed Conclusion:
The relationship between TNF-α/IL-6 and STBMs suggests that syncytiotrophoblast microvesicles may have a role in cytokine pro-
duction and in the maintenance of the Th1/Th2 immune adaptation in normal pregnancy.  
Key words: IL-6; TNF-α; Syncytiotrophoblast microvesicles; Early pregnancy.
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have shown that both TNF-α and IL-6 have a synergistic
role in regulating placental morphogenesis by co-ordinating
trophoblast proliferation, migration, differentiation, and se-
cretory function [10-12]. Additionally, ex-vivo studies have
shown that STBMs stimulate the production of cytokines
and therefore have an immune modulatory role in preg-
nancy. Syncytiotrophoblast microvesicles could therefore
be responsible for the shift in Th1/Th2 immune adaptation
in normal and complicated pregnancies [5]. It has been es-
tablished that a shift from type 1 (Th1) to type 2 (Th2) im-
munity is an essential requirement for normal pregnancy
and failure to make this shift results in a compromised or
failed pregnancy [7]. The classical Th1/Th2 cytokine par-
adigm in pregnancy is a universally accepted concept even
though placental-derived factors in relation to the maternal
immune adaptation are not fully understood [13]. 
Previous studies have focused on maternal systemic lev-
els of TNF-α and IL-6 in the second and third trimesters of
pregnancy without determining the relative concentration
of STBMs in maternal circulation [14-16]. In this study, the
authors therefore aim to identify the possible relationship
between maternal circulatory levels of cytokines (TNF-α
and IL-6) and STBMs in the first trimester of pregnancy,
the “black-box” period of pregnancy. 
Materials and Methods
Regulatory ethical and institutional approval were obtained
from the Biomedical Research Ethics Committee of the Univer-
sity of KwaZulu-Natal, South Africa (BE036/12). All patients
were recruited by informed consent.
Primiparous women in the first trimester of pregnancy at 5, 6,
8, 10, 11, and 12 weeks of gestation (n = 3, 5, 12, 15, 15, and 15,
respectively). Normotensive pregnant women were classified by
a blood pressure of 120±10 / 80±5 (systolic/diastolic mmHg) and
absent proteinuria. Women had singleton pregnancies and those
with evidence of any infections or medical, surgical or other ob-
stetric complications were excluded. Blood samples were col-
lected and the plasma samples were stored at -80°C for analyses. 
Plasma concentrations of TNF-α and IL6 were measured using
commercially available sandwich enzyme-linked immunosorbent
assays (TNF-α & IL6 quantification kits). Briefly, specific mon-
oclonal antibody (TNF-α/IL-6) was immobilised onto each well
overnight at 4°C using the antibody binding buffer supplied. To
prevent non-specific binding; wells were washed and 200 µl of
assay diluent was added to each well and incubated at room tem-
perature for one hour with agitation. Plates were thereafter washed
with buffer and 100 µl of diluted plasma sample or standards were
added to each well. Antigens were allowed to bind to primary an-
tibodies at room temperature for two hours with agitation. Plates
were washed with buffer followed by addition of 100 µl of HRP
detection antibody into each well and incubated at room temper-
ature for one hour with agitation. Plates were thereafter washed
with buffer and 100 µl of Avidin-HRP was added to each well and
incubated at room temperature for 30 minutes with agitation.
Plates were washed and 100 µl of TMB substrate solution was
added to each well and incubated for 15 minutes with no exposure
to light. The reaction was monitored for colour change and
stopped using the stop solution provided. The absorbance was
read at 450 nm. 
Microvesicles in maternal circulation was isolated according to
a modified method as described by Dragovic et al. [17]. Mi-
crovesicle protein concentration was determined using a protein
assay. Placental alkaline phosphatase concentration in maternal
circulation was measured using a sandwich ELISA test. Plates
were pre-coated with specific PLAP primary antibodies by the
manufacturer. Approximately 25 µg of isolated microvesicles
were added to each well and incubated at 37°C for 30 minutes.
Plates were thereafter washed and 50 µl of HRP-conjugate was
added to each well followed by incubation at 37°C for 20 min-
utes. Plates were thereafter washed and substrate solution A (50
µl) and B (50 µl) was added to each well and incubated at room
temperature for ten minutes with no exposure to light. The reac-
tion was terminated by the addition of 50 µl of stop solution and
the absorbencies were read at 450 nm.
The data is presented as mean ± SEM. Differences in STBMs,
IL6 and TNF-α concentration between pregnant women were de-
termined using ANOVA with post-hoc analyses (Tukey-Kramer,
95% CI). Statistical analysis was performed using Prism 6. Cor-
relation analysis was done using the Pearson’s correlation test.
Statistical significance was defined as p < 0.05.
Results
The clinical characteristics of the study groups are rep-
resented in Table 1. There was no statistical significance in
the clinical data between the groups (p > 0.05). 
The concentration of TNF-α and IL-6 in maternal circu-
lation are represented in Figures 1A and B, respectively.
TNF-α and IL-6 levels during early pregnancy (5-10
weeks) remained constant with no statistically significant
differences (p > 0.05). A significant increase in TNF-α in
weeks 11 (8.056 ± 0.15 pg/ml) and 12 (8.46 ± 0.19 pg/ml)
was observed in comparison to weeks 5 (7.004 ± 0.20
pg/ml), 6 (7.345 ± 0.120), 8 (7.122 ± 0.12 pg/ml), and 10
(7.36 ± 0.05 pg/ml), p < 0.05. Conversely, the IL-6 levels
significantly decrease in weeks 11 (14.32 ± 0.75 pg/ml) and
12 (13.47 ± 0.45 pg/ml) in comparison to week 10 (15.75
Table 1. — Clinical characteristics of patients.
Variables Gestational age (weeks)
5 (n = 3) 6 (n = 5) 8 (n = 12) 10 (n = 15) 11 (n = 15) 12 (n = 15) 
Maternal age (years) 31.33 ± 4.81 26.83 ± 2.04 24.83 ± 2.19 25.16 ± 0.92 25.20 ± 1.27 25.91 ± 1.27  
Parity 1 ± 0.33 1 ± 0.37 1 ± 0.29 1 ± 0.20 1 ± 0.15 1 ± 0.36  
Systolic/diastolic  121.3/83.33 122.8/80.67 123.2/81.92 123.5/82.50 124.7/82.65 123.6/82.82 
Blood Pressure (mmHg) ± 1.33/0.8 ± 1.64/2.19 ± 0.91/0.56 ± 0.60/0.34 ± 1.22/0.64 ± 1.47/0.63
All values are represented by mean ± SEM. All pregnancies were singleton without intrauterine infection or any other medical condition. Proteinuria was not de-
tected in all patient groups. No statistical significance was identified with parity and blood pressure (p > 0.05).
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± 1.73 pg/ml) and 6 (16.65 ± 1.32 pg/ml), p < 0.05. The
ratio of TNF-α to IL-6 in maternal circulation was calcu-
lated (Figure 1C). This ratio significantly increased in
weeks 11 (0.60 ± 0.03) and 12 (0.64 ± 0.02) in comparison
to weeks 5 (0.45 ± 0.04), 6 (0.49 ± 0.03), 8 (0.48 ± 0.02),
and 10 (0.47 ± 0.02), p < 0.05.
The relationship between TNF-α and IL-6 in pregnant
women was further analysed using Pearson’s correlation
coefficient. The analysis showed a positive correlation in
weeks 6 (r = 0.90, p < 0.05; Figure 2A) and 10 (r = 0.72, p
< 0.01; Figure 2B) of gestation. In contrast, a negative cor-
relation was obtained in 11 (r = -0.56, p < 0.05; Figure 2C)
and 12 (r = -0.92, p < 0.05; Figure 2D) weeks of gestation. 
The differences in the relative concentration of STBMs in
maternal circulation are shown in Figure 3. It is noted that
the relative STBM concentration remained constant in
weeks 5-10 (averages -905 ± 83.74 pg/ml) of pregnancy.
However, a decrease in weeks 11 (508.9 ± 35.66 pg/ml) and
12 (556.7 ± 54.91 pg/ml) in comparison to weeks 5-10 was
observed (p < 0.05).
Pearson’s correlation coefficient analysis was used to fur-
ther analyse the relationship between the relative STBM
concentration and inflammatory cytokines (TNF-α and IL-
6) during the first trimester of pregnancy. No correlation
was obtained in the 8
th
week of gestation. However, the
analysis indicates a positive correlation between relative
STBM concentration and TNF-α in weeks 6 (r = 0.96, p <
0.05; Figure 4A), 10 (r = 0.55, p < 0.05; Figure 4B), 11 (r
= 0.59, p < 0.05; Figure 4C) and 12 (r = 76, p < 0.01; Fig-
ure 4D) of gestation. In contrast, a negative correlation be-
tween relative STBM concentration and IL-6 in weeks 6 (r
= -0.92, p < 0.05; Figure 4E), 10 (r = -0.79, p < 0.01; Fig-
ure 4F), 11 (r = -0.53, p < 0.05; Figure 4G), and 12 (r = -
0.55, p < 0.05; Figure 4H) of gestation was obtained.
Discussion
In this study, the authors quantified cytokines TNF-α and
IL-6 relative to the concentration of STBMs in maternal
circulation over the first trimester of pregnancy, an under-
reported phase of pregnancy due to participant recruitment
challenges. The study, therefore, provides data regarding
the maternal circulatory levels of cytokines relative to
STBMs in the first trimester of pregnancy. The main find-
ings of the study showed constant levels of TNF-α, IL-6,
and STBM levels in weeks 5-10 of pregnancy. However,
in comparison, at weeks 11 and 12, TNF-α increases while
IL-6 and STBM decline. Further analysis of the data
showed an increased ratio of TNF-α/IL-6 (Th1/Th2) in
weeks 11 and 12 compared to weeks 5-10. Correlation
analysis between TNF-α and IL-6 displayed a positive cor-
relation in weeks 6 and 10. Conversely, a negative correla-
tion was observed in weeks 11 and 12, suggesting a slight
shift towards Th1 immunity. In addition, the constant pos-
itive correlation between STBMs and TNF-α and negative
correlation between STBM and IL-6 suggests that STBMs
are associated with upregulating Th1 immunity and down-
regulating Th2 immunity in the first trimester of pregnancy.
These findings are indicative of an alteration in immune re-
sponse during the transitioning from organogenesis (5-10
weeks) to fetal development (≥11 weeks). 
Figure 1. — Tumor necrosis factor-alpha (TNF-α) and interleukin-
6 (IL-6) in maternal circulation. Plasma (A) TNF-α (pg/ml) and
(B) IL-6 (pg/ml) concentration measured by enzyme linked im-
munoabsorbency assay and (C) ratio of TNF-α to IL-6 in preg-
nant women at 5, 6, 8, 10, 11, and 12 weeks of gestation.  In A and
B data is presented as an aligned dot plot.  In C data is presented
as a bar graph. Values are represented as mean ± SEM. In A, B,
and C 
### p < 0.01 11 and 12 weeks vs. 5 to 10 weeks. 
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The maintained levels of TNF-α and IL-6 in weeks 5-10
of gestation is in keeping with a previous study which
showed that there are no significant alterations in serum
TNF-α and IL-6 levels during weeks 8-10 of gestation [18].
This could be representative of the maternal immune adap-
tation during organogenesis. Previous studies also showed
that TNF-α and IL-6 increases in the second and third
trimesters of normal pregnancy [14, 16, 18], which is a re-
quirement for the maintenance of Th2 associated immunity.
However, in this study, for the first time, the authors have
shown that there is an increase in TNF-α and decrease in
IL-6 in weeks 11 and 12 of gestation, which represents a
slight shift towards Th1 immunity, which could be repre-
sentative of the transition from organogenesis to fetal de-
velopment. This finding was further assessed by the analysis
of the TNF-α (Th1-pro-inflammatory)/IL-6 (Th2-anti-
inflammatory) ratio. The ratio analysis supports the notion
that in normal pregnancy there is a shift towards Th2 im-
munity, which is a common feature of successful pregnancy
[19]. However, observations made in this study suggest that
there is a greater shift towards Th2 immunity during weeks
5-10 of gestation in comparison to weeks 11 and 12. The
slight shift towards Th1 immunity in weeks 11 and 12 of
gestation probably occurs due to the oxygen demand for
rapid fetal growth, which results in enhanced inflammation
to support the increase in trophoblast invasion and vessel
transformation; a critical requirement for spiral artery re-
modelling [4]. These findings support the theory that pla-
cental morphogenesis requires both a pro- and
anti-inflammatory state during the first trimester of preg-
nancy [20]. It has been recognised that STBMs, released
into maternal circulation could play a regulatory role in
Th1/Th2 immunity which may mediate the synthesis of
pro- and anti-inflammatory cytokines in maternal circula-
tion [5].
Elevated STBMs in maternal circulation have been as-
sociated with pregnancy-related complications, such as
preeclampsia and is indicative of placental function [21,
22]. Placental alkaline phosphatase, a syncytiotrophoblast
membrane-bound allosteric enzyme, has been used to
Figure 2. — The relationship between tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) levels in maternal circulation. The
correlation between TNF-α and IL-6 in (A) 6, (B) 10, (C) 11, and (D) 12 weeks of gestation.  In A and B a (+) Pearson’s correlation. In
D and E a (-) Pearson’s correlation.  
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measure the relative concentration of STBMs in maternal
circulation, mainly in the 2
nd
and 3
rd
trimester of pregnancy.
There is therefore a lack of information regarding the rela-
tive concentration of STBMs in 5-12 weeks of normal preg-
nancy. In this study, the authors therefore isolated and
quantified circulating STBMs by the measurement of
PLAP (stimulus) and related it to the concentration of TNF-
α and IL-6 (maternal inflammatory response) in maternal
circulation. 
More recently ex-vivo studies showed that STBMs play
a central role in promoting Th2 immunity during normal
pregnancy and therefore could possibly play a central role
maintenance of MSIR in normal and complicated pregnan-
cies [5]. In this study, maternal circulatory levels of STBMs
in weeks 5-10 of gestation remained constant with a sig-
nificant decrease in weeks 11-12 of gestation (p < 0.05),
which may occur as a result of the transitioning from
organogenesis to fetal growth as discussed above. 
The decrease in the ratio between TNF-α/IL-6 in weeks
5-10 is probably as a result of the increase in relative STBM
concentration which may have stimulated the Th2 anti-in-
flammatory response leading to the increased synthesis of
IL-6 required for facilitating fetal organ development [11].
In contrast, the rapid decline in STBMs in weeks 11-12 of
gestation may have slightly shifted the inflammatory re-
sponse towards Th1 immunity in comparison to a stronger
Th2 response in weeks 5-10 of gestation. This is probably
due to the synthesis of pro-inflammatory cytokines (TNF-
α) from monocytes which were primed by STBMs earlier
in pregnancy [5]. Further correlation analysis between
STBMs (magnitude of the stimulus) related to TNF-α and
IL-6 (size of the response) in maternal circulation during
weeks 5-12 of gestation. The analysis demonstrates that
STBMs are positively associated with TNF-α and nega-
tively associated with IL-6 in the first trimester of preg-
nancy. These findings suggest that STBMs in the first
trimester of pregnancy is positively associated with Th1
immunity. This is contrary to previous findings whereby
STBMs derived in the third trimester have been shown to
stimulate Th2 immunity [5] and could possibly be due to
key immunological adaptations that occur throughout the
various phases of gestation which ultimately affect the bio-
genesis of STBMs. In addition, it is important to note that
the measurement of PLAP from isolated microvesicles may
not be a true representation of STBMs in maternal circula-
tion as STBMs consist of various types of vesicles. How-
ever, the measurement of PLAP from isolated micro-
vesicles in maternal circulation would represent the rela-
tive concentration of STBMs in maternal circulation and
may therefore be a useful tool in monitoring pregnancy
when combined with pregnancy associated factors such as
TNF-α and IL-6. 
Since STBMs consist of sub-classes of vesicles, it is
therefore necessary that future studies incorporate the iso-
lation and characterisation of individual sub-classes of
STBMs from maternal circulation. Consequently, studies
regarding placental-derived exosomes [23] as biomarkers
of obstetric complications are ongoing within the present
research group. Nonetheless, the findings from this study
indicate that combined analysis of TNF-α/IL-6 ratio and
STBMs in maternal circulation can be incorporated into a
medical algorithm to improve and standardise decisions
made regarding normal and complicated pregnancies.
Conclusions
TNF-α (Th1), IL-6 (Th2) and STBM levels in maternal
circulation remain constant in weeks 5-10 of gestation; a
period of organogenesis. However, in weeks 11-12 of ges-
tation, TNF-α increases with a decline in IL-6 and STBMs,
which is suggestive of the physiological transitioning from
organogenesis to fetal development as a result of enhanced
placental perfusion. Ratio analysis of TNF-α/IL-6 indicates
that there is an enhanced shift towards Th1 immunity in
weeks 11 and 12 of gestation; this may occur in support of
placental spiral artery remodelling, a perquisite for fetal
growth. Additionally, the measurement of the relative con-
centration of STBMs in relation to TNF-α and IL-6 indi-
cates that STBMs may play a key role in the immune
adaptation in early pregnancy. This study shows that com-
bined analysis of TNF-α, IL-6, and STBMs may provide a
useful medical algorithm in ascertaining successful preg-
nancy and impeding obstetric complications in the future.
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